Purification and characterisation of xanthine oxidoreductase from liver by Choudhury, Sharmila
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019
Purification and Characterisation of 
Xanthine Oxidoreductase from Liver
Submitted by Sharmila Choudhury 
for the degree o f  PhD  
o f  the University o f  Bath 
2001
CO PY RIG H T
A ttention is drawn to the fact that the copyright o f  this thesis rests with its 
author. This copy o f  the thesis has been supplied on the condition that anyone 
who consults it is understood to recognise that its copyright rests with its author 
and that no quotation from the thesis and no inform ation derived from it my be 
published w ithout the prior written consent o f  the author.
This thesis may be made available for consultation within the University Library 




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U601840
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
K-.V{>
m OF - •-7H
i *niARY
s s  - 8  MAY 2002
.Ph.D.
This thesis is dedicated to the memory of my father
Acknowledgements
Firstly, I would like to thank both o f my supervisors, Prof. Roger Harrison and Prof. 
Robert Eisenthal, for giving me the opportunity to undertake this project and also for 
the guidance and support that they have given me throughout my PhD. I would like to 
thank the BBSRC for the funding of this project.
I would like to thank Dr. David Tosh for all his help with the confocal microscopy. I 
would also like to thank everybody who has worked in Lab 1.28, both past and present, 
who have not only offered me lots o f invaluable advice, but have also made my time at 
Bath extremely enjoyable. These people include Catherine Hoare, Hannah Martin, 
Tracey Goult, Sue Page, Ben Godber, JJ Doel, Richard Bryant, Frank Sugar, Zoe 
Symons and Stephanie Hazlehurst. I am extremely grateful to Arwen Pearson for her 
expertise and troubleshooting, which have helped me on numerous occasions. Thanks 
also to Sue Miller, for putting up with me as a housemate for three years, and for her 
help with the ‘technical stuff!
Special thanks need to go to John, who I am forever grateful to for all o f his patience, 
understanding and support during my PhD and the writing of this thesis.
Finally, I would like to say a big thank you to my family, without whose love, support 
and encouragement I would not be where I am now.
iv
Abstract
Xanthine oxidoreductase (XOR) is a molybdoflavoenzyme of great interest, particularly 
because of its proposed roles in ischaemia-reperfusion injury and a range of other 
pathological conditions. Xanthine oxidoreductases from bovine milk and rat liver have 
been widely studied, and more recently, the development of a purification procedure for 
the isolation of XOR from human milk has allowed this enzyme to be characterised. 
Human milk xanthine oxidoreductase (HMXOR) has been found to be much less active 
towards traditional substrates, such as hypoxanthine and xanthine, than its bovine 
counterpart. Reported purifications of the human liver enzyme show specific activity 
similar to that of bovine milk, and therefore significantly higher than for human milk 
enzyme.
The work presented here describes the purification and characterisation of human liver 
xanthine oxidoreductase (HLXOR), with the use of immunoaffinity methods. XOR 
was purified from bovine liver to near homogeneity as judged by SDS-PAGE, using 
both affinity and immunoaffinity means of purification. The immunoaffinity 
purification was then optimised for the isolation of XOR from human liver. Affinity- 
purified polyclonal and monoclonal anti-(HMXOR) antibodies were characterised for 
this purpose and the latter were judged to provide better purification, as evidenced by 
SDS-PAGE. Monoclonal immunoaffinity purification resulted in HLXOR that was 
homogeneous on the basis of SDS-PAGE and Western blotting, displaying a major 
band at 150 kDa and a minor band at 130 kDa. This preparation was shown to have a 
specific activity towards xanthine of 170 nmol/min/mg, which is significantly lower 
than that reported by other workers, and more comparable to that of the milk enzyme.
A monoclonal anti-(HMXOR) antibody was used in the immunofluorescence 
localisation of XOR in normal and primary biliary cirrhotic human liver paraffin- 
embedded sections. Strong staining was seen in hepatocytes, bile ductules and some
Kupffer cells. Similar staining was observed in primary biliary cirrhotic liver, with 
further evidence of atypical bile ductule configuration. The specific activity of XOR 
was found to be over 4-fold higher in primary biliary cirrhotic liver homogenate than 
that o f normal liver homogenate, suggesting a form of upregulation of enzyme in the 
diseased liver.
Small human liver XOR crystals were obtained, and these provide a basis for further 
clarification of the structure o f this enzyme.
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Xanthine oxidoreductase (XOR) is a major enzyme involved in purine catabolism, 
participating in the terminal reaction of the purine degradation pathway in man, by 
catalysing the rate—limiting oxidation of hypoxanthine to xanthine, and xanthine to uric 
acid. The enzyme is a molybdoflavoprotein, containing molybdenum, flavin adenine 
dinucleotide (FAD) and iron/sulphur (Fe/S) redox centres, belonging to a family of 
mammalian molybdenum-containing proteins along with aldehyde oxidase (AO) and 
sulfite oxidase (SO).
Xanthine oxidoreductase (XOR) has been extensively studied for over a century, dating 
back to 1882, when Horbaczewski observed the catalysis of hypoxanthine to xanthine 
to uric acid in tissue homogenates (Horbaczewski, 1882). A few years later, it was 
demonstrated by Schardinger that samples of fresh milk were able to decolourise 
methylene blue in the presence of formaldehyde (Schardinger, 1902). The enzyme 
responsible for this activity was originally named Schardinger’s enzyme. Over the next 
two decades, an activity was revealed to be present in cow’s milk, similar to that found 
in tissue homogenates, that had the ability to convert hypoxanthine and xanthine to uric 
acid in the presence and absence of oxygen (Morgan et al., 1922). This activity was 
attributed to an enzyme, XOR. A kinetic analysis of the xanthine and methylene blue 
activity of partially purified XOR was performed by Dixon & Thurlow (1924, 1926),
Chapter 1 2
who showed that the enzyme was able to utilise aldehydes as reducing substrates as well 
as purines, thereby indicating that Schardinger’s enzyme and XOR were the same.
In 1939, an essentially pure preparation of milk XOR was obtained, which possessed a 
visible spectrum resembling that of a flavoprotein (Ball, 1939). The spectrum indicated 
the presence of a second chromophore in addition to flavin; this was later determined to 
be iron (Richert & Westerfeld, 1953). Molybdenum was found to be an additional 
constituent of the enzyme (De Renzo et al., 1953) making XOR the first mammalian 
molydoenzyme to be discovered. The ready availability of XOR on a large scale from 
cows’ milk has allowed the pure enzyme to be studied in detail for over sixty years. In 
particular, the last twenty years have seen enormous advances in structural, sequence, 
and kinetic information relating to XOR, and molybdoenzymes in general.
XOR is a member of a small family of mammalian mononuclear molybdenum- 
containing proteins, all of which share a common molybdenum cofactor binding site 
(Hille, 1996). These molybdoenzymes can be divided into three main categories, 
namely, the XOR family, the sulphite oxidase (SO) family and the DMSO reductase 
family. They are unique in that, unlike other biological hydroxylation systems, they 
utilise water as opposed to molecular oxygen as the source o f oxygen atom incorporated 
into product. Moreover, during turnover, they are able to generate as well as consume 
reducing equivalents. The hydroxylation reaction typically catalysed is represented 
below:
RH + H20 >  ROH + 2e + 2H+
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Mammalian XOR is synthesised as xanthine dehydrogenase (XDH) [E.C. 1.1.1.204] and 
this is the predominant form existing within the cell. However, XDH can be readily 
converted to xanthine oxidase (XO) [E.C. 1.1.3.22] by oxidation of sulphydryl residues 
or proteolysis. The enzyme is thus unique within the molybdoenzyme family in that it 
can exist in either one of two interconvertible forms. These forms have similar 
reactivities towards reducing substrates, such as xanthine and hypoxanthine, but have 
different reactivities towards oxidising substrates. XDH shows a preference for NAD+ 
whereas XO cannot use NAD+, requiring molecular oxygen as its substrate.
XOR catalyses the oxidation of hypoxanthine and xanthine to uric acid, and is best 
recognised for this role as the rate-limiting enzyme in nucleic acid degradation, whereby, 
purines are channelled for terminal oxidation. The hydroxylation of hypoxanthine to 
uric acid is accompanied by the concomitant reduction o f either NAD+ to NADH or 
molecular oxygen to superoxide and hydrogen peroxide, depending on the form of the 
enzyme, whether dehydrogenase or oxidase.
h 2o  h +
Hypoxanthine Xanthine
h 2o  h +
Uric Acid
Figure 1.1 Conversion of hypoxanthine to xanthine and xanthine to
uric acid catalysed by XOR
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Mechanism of action
XOR exists as a homodimer with a molecular weight of approximately 300 kDa,
per subunit, comprising one molybdopterin cofactor (Rajagopalan & Johnson, 1992), 
two spectroscopically distinct iron-sulphur (Fe/S) centres (Hille & Anderson, 1991),
fragments, sequence analysis of which has revealed the molybdenum centre to be 
located in the C-terminal fragment of 85 kDa, the two Fe/S centres in the N-terminal 
20 kDa fragment, and the FAD in the intermediate 40 kDa fragment (Hille & Nishino, 
1995). All of these centres have been implicated in catalysis, and a schematic 
representation of the mechanism of this involvement is shown below:
composed o f two identical sub-units each of 150 kDa. It contains four redox centres
and one FAD cofactor. Limited proteolysis o f the enzyme results in cleavage into three









Figure 1.2 Proposed mechanism of action of XOR
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Xanthine, and the majority of other reducing substrates, interact with XOR at the 
molybdopterin centre, reducing Mo(VI) to Mo(TV) (Bray, 1988). Reducing equivalents 
are subsequently transferred to the FAD centre of the enzyme by intramolecular 
transfer of electrons via the Fe/S centres (Olson et al., 1974). Reduction of NAD+ or 
molecular oxygen occurs through FAD. Molecular oxygen can be univalendy or 
divalendy reduced at the FAD site to yield superoxide or hydrogen peroxide respectively 
(Bray, 1975). These can in turn give rise to secondary radicals including the 
considerably more reactive hydroxyl radical via the Fenton and iron—mediated Haber— 
Weiss reactions, as shown below:
XO
0 2 + 2e + 2H+
0 2 + e~
Figure 1.3 Univalent and divalent reduction of oxygen
Fe2+ + H20 2 >  OH * + OH ' + Fe3+
o 2-  + h 2o 2
Fe
0 2 + O H * +  OH"
Figure 1.4 The Fenton reaction and the iron—mediated Haber—Weiss
reaction
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This generation of reactive oxygen species (ROS) by the above reactions is well 
documented, and has led to much interest in XOR as a destructive agent in a range of 
pathological and physiological conditions, particularly those involving ischaemia— 
reperfusion tissue injury (McCord, 1985; Sussman & Bulkley, 1990).
It has been shown by spectrophotometric and EPR studies that XOR can accept up to 
six electrons per subunit (Olson et al., 1974; Bray, 1975). The Fe/S centres are thought 
to act as an electron ‘sink’, maintaining the other centres in the optimum redox state 
(Olson et al., 1974). In addition, they are capable of reducing some artificial substrates 
such as ferricyanide and methylene blue (Fried & Fried, 1974). As well as xanthine and 
hypoxanthine, XOR has also been shown to oxidise, by a similar mechanism, a wide 
range of substrates, including other purines, pyrimidines, pteridines and aldehydes 
(Massey, 1973; Krenitsky et al., 1986). Despite the broad specificity of the enzyme, it is 
thought that the high specific activities and low KM’s for hypoxanthine and xanthine 
identify them as the physiological substrates of XOR.
Both forms of XOR have been shown to catalyse the oxidation of NADH to NAD+. 
This NADH-oxidising activity is less widely recognised, although it has been 
documented for human and bovine milk XOR (Nakamura et al, 1991; Sanders et al, 
1997) as well as for turkey and chicken liver XDH (Fhaolain & Coughlan, 1976). 
NADH donates electrons at the FAD site, in contrast to the other reducing substrates. 
The oxidation of NADH is catalysed significantly faster by the dehydrogenase form 
than by the oxidase form of the enzyme and, in both cases, reduction of molecular
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oxygen occurs to generate superoxide anion. The NADH oxidising activity is 
unaffected by all conventional inhibitors which act at the molybdenum centre, such as 
allopurinol and oxypurinol (Moorhouse et al, 1987), amfluti2ole (Wems et al., 1991) and 
BOF-4272 (Uematsu & Nakashima, 1994). The activity is, however, blocked by 
conventional flavin site inhibitors such as diphenylene iodonium (Robertson et al, 
1990). Human milk XOR possesses very low activity to xanthine and hypoxanthine 
(Abadeh et al, 1992); a fact attributable to its low molybdenum content (Bray et al,
2000). Its NADH oxidase activity is, however, similar to that of the bovine milk 
enzyme, consistent with the involvement of the FAD site in this reaction. It has been 
suggested that the ‘unimpaired’ NADH oxidase activity with regard to the human 
en2yme reflects a physiological role (Harrison, 1997).
A more recently recognised and much less publicised role for XOR is its capacity to 
reduce nitrates and nitrites to nitric oxide under anaerobic conditions (Godber et al, 
2000a & b; Doel et al, 2000, 2001; Godber et al, 2001), a property perhaps unsurprising 
in view of the many structural and catalytic similarities XOR shares with plant nitrate 
reductases (Hille, 1996).
Inhibitors of XOR can be categorised into two groups; those that are structural 
analogues of purine substrates, and those that are not structurally related to the 
physiological substrates. Well-known structurally similar inhibitors are allopurinol and 
oxypurinol (Moorhouse et al, 1987), the former of which undergoes oxidation to 
produce the latter, which binds tightly to the reduced form of XOR (Massey &
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Edmondson, 1970; Robins et al.y 1985). Less structurally similar molecules include 
amflutizole (Wems et al., 1991) and BOF-4272 (Okamoto & Nishino, 1995). All of 
these inhibitors act at the molybdenum site of the enzyme, and, as noted above, do not 
affect NADH oxidation.
Xanthine oxidase (XO) and xanthine dehydrogenase (XDH)
Mammalian XOR exists in vivo predominantly as XDH, although it may be converted to 
XO. Both of these species have a similar KM for xanthine (Waud & Rajagopalan, 1976), 
however, they differ in terms of electron acceptor. XDH is characterised by a high 
xanthine to NAD+ activity, whereas XO is characterised by a high xanthine to molecular 
oxygen activity, and is unable to reduce NAD+. It was first observed in 1969 that XOR 
was largely present in crude homogenate from rats as the NAD+-dehydrogenase form, 
whereas the purified enzyme was predominantly in the 0 2-dependent oxidase form 
(Stirpe & Della Corte, 1969). Della Corte and Stirpe went on to demonstrate that the 
two forms were the same enzyme, and that conversion of XDH to XO could be 
reversible or irreversible (Della Corte & Stirpe, 1972).
XDH may be readily converted to XO by a variety of conditions, for example, 
incubation at 37 °C, storage at -20 °C, treatment with organic solvents and with 
sulphydryl reagents (Stirpe & Della Corte, 1969). These reversible interconversions 
were attributed to the formation or breakage of disulphide bonds. XDH contains 
fourteen free sulphydryls per subunit, of which eight can readily form four sulphydryl 
bonds, although not all of these are involved in X D H /X O  interconversion (Waud &
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Rajagopalan, 1976; Saito, 1987; Hunt & Massey, 1992). XO is formed irreversibly by 
proteolysis, which effects the cleavage of a 20 kDa fragment from the 150 kDa subunit. 
This fragment is not required for oxidase activity o f the enzyme, but appears to be 
essential for the stabilisation of enzyme conformation, and the proper binding and 






proteolysis cleavage of 20 kD a fragment
Irreversible Oxidase
Figure 1.5 Dehydrogenase/oxidase interconversion
Conversion of XDH to XO results in a conformational change in the FAD binding 
region, involving destabilisation of the anionic forms of the flavin (Saito et al., 1989). In 
a recent study on the crystal structures of XDH and XO from bovine milk, Enroth et al. 
(2000) observed that cleavage o f surface—exposed loops o f XDH occurs on proteolytic 
conversion to XO, causing major structural rearrangement of another loop close to the
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flavin ring. This movement prevents NAD binding by partially blocking its access to 
the FAD cofactor, and thus altering the electrostatic environment of the active site.
Manipulation of sulphydryl reagents allows isolation o f bovine milk XOR 
predominantly in its XDH or XO forms (Nishino et al., 1986; Massey et al, 1989). The 
two forms of the enzyme are however, encoded by the same gene and can only be easily 
differentiated by their preference for electron accepting species (Xu et al., 1994; Saksela 
& Raivio, 1996). There are no distinguishable absorption spectra differences nor are 
there any marked differences in their Revalues for xanthine (Massey et al., 1989).
Sakuma et al. (1997) showed that peroxynitrite can induce reversible conversion of 
XDH and XO and proposed a metabolic role for this reaction in the liver under certain 
pathological conditions. It has also been suggested that irreversible conversion of XDH 
to XO may occur as a result of an uncharacterised proteolytic process taking place in 
human liver, involving a novel type of proteolytic enzyme that, when triggered by 
mitochondrial damage, is released from the mitochondria into the cytosol (Saksela et al, 
1999).
Inactive forms
Purified preparations of XOR contain inactive forms of the enzyme (Morell, 1952), two 
of which exist in vivo, namely desulpho and demolybdo enzyme.
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The desulpho form lacks an Mo=S grouping, essential for molybdenum activity, which 
is replaced by M o= 0  (Bray, 1975). It occurs in enzyme preparations from bovine milk 
and rat liver (Hart et al, 1970; Ikegami & Nishino, 1986) and makes up approximately 
40% of the Mo-containing enzyme in human milk (Godber, B., Ph.D. Thesis, 1998; 
Bray et al., 1999). Desulpho-XOR can be separated from active enzyme using folate 
affinity chromatography (Nishino et al., 1981). It can be produced in the laboratory by 
treatment of reduced enzyme with cyanide (Massey & Edmondson, 1970), which causes 
the release of sulphur as thiocyanate. This process can be reversed by incubation with 
sulphide (Massey & Edmondson, 1970; Cleere & Coughlan, 1974; Nishino et al., 1983). 
Crude and purified rat liver enzyme preparations have been found to consist of up to 40 
% desulpho enzyme (Ikegami & Nishino, 1986). Itoh et al. (1978) have reported an 
increase in the specific activity XOR purified from the livers of chickens fed on a diet 
high in protein, when compared with that of chickens fed on a low protein diet. This 
increase was attributed to in vivo resulphuration of desulpho-enzyme.
Demolybdo-XOR lacks the molybdenum (Mo) atom (Bray, 1975), and to some extent, 
the associated pterin cofactor. This form of the enzyme makes up some 40 % of 
bovine milk XOR (Godber, B., Ph.D. Thesis, 1998; Bray et al., 1999). Bray and 
colleagues have proposed that this percentage reflects dietary intake of Mo. The 
incorporation of Mo into XOR is one of the final stages in the biosynthesis of the 
enzyme (Hart et al, 1970; Ventom et al., 1988). Human milk XOR has a very high 
content (greater than 95 %) of demolybdo-XOR, which explains its low activity towards 
xanthine and conventional reducing substrates (Abadeh et al., 1992; Godber, B., Ph.D.
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Thesis, 1998; Bray et al., 1999). As noted above, NADH oxidase activity of human milk 
XOR is unaffected by the low Mo content because this activity depends only on the 
FAD site. Lack of molybdenum and its cofactor may affect the conformation of the 
enzyme, perhaps accounting for the variation in Fe/S clusters. Bray et al. (1999) found 
that human milk XOR was up to 30 % deficient in Fe/S I, contrasting with bovine milk 
XOR, which showed little deficiency.
A third inactive form of XOR can be produced in the laboratory but does not appear to 
exist naturally. This deflavo form lacks FAD and can be produced by treatment of 
XOR with high concentrations of salt. Its composition of Mo, Fe and sulphur is 
unchanged. The absorption spectrum, not surprisingly, differs markedly from that of 
fully active XOR. According to Hille and Massey (1991), it is possible to regain 
approximately 60 % of the original oxidase activity upon incubation of deflavo XOR 
with free flavin.
Gene structure and regulation
XOR enzymes isolated from different species show a very high amino acid sequence 
identity with each other (Glatigny & Scazzocchio, 1995), indicating a high degree of 
conservation. The mammalian XOR gene sequence is also very similar to that of 
another molybdoflavoprotein, namely, aldehyde oxidase (AO). Bovine liver AO amino 
acid sequence shares 50 % identity with that of bovine liver XOR (Li Calzi et al., 1995). 
Human AO cDNA is 64 % similar to that of human XOR, and the deduced amino acid 
sequence of human XOR is 49 % homologous with that o f human AO (Wright et al.,
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1993). In addition, the two enzymes possess an overlapping substrate specificity, similar 
subunit composition and redox centre distribution. It is possible that the two genes 
arose as the consequence of a duplication event from the same ancestral gene, as they 
are located on the same human chromosome, separated only by a short distance (Amaya 
et al., 1990).
AO is a homodimer, consisting of two identical subunits of 150 kDa. The enzyme is 
expressed at high levels in the liver and small intestine of various animal species 
(Krenitsky et al., 1974), although levels of AO activity in human tissues appear to be 
lower than corresponding XOR activities. XOR mRNA is barely detectable in striated 
muscle and duodenum, whereas significant levels of the AO transcript are present in 
these organs. In the brain, XOR is present in similarly low quantities, whilst AO again 
shows differences in regional distribution. It is possible to distinguish AO from XOR 
on the basis of its greater preference for simple aldehydes and iV-methylnicotinamide 
over xanthine. Krenitsky (1978) proposed that XOR and AO together constitute a 
protective barrier, detoxifying polar aromatic compounds such as nitrogen-containing 
heterocycles.
The structure of the genes coding for human and mouse XOR have been recently 
elucidated and found to be very similar (Cazzaniga et al., 1994; Xu et al., 1996), with the 
exon/intron boundaries of the genes very highly conserved, suggesting the presence of 
evolutionarily conserved functional domains. The amino acid sequence of bovine milk 
XOR shows 90 % sequence identity with that of the human liver enzyme (Ichida et al.,
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1993; Hille & Nishino, 1995; Berglund et al., 1996) and also with those of rat liver 
(Amaya et al., 1990) and chicken liver (Sato et al., 1995) enzymes. Properties of XOR 
cloned from various sources are shown in Table 1.1.
The amino acid sequences of XDH from human liver and intestine, traditionally 
regarded as 'high’ activity tissues (Abadeh et al, 1992; Harrison, 1997) have been 
reported and also found to be essentially identical (Ichida et al., 1993; Saksela & Raivio, 
1996; Yamamoto et al., 2001). Recent work has also found the cDNA sequence of 
human mammary gland XDH, a source of comparatively low ’ activity XOR, to be 
identical to the other human cDNA sequences (Briggs, 1997; Pearson, A., Ph.D. Thesis,
2001). All the sequences consist of approximately 1,330 amino acids. A weaker 
homology has been found to exist between the mammalian and Drosophila enzymes 











Ichida et al., 1993 
Saksela & Raivio, 1996
Bovine Mammary
gland
1331 146681 Berglund et al., 1996
Mouse Liver and 
spleen
1335 146517 Terao et al., 1992 
Cazzaniga et al, 1994
Rat Liver 1330 146111 Amaya et al, 1990




1335 146925 Lee et al, 1987 




1342 147422 Riley, 1989
Table 1.1 Properties of XOR cloned from different sources
It has been postulated that there is some degree of post—translational activation of 
XOR. Evidence for this has been found to exist in in vivo systems; XOR has been 
reported to be upregulated in response to interferon-y (IFN-y), in a mouse endothelial 
cell line (Falciani et al., 1994). Brown et al. (1995) suggested presence of hormone 
control of post—translational activation, which would go some way towards explaining 
the high initial enzymic activity of XOR in human milk during the first two weeks of 
lactation, after which activity was shown to decline, an observation not mirrored by a
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corresponding decrease in enzyme concentration. Page and colleagues observed that 
the specific activity of XOR in a human mammary gland epithelial cell line is 
upregulated by various cytokines, and reported an 8-fold increase in XOR activity. This 
was accompanied by only a 2- to 3-fold increase in XDH mRNA and protein (Page et 
al., 1998).
Tissue distribution and cellular localisation of XOR
XOR has been detected in all species studied to date, ranging from mammals to 
bacteria. O f all mammals studied, XOR has been found to exist in the highest levels in 
the liver and intestine (Krenitsky et al., 1974). The tissue localisation of XOR in humans 
has been extensively investigated, particularly since the enzyme has been implicated in 
the pathogenesis of post-ischaemic reperfusion tissue injury through its ability to 
produce free radicals (McCord, 1985). However, compared with mammals, XOR 
activity in man is relatively low (Parks & Granger, 1986). This may reflect major 
variations in the DNA sequence in the 5’ — flanking regions, shown for the rat (Chow et 
al., 1995), mouse (Cazzaniga et al., 1994) and human (Xu et al., 1996) XOR genes, 
although this contrasts with the high degree of homology in the coding regions and 
intron-exon structure as discussed earlier. As noted above, at least in breast milk, 
human XOR has low Mo content and this is reflected in its low activity. For these 
reasons, conclusions derived from animal experiments may not direcdy be extrapolated 
to humans.
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Progress in the development of reliable histochemical methods for the detection of 
XOR has been hindered by confusion surrounding the properties of the enzyme (Kooij 
et al, 1991) and the predominance in tissues of the dehydrogenase form; a fact not really 
realised until 1972 (Battelli et al., 1972). Enzyme activity stains include those based on 
tetrazolium salts (such as tetranitro blue tetrazolium) (Kooij et al., 1991), or 
ferri(III)cyanide (Dikov et al., 1988), as electron acceptors. Van Noorden and colleagues 
(1993) have developed an effective cerium stain, while immunohistochemical methods 
have been widely used but have suffered from lack of specificity, particularly in the case 
of polyclonal antibodies (Jarasch et al., 1981; Clare & Lecce, 1991; Hellsten-Westing, 
1993; Moriwaki et al., 1996a; Rouquette et al., 1998). The wide range of techniques used 
in the detection of XOR have led to contradictory results. However, it is widely 
accepted that XOR is present in the liver and small intestine, as well as the mammary 
epithelium and capillary endothelium of most tissues.
In cells, XOR is generally understood to be cytosolic, although there have been few 
extensive published investigations as to its exact subcellular localisation. XOR has been 
detected in milk-secreting epithelial cells and capillary endothelial cells of the mammary 
gland, liver sinusoid, heart, lung, intestine and skeletal muscles (Bruder et al., 1983). In 
rat tissues, liver and renal tubules, as well as the epithelium of the esophagus, small and 
large intestine and bronchioles stained strongly for XOR, with weaker positive staining 
detected in the adrenal gland, skeletal muscle, spleen and cerebral hippocampus 
(Moriwaki et al., 1996a). The detection of XOR in several immune cells (Bruder et al.,
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1983; Hellsten-Westing, 1993; Moriwaki et al, 1996a) suggests a possible immunological 
role for the enzyme.
Despite great interest in a possible role of XOR in the pathogenesis of ischaemia- 
reperfusion damage, there are few reports on the localisation of XOR protein in human 
tissues (Hellsten-Westing, 1993; Moriwaki et al., 1996b; Linder et al, 1999). Localisation 
studies of both XOR protein and rnRNA are complicated by their close similarity with 
those o f AO, and it is important that detection methods, such as activity assays and 
antibodies, are carefully characterised. Auscher et al. (1980) used radiolabelled xanthine, 
which detected XOR activity in the epithelial villi o f the duodenum and jejunum, but 
not in the large intestine or rectum. Kooij et al. (1992) similarly demonstrated the 
presence of XOR activity in only the liver and jejunum; findings that were consistent 
with biochemical results. The precise cellular whereabouts o f enzymic activity in the 
human liver are, however, unclear. Kooij et al. (1992) localised XOR activity in 
sinusoidal cells and in both periportal and pericentral hepatocytes of the liver. Moriwaki 
et al. (1996b) using immunohistochemistry, revealed the presence of XOR in the 
pericentral and periportal hepatocytes with weaker staining in the mid-zonal area. These 
workers also found staining in the sinusoidal cells and bile ducts. In contrast, Linder et 
al. (1999), using a similar method of localisation, reported negative staining in the bile 
ducts and positive staining in Kupffer cells, findings not reported by Moriwaki et al. 
(1996b). They did, however, confirm XOR staining in the cytoplasm of periportal 
hepatocytes (Linder et al., 1999).
Chapter 1 19
Hellsten-Westing (1993) observed immunoreactivity of XOR in vascular smooth muscle 
cells, endothelial cells of the capillaries, small vessels in cardiac and skeletal muscle, and 
in addition, macrophage and mast cells. XOR protein has been shown to be present in 
the human heart although corresponding enzyme activity is low, and it has been 
suggested to be largely in an inactive form, similar to that of human milk enzyme (de 
Jong et al, 1990; Abadeh et al, 1993). Some authors have been unable to detect any 
activity whatsoever (Downey et al., 1988; Grum et al., 1989). The latter authors 
concluded that XOR cannot be responsible for the production of harmful oxygen 
radicals leading to tissue injury in the human heart due to lack of detectable enzyme 
activity in this organ. It has been suggested that there is a cytosolic inhibitor of XOR, 
which could account for the apparent lack of enzyme activity in heart (Bray et al, 1959). 
Hellsten-Westing (1997) demonstrated the presence of XOR in cardiac and skeletal 
muscle by the use of an immunoaffinity method, and suggested that in view of the 
overall low or negligible XOR activity in heart tissue homogenates, tissue injury may be 
initiated at localised vessel sites.
XOR has long been known to be present in relatively high concentrations in milk, 
where it is associated predominantly with the lipid globule membrane (Patton & 
Keenan, 1975). As noted above, although amounts of XOR in human and bovine milk 
are similar, enzyme in human milk has relatively low specific activity, approximately 2 % 
of that o f bovine milk XOR (Jarasch et al, 1986; Abadeh et al, 1992; Harrison, 1997; 
Sanders et al, 1997). Samesto et al (1996) found that the specific activity of human milk 
enzyme is significandy lower than that found in human liver and intestine.
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Circulating XOR
The existence of XOR activity in human serum has long been recognised, although 
levels have been reported to be very low in normal subjects (Yamamoto et al, 1996). 
However, several links have been made between disease states and elevated circulatory 
XOR. Significant increases have been found in incidents of liver (Ramboer et al., 1972; 
Shamma’a et al., 1973; Giler et al, 1975) and rheumatic (Miesel et al., 1993) diseases and 
following ischaemia-reperfusion (Friedl et al, 1991; Tan et al, 1993; Trewick et al, 1996). 
Because of the potential of free circulating XOR to generate harmful ROS, anti-(XOR) 
antibodies present in serum are especially relevant as they have the capacity to reduce 
the extent of such injury via inhibitory binding to the enzyme, or by clearance in the 
form of immune complexes. Antibodies to XOR have not only been reported to be 
present in human serum (Oster et al, 1974; Bruder et al, 1984; Harrison et al, 1990; Ng 
et al, 1990; Lewis et al, 1991), but have also been shown to be elevated in patients who 
had suffered a myocardial infarction (Harrison et al, 1990). These anti-(XOR) 
antibodies are suggested to be one of the few recognised examples o f naturally 
occurring and beneficial autoantibodies (Benboubetra et al, 1997). An earlier view was 
that these antibodies could arise from the ingestion of cows’ milk or its products, and 
Rzucidlo and Zikakis (1979) reported an increase in antibodies to bovine milk XOR 
with increase in milk consumption.
Possible roles of XOR
The ubiquitous localisation of XOR demonstrated by en2yme studies and 
immunohistochemistry indicate a multi-functional role of this en2yme. Its ability to
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generate ROS and free radicals has led to its implication in the pathogenesis of post- 
ischaemic tissue injury (McCord, 1985). On the other hand, such species may play a 
beneficial role in signalling (Moulton et al., 2000) or by exerting anti-microbial effects 
(Tubaro et al., 1980; Van den Munckhof et al., 1995).
Physiological roles
The earliest physiological role attributed to XOR is the catalysis of the oxidation of 
hypoxanthine and xanthine to uric acid. This rate—limiting reaction is the terminal step 
of the breakdown of ATP in the purine degradation pathway in man, whereby uric acid 
is an excretion product. An additional step in this pathway exists in non-primates, 
where urate oxidase catalyses the further oxidation of uric acid to allantoin. As a result, 
humans and most primates have higher uric acid concentrations than other mammals, 
and it has been suggested that physiological levels of uric acid are sufficient to inhibit 
XOR activity in man (Tan et al., 1993). Uric acid is a powerful antioxidant (Becker, 
1993) and has been proposed to act as a chelator of transition metals such as iron and 
copper (Chappie, 1997). Uric acid production in man is thought to occur mainly at the 
sites of the liver and intestine, where XOR has been found to be most abundant (Kelley 
et al., 1989). Although this is certainly an important role o f XOR, the enzyme has also 
been implicated in numerous alternative roles, based on its tissue-specific distribution 
and wide substrate specificity.
Xanthinuria, first described by Dent and Philpot (1954), is a disease resulting from a 
lack of functional XOR. It manifests itself by the accumulation of extracellular
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xanthine, sometimes known as xanthine stones. The fact that this disease is not life 
threatening is interesting, as it suggests that the participation of XOR in the catabolism 
of purines is not crucial. Gout, which is characterised by excess uric acid accumulation, 
can be effectively managed by treatment with allopurinol, a well-known inhibitor of 
XOR, which is able to lower serum uric acid in a dose-related manner.
There is evidence for participation of XOR in iron absorption and mobilisation in the 
small intestine and liver (Topham et al., 1982a; Cohen et al., 1985), utilising NADH and 
xanthine as reducing substrates to liberate iron from ferritin. Dietary intake studies on 
the intestine indicate that ingested iron, which is absorbed almost entirely in the ferrous 
state, is oxidised to the ferric state by XOR in the mucosal cell, which promotes the 
transcellular transport of iron. Dietary supplementation o f tungsten results in rapid 
inactivation of XOR in the intestinal mucosa, associated with a concomitant reduction 
of iron transport to blood (Topham et al., 1982b). Also within the liver, a detoxification 
role has been attributed to the enzyme, based on its wide substrate specificity, and its 
ability to rapidly catalyse the oxidation of drugs such as the thiopurines and 
methylxanthines, as well as being able to oxidise even relatively inefficient substrates 
that may have been ingested, such as deoxyacyclovir, an anti-herpetic prodrug, to 
acyclovir (Krenitsky et al., 1986).
XOR may fulfil a microbicidal function in milk, as suggested by Bjorck and Claesson 
(1979), and based on XOR-catalysed production of hydrogen peroxide and superoxide. 
The recent demonstrations that XOR can catalyse reduction of nitrates and nitrites to
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nitric oxide have rekindled interest in a microbicidal role for the enzyme, in the 
mammary gland, and the neonatal gut (Godber et al, 2000a, 2000b, 2001; Doel et al., 
2000, 2001).
ROS are increasingly recognised as cell signalling molecules, thereby implicating the 
enzyme in signal transduction processes (Khan & Wilson, 1995; Blake et al, 1997). In 
endothelial cells, XOR is localised extracellularly on surfaces apposing those of other 
closely neighbouring cells (Rouquette et al., 1998), implying a role in cell-cell interaction, 
perhaps through ROS. ROS are also known to participate in cell differentiation, 
metabolism of xenobiotics and the recruitment and activation of polymorphonuclear 
leukocytes (Granger et al, 1981).
XOR may be involved in a cascade of regulators in the inflammatory process (Harrison, 
2000). Interferon-y (IFN-y), an inflammatory cytokine, and some IFN-y inducers, have 
been demonstrated by several groups to upregulate expression and activity of XOR in 
various mammalian cell lines (Ghezzi et al, 1984; Dupont et al, 1992; Falciani et al, 
1994; Pfeffer et al, 1994). More recently, it has been found that tumour necrosis factor- 
a  (TNF-a) and interleukin-1 (IL-1), result in the upregulation and post-translational 
activation o f XOR (Page et al, 1998). These cytokines appear to target endothelial cells, 
in a process by which the cells respond by upregulating cell adhesion molecules. XOR- 
derived ROS have been proposed to mediate the upregulation of such transcription 
factors, which in turn mediate molecules involved in neutrophil adhesion, and thus may 
play a significant role in inflammatory processes. Lipopolysaccharide, bacteria and
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protozoa have been reported to have a similar enhancing effect on XOR activity 
(Tubaro et al, 1976; Carpani et al, 1990).
Pathological roles of XOR
Proposed pathological roles of XOR primarily involve production of ROS. XOR- 
derived ROS have been implicated a wide range of pathological conditions, particularly 
in inflammatory disorders. Examples of such conditions include respiratory distress 
syndrome, endotoxemia, myocardial infarction, hypertension, rheumatoid arthritis, 
atherosclerosis and ischaemia-reperfusion (I-R) injury (Granger et al, 1986; McCord, 
1987; Sussman & Bulkley, 1990; Winrow et al, 1992; Zweier et al, 1994; Burton et al, 
1995).
Ischaemia -  reperfusion (I-R) injury
I-R injury is characterised by tissue damage caused by the re-oxygenation of tissues, or 
reperfusion, that have been subjected to a period of oxygen deprivation, or ischaemia 
(McCord, 1985). Ischaemia is a widely occurring event, which usually takes place during 
surgery, under conditions o f shock and stress or following organ transplantation. A 
mechanism for I-R injury was first proposed by Granger et al (1981), and involves ROS, 
generated from XO after a period of ischaemia. According to this hypothesis, the 
following sequence of events occurs. During an ischaemic event, tissues are unable to 
maintain energy production, leading to a net catabolism of ATP, in turn, resulting in an 
accumulation of cellular hypoxanthine. As the ATP levels drop, the cells lose their 
ability to maintain low intracellular calcium levels, which are dependent upon the
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Na+/Ca2+ exchanger and Ca2+-ATPase, resulting in an influx of calcium. The high levels 
of calcium stimulate calmodulin-dependent activated proteases, which are thought to 
trigger conversion of naturally-occurring XDH to XO. When oxygen is reintroduced, 
during the reperfusion period, XO proceeds to oxidise the accumulated hypoxanthine, 
resulting in the concomitant generation of superoxide anion and hydrogen peroxide, 
which can further react to produce the more reactive hydroxyl radical. The subsequent 
actions of these ROS are responsible for tissue damage, taking the form of lipid 
peroxidation at the cellular membrane, and degradation of hyaluronic acid, a constituent 
of collagen. This hypothesis has formed the basis for most of the recent research on 
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Figure 1.6 Proposed mechanism for XOR involvement in I-R injury 
(Granger et al., 1981)
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Several approaches have attempted to alleviate I-R associated injuries. Many 
investigators have found free radical scavengers or antioxidant enzymes to reduce the 
extent of reperfusion injury and improve postischaemic function in a variety o f tissues, 
including heart, lung, kidney and brain (Cerutti et al, 1988; Taylor et a l, 1989). Recent 
electron paramagnetic spectroscopy techniques used to measure free radical generation 
in the ischaemic heart have demonstrated a burst of oxygen free radical generation 
following postischaemic reperfusion (Zweier, 1988). XOR inhibitors such as 
allopurinol have been shown to have a positive effect against such injury in both in vitro 
and in vivo model systems (Chambers et al., 1985; Charlat et al., 1986). Methylene blue 
has additionally been shown to have a tissue-protective effect, suggested to be due to its 
ability to act as an alternative electron acceptor in the catalysis of purines by XOR, 
thereby inhibiting superoxide formation (Kelner et al., 1988; Salaris et al., 1991).
However, considerable controversy still remains regarding the process by which 
ischaemia-reperfusion triggers XO-mediated free radical generation (Zweier et al, 1995). 
Some studies have failed to show conversion of XDH to XO during ischaemia in rat 
liver (McKelvey et al., 1988; Kooij et al., 1994; Frederiks & Bosch, 1995). One study 
found that although XDH to XO conversion took place in ischaemic rat liver, this was 
not followed by a comparable increase in other parameters indicating liver damage, and 
it was suggested that such XO formation during ischaemia is only a secondary event 
(Cighetti et al, 1994). Other studies have shown that the XDH-XO conversion 
proceeds only very slowly during prolonged ischaemia and appears to be a consequence 
of cellular injury rather than the initiating factor (Engerson et al., 1987; McKelvey et al,
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1988; Gonzales-Flecha et al, 1993; Brass, 1995). It has been postulated that, as a 
consequence of I-R injury, XDH may be released from intracellular locations into the 
circulation where the conversion to XO may occur, causing additional tissue or cellular 
injury (Kooij et al, 1994). Recent data indicate that such circulatory XOR can bind to 
vascular cells, impairing cell function via oxidative mechanisms (Houston et al, 1999).
A major objection to the involvement of XOR in I-R in the heart is the apparent lack of 
enzyme in this tissue. The heart has been reported several times to be low in, or devoid 
of, detectable endogenous XOR activity. Eddy et al. (1987) could not detect any such 
activity in the human heart and concluded that the enzyme is unlikely to be a significant 
source of ROS in the ischaemic heart. It is possible that superoxide and hydrogen 
peroxide may be derived from sources other than XOR in vivo, a point which has been 
raised by many investigators based on experimental models expressing both high 
(Gonzalez-Flecha et al., 1993; Cighetti et al., 1994) and relatively low (Joannidis et al., 
1990; Dorion et al., 1993) levels of XOR activity. Such alternative sources of ROS may 
include the mitochondrial respiratory chain and neutrophil NADPH oxidase, although 
evidence derived from a knockout mouse study has questioned the significance o f the 
latter in free-radical mediated tissue injury (Kubo et al., 1996). The enzymes cyclo- 
oxygenase, lipoxygenase and nitric oxide synthase have been cited as additional 
candidates (Zimmerman, 1995). However, a recent investigation using a combination 
of immunoaffinity and biochemical methods to measure XOR expression and activity 
has found that both expression and activity were elevated in the failing rat heart but not 
in the hypertrophic ventricles, suggesting a possible role of the enzyme in the transition 
from cardiac hypertrophy to failure (de Jong et al., 2000). It is worth noting however,
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that this latter data has been obtained in rats, and it is possible that such a role may not 
apply in humans.
Human XOR
To date, XOR has been purified from only a few human tissues. An affinity 
purification of XOR from human liver (Krenitsky et al, 1986) was reported to have 
specific activity very similar to that of XOR from bovine milk. Activity and enzyme- 
linked immunosorbent assay (ELISA) studies of small intestine also showed relatively 
high XOR activity (Samesto et al., 1996), although the pure enzyme has not been 
isolated from this tissue as yet.
Abadeh et al. (1992) purified XOR from breast milk, which showed a very low specific 
activity towards conventional reducing substrates, yet shared similar physical properties 
with bovine milk XOR. This lack of activity was shown to be due to the high 
proportion of inactive demolybdo and desulpho forms of XOR in human milk (Godber 
et al., 1997; Bray et al., 1999). An analogous pattern of low activity was also observed in 
XOR immunopurified from human heart (Abadeh et al., 1993), leading to the suggestion 
that tissue-specific isoforms of XOR might exist, accounting for such disparity in XOR 
activity (Harrison, 1997). An alternative explanation might include some form of post- 




XOR from bovine milk fat globule membrane has been intensively studied for many 
years, and in its pure form for over five decades. Its physicochemical properties have, 
accordingly, been explored in detail. Significantly less is known about the human 
enzyme. XOR from the breast milk fat globule membrane has been purified and 
characterised, showing surprisingly low specific activity to xanthine and related 
substrates. In contrast, the less-studied enzyme from liver appears to display a relatively 
high specific activity to xanthine.
In view of indications that the activity of human XOR is variable and tissue-specific, the 
present work aimed to develop a purification procedure for the isolation and the 
subsequent characterisation of XOR from human liver. A procedure so-developed 
could be applied to other human tissues, which, like liver, contain many more proteins 
than does the milk fat globule membrane. A primary aim of this work was to use rabbit 
polyclonal antibodies against the human milk XOR as a tool in the affinity purification 
o f enzyme from bovine liver, which could be used as a model for the purification of 
XOR from human liver. Characterisation of anti-(XOR) antibodies, polyclonal and 
monoclonal, constituted another aim of this thesis, with an investigation into their 
potential use in histochemical localisation in tissues.
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3. General Materials and Methods
3.1 Materials
3.1.1 Chemicals
Bovine milk xanthine oxidoreductase (from buttermilk) was obtained from Biozyme, 
Blaenavon, Gwent. Bio-Rad protein assay reagent was purchased from BioRad, Hemel 
Hempstead, Hertfordshire. DL-dithiothreitol (DTT) was obtained from Alexis 
Corporation. Sephadex G25 PD-10 buffer exchange columns were obtained from 
Pharmacia, Uppsala, Sweden. All other chemicals were obtained from Sigma - Aldrich, 
Poole, Dorset, unless stated otherwise.
3.1.2 Column chromatography matrices
Sephadex G-25 in the form of a PD-10 prepacked column was obtained from 
Pharmacia Biotech, Uppsala, Sweden.
3.1.3 Instruments
SDS-PAGE was performed using a Bio-Rad mini protean II electrophoresis cell, and 
Western blotting was carried out using a Pharmacia Biotech nova blot apparatus. 
Absorbance spectra, Bio — Rad protein estimations, urate and NADH oxidase enzyme 
assays were performed on a Cary 100 Bio UV-Visible Spectrophotometer.
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Fluorescent pterin assays were measured using a Perkin Elmer luminescence 
spectrometer LS50B. ELISA plates were read on a Tecan Spectra plate-reader 
(Rainbow Thermo).
3.2 General Methods
3.2.1 SDS-PAGE and Western blotting
3.2.1.1 SDS-PAGE
SDS-PAGE was carried out according to the method of Laemmli (1970), using vertical 
slab gels. Samples to be electrophoresed were diluted 1:1 with reducing sample buffer 
(62 mM Tris, pH 6.8, 10 % (Yv) glycerol, 2 % (Vv) SDS, 5 % (Vv) P-mercaptoethanol, 
1.25 % (Vv) bromophenol blue), vortexed briefly then boiled for 3 min. Separating gel 
was made up of distilled H20 ,  10 % (Yv) acrylamide, 2.67 % (Yv) N ’N bis methylene 
acrylamide, 375 mM Tris, pH 8.8, 0.1 % ( 7 V) SDS, 0.05 % ( 7 V) APS and 0.05 % ( 7 V) 
TEMED (NNN’N ’-tetramethylethylenediamine). The gel was left to set, during which 
the stacking gel was made, consisting of distilled HzO, 4 % acrylamide, 0.9 % N ’N bis 
methylene acrylamide, 125 mM Tris, pH 6.8, 0.1 % (Vv) TEMED. This was layered 
onto the separating gel and the gel comb placed. Once the stacking gel had set, the well 
comb was removed and the samples were loaded into the wells. The electrophoresis 
was carried out at 75 V initially, in a tank containing running buffer consisting of 0.192 
M glycine, 0.025 M Tris, 0.1 % (Vv) SDS, pH 8.3, diluted 1:10 with distilled H20 ,  and 
once samples had passed into the separating layer, the voltage was increased to 200 V.
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Electrophoresis was complete when samples had run off the gel. Once elecrophoresis 
had been completed, unless used for electrotransfer, the gel was removed and stained 
with Coomassie blue stain [45 % (Yv) methanol, 10 % (Yv) acetic acid and 0.1 % (Vv) 
Coomassie Brilliant Blue] for 1 h on a shaking platform, and then destaining solution [5 
% (Yv) methanol and 7.5 % (Yv) acetic acid] for 3 h at room temperature to visualise 
proteins.
Molecular weights were estimated by the construction of a standard curve of log 
molecular weight (Mr) against the relative mobility (Ri), calculated from the total 
migration distance o f the protein divided by that o f the dye front. This was done with 
the high molecular weight standard markers (Sigma-Aldrich) and the molecular weights 
of unknowns were read using the curve.
3.2.1.2 Western transfer
Four pieces of extra thick filter paper and a single piece of nitrocellulose membrane, 
corresponding to the she of the gel were soaked in transfer buffer (20 mM Tris-HCl, 
containing 150 mM glycine, and 20 % (v/v) methanol, pH 8.3). Two pieces of filter 
paper were placed on the graphite anode plate of the transfer apparatus, also wetted 
with transfer buffer, followed by the layer of nitrocellulose, then the separating gel, 
from which the stacking gel had been discarded, was placed on top of the nitrocellulose. 
The sandwich was completed with the addition o f the remaining two filter papers on 
top of the gel. The cathode plate, also wetted with transfer buffer was placed on top 
and the transfer run at 0.8 mA/cm2 for 2 h. To determine whether the transfer had
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been complete, colour (rainbow) markers were used, or the membrane was stained with 
Ponceau S Red and the gel stained with Coomassie blue to visualise proteins.
3.2.1.3 Immunoprobing
Primary antibodies used: affinity—purified polyclonal rabbit anti—(HMXOR), polyclonal 
rabbit anti—(BMXOR) (Chemicon International), monoclonal mouse anti-(HMXOR) 
(clone 1D9D1 in the majority of cases) kindly supplied by Eurogenetics, Belgium. 
Secondary antibodies: anti—(rabbit IgG) (whole molecule) peroxidase conjugate available 
from Sigma—Aldrich, Dorset, or mouse immunoglobulins peroxidase conjugate available 
from DAKO A/S, Denmark.
Following transfer, the nitrocellulose membrane was rinsed with distilled H20  and then 
washed with TBS [10 mM Tris, 0.9 % (Vv) NaCl, pH 7.4] for 5 min at room 
temperature on a shaking platform. The TBS was replaced with 2 % BSA /  TBS to 
block non-specific binding sites and the membrane was incubated overnight at 4 °C. 
Washing was performed in triplicate with TBS-T [TBS containing 0.05 % Tween 20] on 
a shaking platform at room temperature, for 5 min/wash. The membrane was then 
incubated with primary antibody [1:1000 dilution in TBS-T and 1 % (Vv) BSA] and 
incubated for 2 h on a shaking platform at room temperature. The membrane was 
washed three times with TBS-T, and the secondary antibody [1:1000 dilution in TBS-T 
and 1 % ("/ v) BSA] was applied. The membrane was incubated for 1 h 30 min on a 
shaking platform at room temperature. Following incubation, the membrane was 
washed three times with TBS-T and then finally with TBS. To visualise XOR protein,
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the membrane was incubated with 4-chloro-2-napthol [3 mg/ml solution in methanol; 
16.6 % (7 V)], 83.3 % (7 V) TBS and 0.04 % (7 V) H20 2 [30 % ( 7 W) volume)] in a final 
volume of 10 ml.
3.2.2 Gel filtration using a Sephadex G-25 PD-10 column
Samples were run through a PD-10 column, prior to further column chromatography or 
assays, for buffer exchange purposes and the removal o f low molecular weight 
endogenous inhibitors, the presence of which might affect assay results. The column 
was equilibrated with desired buffer (25 ml), and sample was applied in a final volume 
o f 2.5 ml and allowed to run into the column. The same buffer (3.5 ml) was applied to 
the column and the eluate collected, composing of the larger proteins.
3.2.3 Protein estimation
Total protein content of samples was estimated using the method of Bradford (1976). 
Bovine serum albumin (1 mg/ml) was used to construct a standard curve ranging from
2-10 jLlg, diluted with assay buffer to a final volume of 100 pi. Standard and unknown 
protein samples were added to Bio-Rad protein assay reagent (1 ml) and allowed to 
develop for 15 min. Absorbances were measured in acrylic cuvettes at 595 nm and 
protein concentration was calculated from a linear standard curve.
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3.2.4 XOR activity assays
3.2.4.1 Pterin assay
The sensitive fluorimetric pterin assay was carried out according to the method of 
Beckman et al. (1989) with a few modifications.
The fluorimeter was used with an excitation wavelength of 345 nm and an emission 
wavelength of 390 nm with 5 nm band width slits. All assays were performed at 25 °C. 
Samples were diluted with assay buffer [50 mM potassium phosphate buffer, containing 
0.1 mM EDTA, pH 7.4] in 1 ml quartz fluorimeter cuvettes] to a final volume of 1 ml. 
A stable baseline was first obtained before the addition of substrates. The reducing 
substrate, 10 pM pterin, was added first, and the cuvette contents mixed by inversion, to 
determine the oxidase activity of the XOR-containing sample. The production of the 
fluorescent product isoxanthopterin from pterin, catalysed at the molybdenum site of 
the enzyme, corresponds with an increase in fluorescence. To assess total activity of 
XOR, 10 pM methylene blue in addition to the pterin was added. After measuring the 
resulting reaction rate, the reaction was stopped with the addition o f 50 pM allopurinol.
In order to calibrate the reaction and to provide an internal standard accounting for 
quenching of fluorescence and light scattering of the sample, sequential additions of 10 
pM isoxanthopterin (performed five times) were conducted. The reaction rate was 
calculated and expressed in pmol isoxanthopterin/min/mg total protein. Total protein 
was estimated by the Bio-Rad protein assay.
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3.2.4.2 Urate assay
This assay is a less sensitive method of measuring XOR activity than the fluorimetric 
method (Section 3.2.4.1). The rate of formation of uric acid from xanthine by the 
enzyme was followed at 295 nm at 25 °C, using an absorption coefficient of 9.6 mM 
T m 1 (Avis et al,!, 1956). The assay mixture consisted of sample diluted in 50 mM Na- 
Bicine buffer, pH 8.3, in a 1 ml cuvette to which 100 pM xanthine (100 pi) was added 
to measure the oxidase form of XOR. 500 pM NAD+ (100 pi) was then added to the 
reaction mixture, to provide total activity measurement of XOR. The corresponding 
dehydrogenase activity was calculated by subtracting the oxidase rate from the rate for 
total activity.
3.2.4.3 NADH oxidase assay
The NADH oxidase activity of XOR was measured by following the depletion of 
NADH, forming NAD+, at 340 nm at 25 °C in air — saturated 50 mM MOPS, pH 7.5. 
The absorption coefficient used was 6220 M^cm'1 for NADH (Horecker & Komberg, 
1948). The assay mixture consisted o f sample diluted in MOPS buffer in a 1 ml acrylic 
cuvette, to which 50 pM NADH was added, and the resulting decrease in absorbance 
was followed.
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3.2.5 Enzyme -  linked immunosorbent assay (ELISA)
3.2.5.1 ELISA for the determination of XOR protein
ELISA kits used for this purpose were kindly donated by Eurogenetics, Belgium. Plates 
coated with HXO standards were prepared by reconstituting the contents of a vial 
(containing lyophilised HMXOR) with zero standard/sample diluent (1 ml) to obtain a 
stock solution o f 80 ng/ml. Serial dilutions from this stock were made corresponding 
to 40, 20, 10, 5, 2.5 and 1.25 ng/ml. Unknown samples were prepared at a range of 
dilutions in zero standard/sample diluent.
Standards and samples were added to the wells in a total volume of 120 pi, with 
unknown samples being in triplicate. Plates were sealed and incubated for 120 + /-  10 
min at 37 °C. Plates were washed following incubation five times by soaking and 
inverting with Washing Buffer (400 pi/well, 5 min per wash) at room temperature on a 
shaking platform.
Bio tin—anti— (HXO) conjugate (100 pi) was added, and sealed plates were incubated for 
60 + /-  5 mins at 37 °C. Washing was repeated as before. Mixed solution A [citrate — 
phosphate buffer with peroxide at working strength] and B [3, 3,-5, 5’ 
tetramethylbenzidine solution] (100 pi of each) was added to the wells and incubation 
was carried out for 20 + /-  2 min at room temperature. Finally Stopping Solution 
(sulphuric acid, 50 pi) was added to the wells and plates were read at 450 and 650 nm.
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3.2.5.2 ELISA for the determination of titre of polyclonal antibodies to
XOR
Purified HMXOR was suspended in Coating Buffer [50 mM Na-carbonate, pH 9.6] to a 
final concentration of 10 pg/ml. The enzyme was added to wells (100 pi/well) and 
plates were incubated overnight at 4 °C. Wells were washed with PBS-T in triplicate 
[PBS containing 0.01 % (Vv) Tween 20, 400 pi/well] and then blocked with PBS-T 
containing 1 % (Vv) BSA (200 pl/well) for 1.5 h at room temperature. Washes were 
performed as before.
Serial dilutions of normal rabbit serum (NRS) and immune rabbit sera (in PBS-T 
containing 1 % (Vv) BSA) were performed and these were added to the wells in 
triplicate. Incubation of the plates for 2 h at 37 °C was carried out. Plates were washed 
with PBS-T as before.
Secondary antibody [anti—(rabbit IgG) (whole molecule) peroxidase conjugate, diluted 
1:5000 in PBS-T containing 1% (Vv) BSA, 100 pl/well) was added and the plates were 
incubated for 1.5 h at room temperature. Following incubation, plates were washed as 
described previously, and substrate [1 % TMB in DMSO, diluted 1:100 in 0.5 M Na- 
acetate-citrate buffer, pH 6, with 30 % (w/ v) aqueous hydrogen peroxide added just 
before use, 100 pl/well]. Colour was left to develop and 0.05 M sulphuric acid (50 
pl/well) was added to stop the reaction. After 5-10 min, plates were read at 450 nm.
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3.2.6 Aldehyde oxidase (AO) activity assay
Aldehyde oxidase activity in samples was determined at 300 nm, with 1- 
methylnicotinamide as substrate, at 25 °C, in 50 mM potassium phosphate, pH 7.8, 
using an extinction coefficient of 4.17 mM'1 cm'1 (Felsted et al., 1973).
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4. The purification of human milk xanthine
oxidoreductase (HMXOR)
4.1 Introduction
XOR was first purified from bovine milk in 1939 (Ball, 1939), in a form that was 
sufficiently pure to provide a visible spectrum, showing the presence of flavin and 
possibly another chromophore, later discovered to be iron. The bovine enzyme 
(BMXOR) has since been routinely purified and extensively characterised, because of its 
relative ease of extraction and its abundance in milk (Bray, 1975). Originally named 
aldehyde oxidase (Schardinger, 1902), BMXOR has since proved to be a model for the 
whole class of complex molybdoflavoproteins (Massey & Harris, 1997).
A purification procedure was developed in 1955 by Avis et aL, which yielded crystalline 
XOR. Its UV-visible spectrum gave a protein (280 nm) to flavin (450 nm) ratio (PFR) 
of between 5.0 and 5.2, which was later accepted to be indicative of a very high level of 
purity. This procedure utilised a protease (pancreatin), in the initial steps of preparation, 
which was found to selectively denature and precipitate contaminating casein. Protease 
treatment was followed by pressure filtration and adsorption on a calcium phosphate 
column. More reports describing the preparation of pure XOR from bovine milk and 
other animal sources followed in subsequent years, the majority of which were relatively 
harsh by current standards, involving heat and acid treatment, drying, solvent extraction 
and exposure to pro teases (Massey & Harris, 1997).
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Much of the XOR in milk is reported to be associated with the milk fat globule 
membrane, thought to be direcdy derived from the mammary gland secretory cell. 
Proteolysis has been found to release enzyme from this membrane (Briley & Eisenthal, 
1974; 1975). The use of proteases during purification results in a preparation consisting 
almost entirely of the oxidase form of the enzyme. It is unsurprising, therefore, that not 
until 1969 was it recognised that there also exists a dehydrogenase form of XOR. Stirpe 
and Della Corte (1969) reported the apparent activation of rat liver XOR in the 
presence of proteases, and went on to propose that proteases were able to induce 
irreversible XDH-XO conversion (see the Introduction section). Nakamura and 
Yamazaki (1982) found that, by including dithiothreitol (DTT, 2.5 mM) throughout 
their purification procedure, they could produce XOR consisting of 94 % 
dehydrogenase form. Upon removal of DTT, reversible conversion to XO occurred; a 
conversion that they ascribed to the oxidation of sulphydryl groups.
Purification procedures for the isolation of XOR from milk have generally employed 
centrifugation of whole milk to separate out the cream, followed by butanol treatment 
and two-step ammonium sulphate precipitation. Various affinity chromatographic steps 
followed. Calcium phosphate, or hydroxyapatite chromatography, has been widely used 
and typically gives an increase in purity accompanied by litde loss of enzymic activity. 
Other steps include gel filtration and anion exchange chromatography. A novel affinity 
chromatographic method was reported by Nishino et al. (1981) using folate, a 
competitive inhibitor of XOR, covalendy bound to Sepharose. Folate can only bind 
molybdenum-containing, or active enzyme, and is therefore also able to resolve active
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and inactive forms of XOR. The folate affinity method was based on a previously 
reported procedure in which an allopurinol analogue, used also as an affinity ligand, was 
shown to facilitate separation of active forms of XOR (Edmondson et al., 1972). This 
supported the earlier claim by Morell (1952) that XOR preparations contain non­
functional enzyme.
There have been few reports on the purification of human milk XOR (HMXOR), 
largely because activity assays led to the conclusion that it was essentially absent in this 
source. Zikakis and McGinnis (1987) obtained a crude enzyme preparation from 
human colostrom using a combination of salt precipitation, batch-wise hydroxyapatite 
chromatography, gel filtration and anion exchange chromatography. Their preparation 
had a molecular weight of 322 kDa and displayed multiple bands on SDS-PAGE gel, 
along with evidence of aggregation. Graham et al. (1989) purified HMXOR, by using 
salt precipitation followed by hydroxyapatite chromatography, for the purpose of raising 
antibodies. Their preparation was contaminated by caseins, and as it had a molecular 
weight of 120 kDa, as judged by SDS-PAGE, it was very likely proteolysed. Hellsten- 
Westing (1993) purified HMXOR in a similar manner using salt precipitation followed 
by anion exchange chromatography, also for the purpose of raising antibodies. Again, 
their purified enzyme was not characterised, and its purity was not mentioned. Abadeh 
et al. (1992) obtained relatively pure HMXOR, using a method based on that of 
Nakamura & Yamazaki (1982) used for BMXOR purification. This procedure involved 
solubilisation of enzyme with butanol, and ammonium sulphate precipitation, followed 
by calcium phosphate chromatography. Yields of enzyme were comparable with those
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obtained from bovine milk, having a PFR of 5.13, and indicating a high degree of purity. 
This method was developed further within our laboratory with the replacement of the 
calcium phosphate chromatography step (which rapidly lost efficiency with use) by 
heparin chromatography (Sanders et al1, 1997). This followed the findings of Adachi et 
al (1993), who demonstrated the binding of HMXOR to heparin in a study of XOR 
binding to cell surfaces. Subsequently, Fukushima et al. (1995) showed that XOR was 
able to bind to sulphated glycosaminoglycans, through lysine and arginine rich peptides. 
Kjellen and Lindahl (1991) have reviewed the use of heparin in purification of 
proteoglycans. In our laboratory, the use of heparin cross-linked to 4 % agarose has 
allowed consistent purification of both BMXOR and HMXOR, in high yields, and with 
good recovery of enzyme activity.
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4.2 Materials and Methods
4.2.1 Materials
Frozen human milk was kindly donated by mothers in the Special Care Baby Units of 
the Royal United Hospital, Bath; Southmead Hospital, Bristol; Bristol Royal Infirmary 
and Princess Margaret Hospital, Swindon. Fresh bovine milk was obtained from a local 
dairy herd in Claverton, Bath. Heparin-agarose (Type I) was obtained from Sigma- 
Aldrich, Poole, Dorset. Hitrap Q ion exchange columns were obtained from 
Pharmacia, Uppsala, Sweden. Syringe filters were acquired from Whatman, Maidstone, 
Kent. All other chemicals were obtained from Sigma-Aldrich, Poole, Dorset.
4.2.2 Methods
4.2.2.1 Preparation of crude HMXOR
XOR was purified from human milk essentially as described by Godber et al. (2000). 
The method used is mild, causing minimal proteolysis and degradation of the enzyme.
Fresh bovine milk (or thawed human milk) (1500-2000 ml) was centrifuged at 2000 g 
for 30 min at 4 °C to separate the cream. All subsequent operations were carried out at 
4 °C. The cream was resuspended in 5 vols 0.2 M K2H P 0 4, containing 1 mM EDTA 
and 4 mM DTT, with stirring for 90 min. The suspension was centrifuged at 3000 g for 
30 min, and the subnatant was collected. The subnatant was filtered through glass wool
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and 15 % (Vv) ice-cold butanol was added. Ammonium sulphate (15 g/100 ml) was 
added slowly to the subnatant with stirring, and stirring continued for 1 h. 
Centrifugation at 8000 g for 20 min followed and the resulting supernatant was filtered 
through glass wool. Ammonium sulphate (20 g/100 ml) was then added slowly to the 
supernatant with mixing, and the suspension was stirred for a further 30 min before 
centrifugation at 9500 g for 30 min. The resulting brown precipitate was collected and 
resuspended in a small volume of buffer (25 mM Na-phosphate, containing 1 mM 
EDTA, pH 7.4). Dialysis against the same buffer (3.5 1) overnight followed. Any 
remaining precipitate was removed by centrifugation at 10000 g for 60 min, and the 
supernatant was syringe-filtered through a 0.22 pm membrane prior to heparin 
chromatography.
4.2.2.2 Heparin chromatography
The crude en2yme preparation was subjected to affinity chromatography on heparin- 
agarose. It was applied (flow rate 20 ml/h) to a column (1 cm x 9 cm) of heparin 
immobilised on cross-linked 4 % beaded agarose pre-equilibrated in equlibration buffer 
(25 mM Na-phosphate, containing 1 mM EDTA, pH 7.4). The column was initially 
washed with the equilibration buffer, to remove unbound protein, followed by 0.05 M 
NaCl added to the same buffer (20 ml). Elution of XOR was carried out with 0.4 M 
NaCl added again to the same buffer. Washing of the column following elution was 
performed with 1 M NaCl added to the equilibration buffer.
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Alternatively, for the purification of BMXOR, 25 mM Na-phosphate, pH 7.4, was 
replaced by 25 mM sodium MES, pH 6, and elution was performed with 0.25 M NaCl 
added to this buffer.
4.2.2.3 Ion-exchange chromatography using HiTrap Q
Further purification of milk XOR, if necessary, was effected by ion-exchange 
chromatography on HiTrap Q. Protein eluted from the heparin column was dialysed 
into 50 mM Na-Bicine, containing 0.05 M NaCl, pH 8.3, syringe-filtered through a 0.22 
pm membrane and applied to an equilibrated Hitrap Q ion-exchange column (5 ml) at a 
flow rate of 1 ml/min for fast protein liquid chromatography (FPLC). Bound protein 
was eluted by an increasing salt gradient from 0.05 M NaCl to 0.5 M NaCl in 50 mM 
Na-Bicine, pH 8.3, over a period of 30 min. Enzyme-containing fractions were pooled 
and concentrated. Following purification, enzyme was drip frozen into liquid nitrogen 
and stored at —70 °C until further use.
4.2.2.4 Calculation of protein to flavin ratio (PFR)
In order to assess the purity of samples of enzyme, it was necessary to scan them to 
obtain their UV-visible absorbance spectra. Spectra were typically measured from 700 
nm to 250 nm. The ratio of protein (280 nm) to flavin (450 nm) was calculated as 
A280/A 450 t°  give a convenient measure of purity. XOR concentration was also derived
from the spectra, using the extinction coefficient, E450 of 36000 M 1 cm'1; a value which
assumes fully functional enzyme (Bray, 1975).
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4.3 Results
HMXOR was purified from frozen human milk, as described in the Methods section. 
Yields of 10 mg purified enzyme were routinely obtained from 2000 ml milk, following 
ammonium sulphate precipitation, heparin-agarose chromatography and Hitrap Q ion- 
exchange chromatography. Typical purification data are shown in Table 4.3.1. Elution 
profiles from the heparin and Hitrap Q columns are shown in Figures 4.3.1 and 4.3.2 
respectively. Typical UV-visible spectrum and SDS-PAGE gels of purified enzyme are 
shown in Figures 4.3.3 and 4.3.4 respectively.
The purified HMXOR was used for many purposes including activity assays, SDS- 
PAGE analysis, immunisation of rabbits for the production of antibodies, and 
subsequent affinity purification of specific anti-(HXO) antibodies from rabbit serum.
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Milk 2000 2941 40290 73 100
Resuspended
cream








376 1088 327 3327 37
Purified XOR 
(post Mono Q)
7 382 9.2 41521 13
Table 4.3.1 Purification table
XOR activity was determined using the pterin assay (Section 3.2.4.1). Protein 
quantification was carried out using the Bradford method (Section 3.2.3).
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0.05 M NaCl 0.4 M NaCl 1 M NaCl
Elution Volume
Figure 4.3.1 Elution profile of purification of HMXOR from heparin-
agarose column
HMXOR eluted from the column is represented by the middle peak. Elution occurred 
with 25 mM Na-phosphate, containing 0.4 mM NaCl and 1 mM EDTA, pH 7.4.
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4.3.3 Elution of HMXOR from Hitrap Q ion-exchange column
UV Absorption 
(280 nm)
Figure 4.3.2 Elution profile of purification of HMXOR from Hitrap Q
ion-exchange column
Straight line (red) indicates the increasing salt concentration (from 0.05 NaCl to 0.5 M 
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Figure 4.3.3 Typical UV-visible spectrum of purified HMXOR
The above scan represents purified HMXOR after heparin followed by Hitrap Q ion- 
exchange. Enzyme so prepared typically had a PFR of 5.0 — 5.3.
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4.3.5 SDS-PAGE gel of purified HMXOR
Figure 4.3.4 7.5 % SDS-PAGE gel of purified HMXOR
An SDS-PAGE gel showing in lane 1, high range molecular weight standards, lane 2, 
ammonium sulphate fraction, lane 3, purified XOR after heparin chromatography, and 
lane 4, purified XOR after Hitrap Q ion-exchange.
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5. The affinity purification of bovine fiver xanthine
oxidoreductase (BLXOR)
5.1 Introduction
XOR has been isolated and well characterised from bovine milk, rat and chicken liver, 
and characterised to a lesser extent from human milk. It is known that high levels of 
XOR are present in the liver and small intestine of all species (Krenitsky et al, 1974), 
and it has been proposed that XOR and the enzyme aldehyde oxidase (AO), also 
present in high amounts in the liver, are together responsible for the detoxification of 
polar aromatic compounds, due to their overlapping substrate specificity (Krenitsky, 
1978).
In the organisms studied to date, XDH is the predominant form in mammalian tissues 
(Nishino, 1994), although mammalian XDH can be converted to XO through 
sulphydryl oxidation or proteolytic action (Waud & Rajagopalan, 1976). Because XDH- 
XO conversion is linked to generation of ROS and consequent reperfusion injury, 
considerable interest has been focussed on the XOR enzymes in different tissues. In 
order to study them it is necessary to achieve effective purification procedures for their 
isolation. Ikegami and Nishino (1986) reported a high yield purification of rat liver XOR 
to apparent homogeneity. Their procedure involved hydroxyapatite chromatography, 
after which folate chromatography was used to separate out inactive forms of the 
enzyme. A protein to flavin ratio of between 5.2 and 5.6 was obtained, typical of highly
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purified XOR protein. However, this preparation was found to contain both inactive 
desulpho-XOR and, to a lesser extent, demolybdo-XOR. These inactive forms 
accounted for up to 50 % of the purified enzyme and a similar level was also found to 
exist in crude preparations. Ikegami and Nishino (1986) suggested that desulpho-XOR 
might exist naturally in liver.
A decade later, McManaman et al. (1996) reported a novel affinity method for the 
isolation of rat liver XOR. This group commented that previous affinity methods often 
involved difficult synthesis and chromatography under anaerobic conditions 
(Edmondson et a l 1972). They also often involved lengthy procedures, with many 
chromatographic steps (Ikegami & Nishino, 1986; Abadeh et al., 1992), which may 
prove deleterious to the enzyme. McManaman et al. (1996) developed a purification 
procedure using immobilised benzamidine as an affinity ligand linked to Sepharose. 
The structure of benzamidine is similar to that of salicylate, another competitive 
inhibitor of XOR (Bergel & Bray, 1959). Benzamidine is also a well-known inhibitor of 
serine proteases, for which it serves as an affinity adsorbent. Furthermore, it has been 
shown to be an effective inhibitor of aldehyde oxidase (AO), reflecting the overlapping 
substrate specificity of the two enzymes. The chromatographic procedure employed by 
McManaman and colleagues was carried out at a pH of 9, and elution effected with 25 
mM benzamidine. This step was used in conjunction with heat treatment and 
ammonium sulphate precipitation as first and second steps respectively. By this method 
they obtained a near 200-fold purification and an XOR preparation almost free of 
contaminating proteins.
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In contrast to XOR from bovine milk, the enzyme from bovine liver has been little 
studied. In a histochemical study of bovine liver, XOR was shown to be localised 
exclusively to the cytoplasm of capillary endothelial cells, with no expression seen in the 
hepatocytes or Kupffer cells (Jarasch et al^  1981). Current views on the cellular 
localisation of XOR in humans are mainly based on this study on bovine organs.
One report exists concerning the purification of XOR from bovine liver (Cabre & 
Canela, 1986). These workers reported a good recovery and outlined some properties 
of their purified enzyme (BLXOR). Their procedure involved a combination of heat 
treatment, acetone precipitation, and hydroxyapatite chromatography, followed by 
several more chromatographic steps. A protein flavin ratio of 5.64 was quoted, and 
four bands were obtained on SDS-PAGE gel, the largest of which was 135 kDa, these 
findings probably indicative of a proteolysed preparation. The procedure appeared 
lengthy, and it has been reported that acetone precipitation can result in chemical 
modification of the molybdenum centre of XOR (Barber et al1,1976).
This Chapter explores potential methods for the purification of XOR from bovine liver, 
some of which have been derived from the successful milk XOR purification described 
in the previous Chapter.
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5.2 Materials and Methods
5.2.1 Materials
Fresh calves’ liver was obtained from a local butchers in Bath, and kept on ice until 
ready for use. Benzamidine-Sepharose 4B was obtained from Pharmacia, Uppsala, 
Sweden. Commercial bovine milk XOR was purchased from Biozyme, Blaenavon, 
Gwent. Dithiothreitol was purchased from Alexis Corporation. All other chemicals 
were obtained from Sigma-Aldrich, Poole, Dorset.
5.2.2 Methods
5.2.2.1 Homogenisation of liver and preparation of ammonium sulphate
fraction
All operations were carried out at 4 °C, and all equipment was cooled to 4 °C prior to 
use. Fresh bovine calves’ liver (30-50 g) was rinsed in ice-cold PBS, containing protease 
inhibitors as follows: 5 pM leupeptin, 10 pM chymostatin, 1 pM pepstatin A and 10 pM 
APMSF, with the addition o f 1 mM EDTA and 4 mM DTT. The liver was 
homogenised in a series of short bursts, using a Waring blender. The resultant 
homogenate was centrifuged at 5000 rpm, for 30 min. Ground ammonium sulphate 
was added slowly to the supernatant whilst stirring, to 35 % saturation (19.7 g/100 ml). 
The suspension was stirred for 1 h. Following stirring, the suspension was centrifuged 
at 10000 rpm for 35 min. Ammonium sulphate was added a second time to 60 % 
saturation (15.3 g/ml) and stirred for 1 h. Centrifugation was repeated, at 12500 rpm
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for 30 min. The resulting pellet was redissolved in PBS, or the appropriate buffer 
depending on the chromatography method chosen, containing 1 mM EDTA and 4 mM 
DTT, and dialysed against 3 1 of the same buffer overnight (with two changes). The 
dialysed ammonium sulphate liver fraction was syringe-filtered using a 0.2 pm 
disposable syringe filter. Prior to further purification, to remove small molecular weight 
inhibitors, such as purines, gel filtration was employed, using a Sephadex G-25 PD-10 
column (Section 3.2.2).
5.2.2.2 Benzamidine-Sepharose chromatography
This was carried out according to McManaman et al. (1996) with a few modifications. 
Post-ammonium sulphate bovine liver fraction was dialysed against 0.1 M glycine, 
containing 0.1 M NaCl and protease inhibitors (as in Section 5.2.2.1), pH 9.2. The pH 
was raised slighdy from 9 (McManaman et al., 1996) to 9.2, as this appeared to promote 
binding.
Benzamidine-Sepharose (5 ml) was poured into a column, and treated according to the 
manufacturer’s instructions. The liver fraction was applied to the benzamidine- 
Sepharose column equilibrated with 0.1 M glycine, containing 0.1 M NaCl, pH 9.2. The 
column was washed with 7 vol of this buffer. Weakly-bound protein was eluted from 
the column with 25 mM benzamidine added to the above buffer, whereas the more 
strongly bound protein, containing XOR, was eluted with the addition o f 50 mM 
benzamidine. Enzyme-containing fractions were collected in tubes containing 50 mM 
Na-Bicine, pH 8.3, for neutralisation purposes. Column cleaning and regeneration was
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achieved by alternately washing with several column volumes of 0.1 M Tris-HCl 
containing 0.5 M NaCl, pH 8.5, followed by 0.1 M Na-acetate, containing 0.5 M NaCl, 
pH 4.5.
5.2.2.3 Heparin chromatography
Heparin chromatography was performed essentially as described in Section 4.2.2.2, for 
the bovine milk purification. Protein eluted from the benzamidine-Sepharose column 
was dialysed against 25 mM sodium MES, containing protease inhibitors (as in Section
5.2.2.1), as well as 1 mM EDTA, and 4 mM DTT, pH 6. The dialysed protein was 
applied to a heparin-Sepharose column equilibrated in the same buffer. Washing of 
unbound protein was effected with 7 vol of the aforementioned buffer, followed by this 
buffer containing 0.08 M NaCl to remove weakly bound protein. Elution of more 
strongly bound enzyme-containing fractions was carried out with 25 mM sodium MES 
buffer, containing 0.25 M NaCl, pH 6. A final wash to clean the column was carried 
out using this buffer containing 1 M NaCl.
5.2.2.4 HiTrap Q ion-exchange
HiTrap Q ion-exchange was used as a final step, and this was carried out as described in 
Section 4.2.2.3 for the purification of XOR from milk.
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5.3 Results
5.3.1 The effect of benzamidine on commercial BMXOR
As an initial precaution in the development of a purification procedure to isolate 
BLXOR, it was necessary to ascertain the effects of eluants on the enzyme. Here, the 
effects of benzamidine were investigated, using commercially obtainable bovine milk 
enzyme (BMXOR). The specific activity of BMXOR was measured in the presence of 
50 mM benzamidine, in either Buffer A or Buffer B. Buffer A was 0.1 M glycine, pH 
9.2. Buffer B was 50 mM potassium phosphate, pH 7.4. This was compared with the 
specific activity of BMXOR in Buffer B alone.
Conditions of Assay Specific Activity 
(pm ol/m in/m g)
Buffer B alone 38480 ± 5344
Buffer A + 50 mM 
benzamidine 460 ± 58




Buffer B + 50 mM 
benzamidine 6260 ± 410
Table 5.3.1 Effect of benzamidine as eluant
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XOR activity was measured using the pterin assay (Section 3.2.4.1). Values are means ± 
SD (n = 3).
The assay showed that BMXOR in the presence of 0.1 M glycine, pH 9.2, containing 50 
mM benzamidine, resulted in a gready reduced activity, which represented 
approximately 1 % of the original activity. Removal of benzamidine by gel-filtration 
against 50 mM potassium phosphate, pH 7.4, regained approximately 72 % of the 
original activity. 16 % of the original activity remained in the presence of 50 mM 
potassium phosphate, pH 7.4, containing 50 mM benzamidine. This indicates that 
benzamidine is a more effective inhibitor at the higher pH.
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5.3.2 Benzamidine-Sepharose chromatography
Following ammonium sulphate precipitation, bovine liver extract was subjected to 
benzamidine-Sepharose chromatography, as described in Section 5.2.2.2.
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Figure 5.3.1 Elution profile of BLXOR from benzamidine-Sepharose
The above graph shows total protein (mg/ml) represented by the dark blue line, plotted 
with XOR activity (pmol/min/ml), represented by the red line. Arrow A refers to the 
addition o f 25 mM benzamidine, and arrow B refers to the addition o f 50 mM 
benzamidine. Total protein was estimated using the Bradford method (Section 3.2.3), 
and XOR activity was measured with the pterin assay (Section 3.2.4.1). XOR activity- 
containing fractions were eluted from the column with 50 mM benzamidine, and
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The dialysed XOR-containing eluate from benzamidine-Sepharose chromatography was 








Figure 5.3.2 Elution profile of BLXOR from heparin column
XOR activity was detected in the second major peak only, eluting from the column with 
0.25 M NaCl. Resulting XOR activity-containing fractions were pooled and dialysed 
into 50 mM Na-Bicine, containing 0.05 M NaCl, and protease inhibitors, pH 8.3, in 
preparation for HiTrap Q ion-exchange chromatography.
Chapter 5 64
5.3.4 HiTrap Q ion-exchange
The dialysed XOR-containing eluate from heparin chromatography was subjected to 







Figure 5.3.3 Elution profile of BLXOR from HiTrap Q ion exchange
column
The red diagonal line represents the salt gradient (0.05 M to 0.5 M NaCl). XOR activity 
was detected in the second major peak (Peak B) only, eluting from the column with 
0.4 M NaCl.
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5.3.5 SDS-PAGE gel and Western blot
The second major peak (peak B) from HiTrap Q ion-exchange chromatography was run 
on a 7.5 % SDS-PAGE gel. The purified protein was also subjected to Western blotting 
using a commercially obtainable anti-(BMXOR) antibody (Chemicon), and was run 
alongside purified HMXOR.




Figure 5.3.4 7.5 % SDS-PAGE gel and Western blot of affinity-purified
BLXOR
Lane 1 corresponds to bovine liver homogenate, lane 2 corresponds to affinity-purified 
BLXOR, and lane 3 corresponds to purified HMXOR. Western blotting was carried 
out as described in Sections 3.2.1.2 and 3.2.1.3, using a commercial polyclonal anti- 
(BMXOR) antibody. In the Western blot, lane 1 corresponds to bovine liver
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homogenate, lane 2 corresponds to affinity-purified BLXOR, lane 3 corresponds to 
purified HMXOR, and lane 4 corresponds to high range colour markers.
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5.3.6 Specific activity
Purified BLXOR was assayed for activity using the urate assay (Section 3.2.4.2). In 
order to ascertain that purified enzyme was BLXOR and not AO, which as mentioned 
earlier also has an affinity for benzamidine, the AO activity assay was performed 












(pm ol/m in/m g)
Fold
Purification




2.5 27 92 16
Benzamidine
pool
1.35 9.4 144 25
Heparin pool 1 1.4 713 124
Hitrap Q 
eluate 0.16 0.1 1581 275
Table 5.3.2 Purification table for XOR from bovine liver
Protein concentrations were determined using the Bradford method (Section 3.2.3). 
Specific activities were determined using the urate assay (Section 3.2.4.2).
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5.4 Discussion
Using a combination of three chromatographic techniques, namely benzamidine- 
Sepharose, heparin-Sepharose, and HiTrap Q ion-exchange, the latter two of which are 
used in the purification of XOR from milk, BLXOR was purified to apparent 
homogeneity as judged by SDS-PAGE gel. The purified enzyme yielded a major band 
of approximately 135 kDa. From the SDS-PAGE gel it can be observed that the liver 
enzyme runs at a slightly lower molecular weight than that of HMXOR. 
Immunoprobing was carried out with commercial polyclonal anti-(BMXOR) antibody. 
Strong staining of the 135 kDa band corresponding to BLXOR is apparent as well as a 
band of slightly higher molecular mass yielded by HMXOR. The overall purification 
achieved was approximately 275-fold.
Cabre and Canela (1986), who are responsible for the only reported purification of 
BLXOR, using a combination of five affinity chromatographic steps, with heat and 
acetone precipitation, obtained BLXOR showing four protein bands on SDS-PAGE 
gel. These bands corresponded to molecular weights of 135 kDa, 95 kDa, 45 kDa and 
15 kDa. This indicates a significantly more proteolysed enzyme than that obtained in 
the present work, which is represented by a band of approximately 135 kDa, with no 
additional bands observed upon gel electrophoresis or Western blotting.
The overall purification of 275-fold (Table 5.3.2) achieved in the present work was 
higher than the 199-fold purification for rat liver XOR obtained by McManaman et al 
(1996), from which the benzamidine-Sepharose method was slightly modified.
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McManaman et al. used a combination of heating, ammonium sulphate precipitation 
and chromatography on benzamidine-Sepharose. Modifications of the present work 
included raising the pH from 9 to 9.2, which appeared to promote binding (data not 
shown), and elution with a higher concentration of benzamidine (50 mM). 25 mM 
benzamidine, as used by McManaman et al, was found to be insufficient to release XOR 
from the column. This concentration of benzamidine (25 mM) was therefore 
incorporated as a washing step to remove non-specifically or weakly bound protein. It 
is likely that differences exist between XOR enzyme from different sources, altering 
their affinity for benzamidine and possibly also the efficiency of the overall purification. 
McManaman et al. (1996) found that although benzamidine inhibited bovine milk XOR, 
inhibition only occurred at very high concentrations (estimated Ki  greater than 100 
mM), in contrast to rat liver XOR.
A consideration that must be taken into account when using benzamidine 
chromatography for the purification of XOR is the potential co-purification of AO, 
which also has an affinity for benzamidine. In the early stages of the development of 
the purification, AO activity was monitored (Section 3.2.6), and activity was detected in 
initial liver homogenate but not following the second ammonium sulphate precipitation, 
of 60 % saturation. AO thus need not pose a co-purification problem when using 
benzamidine-Sepharose chromatography. In support of this, no AO activity was 
detectable in the purified XOR preparation.
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Heparin chromatography used as a second step provided an almost 5-fold purification 
from the benzamidine step (Table 5.3.2). The method was essentially the same as for 
the purification of XOR from bovine milk within the laboratory and different to that 
used for the purification of human milk XOR. It appears, therefore, that BLXOR and 
BMXOR express comparable binding affinities for heparin, which differ from those of 
HMXOR.
Protease inhibitors were included during both benzamidine and heparin 
chromatography. Benzamidine is a well-known serine protease inhibitor (Hixson & 
Nishikawa, 1974). Tryptase, a major protein in mast cells and also a serine protease, has 
been reported to associate with heparin and has indeed been isolated using heparin- 
Sepharose (Chan et al., 1999). This is of importance, because both benzamidine and 
heparin bind serine proteases. Precautions have been taken therefore, to ensure that if 
there are proteases present, these are inhibited and the enzyme thus protected from 
proteolysis.
HiTrap Q ion-exchange chromatography was performed according to the milk 
purification procedure (Section 5.3.4). This step was responsible for removing much 
contaminating protein in the form of both unbound and bound protein, as can be seen 
from the elution profile (Fig 5.3.3), in which peak A relates to bound contaminants. 
The combination of these three methods yielded 0.1 mg pure BLXOR from 35 g liver. 
This compares favourably with McManaman et al. (1996) who obtained a yield of 0.13 
mg pure rat liver XOR (RLXOR), from a similar starting amount of liver (10-30 g liver).
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The purified preparation exhibited a specific activity towards xanthine o f approximately 
1580 pm ol/m in/m g (Table 5.3.2). This activity is lower than that generally shown by 
purified HMXOR (0.3-0.1 pmol/min/mg) (Godber, B, Ph.D. Thesis, 1998). An 
explanation for this low specific activity might include irreversible inhibition by 
benzamidine. Treatment of BMXOR with benzamidine produced complete inhibition, 
yet the majority (72 %) of activity was regained upon removal of benzamidine (Table
5.3.1). However, prolonged incubations of enzyme with benzamidine and specific 
activity measurements were not carried out. In addition, it was not possible to carry out 
inhibition studies on the liver enzyme in its pure form, on which the inhibitor may have 
a more detrimental effect than on the milk enzyme.
Cabre and Canela (1986) obtained a protein flavin ratio from their purified bovine liver 
preparation corresponding to 5.64, although the absorption spectra from which this was 
calculated was not shown. Although it was attempted to acquire an absorption spectra 
from the purified enzyme described in this Chapter, the curve did not resemble the 
typical spectra produced by XOR, therefore it was unfeasible to calculate a protein 
flavin ratio in this instance. Reasons for the presence of an atypical spectrum may 
include proteolysis of the enzyme as a result o f purification, a feature much commented 
upon in previously reported purifications, or minor contamination, not apparent on 
SDS-PAGE gel analysis, ‘masking’ absorption of flavin and iron-sulphur centres, both 
of which are responsible for the characteristic peaks at wavelengths o f approximately 
350 nm and 450 nm.
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6. The purification of polyclonal anti-(HMXOR) IgG
6.1 Introduction
In order to clarify the pathophysiological role of XOR in humans it is vital to investigate 
its localisation and distribution in tissues, and anti-(XOR) antibodies have proved to be 
a useful tool in immunohistochemical studies. Many studies have utilised purified 
polyclonal antibodies to XOR, from both human and bovine sources, in order to 
elucidate the localisation of XOR in a range of bovine (Jarasch et al., 1981) and human 
(Jarasch et al, 1986; Moriwaki et al, 1996b; Linder et al., 1999) tissues. Such 
immunoaffinity detection methods have the advantage over activity staining in that they 
do not distinguish between active and inactive forms of the enzyme and are thus able to 
give a more accurate overall representation as to the distribution of protein in tissues.
The use of anti-(XOR) antibodies in immunoaffinity-based purification provides a 
potentially selective and powerful tool for the rapid isolation of XOR from tissue 
sources. Saksela et al. (1999) purified human liver XOR, using rabbit polyclonal anti- 
(XOR) antiserum, for the purpose of proteolysis studies. However, details of their 
immunoaffinity purification method were not given. Abadeh et al. (1993) reported an 
immunoaffinity purification o f XOR from human heart, using polyclonal antibodies to 
human milk. The resulting heart XOR was found to have very low specific activity 
towards xanthine (as discussed in the Introduction) consistent with a high proportion of 
inactive forms.
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This Chapter describes the development of an immunoaffinity purification method for 
the isolation of XOR from liver sources.
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6.2 Materials and Methods
6.2.1 Materials
Purified HMXOR was prepared as described in Section 4.2.2, and used for the 
immunisation of rabbits. Imject Alum adjuvant was obtained from Pierce, Netherlands. 
All other chemicals were obtained from Sigma-Aldrich, Poole, Dorset.
Rabbits were initially immunised with Imject Alum adjuvant, which encourages the 
induction of a strong antibody response, combined with purified HMXOR (400 pg) in a 
final volume of 0.5 ml. On day 28 following immunisation, a boost injection of purified 
HMXOR (400 pg) was administered. High levels o f IgG antibodies are produced as a 
result o f the second injection, rather than IgM, o f which a substantial proportion is 
present in the sera from primary injections. On day 35, a test bleed was collected, and 
the litre of serum anti-(HMXOR) antibodies were determined by ELISA, using normal 
(non-immunised) rabbit serum (NRS) as a control. Following the boost injection, and 
once a good titre was obtained, further injections were given routinely every 4-6 weeks, 
the response to these injections mirroring that of the secondary injection, with the 
maturation o f the immune response and the production of high-affinity antibodies.
6.2.2 Methods
6.2.2.1 Immunisation of rabbits
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6.2.2.2 Serum preparation
Blood was collected from the rabbits (40 ml/rabbit) and allowed to contract overnight 
at 4 °C. The clot was separated from the sides of the collection vessel using a Pasteur 
pipette and centrifuged at 3000 g for 15 min. Straw-coloured serum was aspirated from 
the surface of the clot, and further centrifuged at 10000 g for 10 min to remove any 
insoluble material. The serum was then aliquoted and stored at —20 °C for later use.
6.2.2.3 Purification of a crude preparation of immunoglobulin
Ammonium sulphate precipitation is a commonly used procedure for removal of 
proteins from solution. Most rabbit antibodies will precipitate from a 50 % saturated 
solution. Saturated ammonium sulphate solution was added slowly to the serum while 
stirring gendy, to bring the solution to 50 % saturation. The antibody solution was left 
stirring overnight at 4 °C. The precipitate was centrifuged at 3000 g for 30 min. The 
supernatant was removed and discarded, and the pellet was resuspended in an equal 
volume of PBS, containing 0.01 % / v) sodium azide. The antibody solution was
dialysed at 4 °C against three changes of the same buffer to remove ammonium 
sulphate, and was then centrifuged or syringe-filtered to remove any remaining insoluble 
debris.
6.2.2.4 Purification of IgG using Protein A-Sepharose
Protein A, a constituent o f the cell wall of S. aureus, has a high affinity for the Fc region 
of rabbit IgG. When linked to Sepharose 4B, it can be used to provide a purification 
matrix for the isolation of IgG from a heterogeneous antibody solution. Protein A- 
Sepharose (5 ml) was swollen and poured into a column following the manufacturer’s
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instructions. Precipitated immunoglobulin (5 ml) (Section 6.2.2.3) was diluted 1:10 in 
PBS and circulated on the column overnight at 4 °C. The column matrix was washed 
extensively with PBS until the A280 had reached baseline, monitored using an attached 
UV detector linked to a chart recorder. Bound IgG was eluted from the column with 
35 mM diethylamine, containing 35 mM NaCl, pH 11.5. The eluted protein was 
collected in neutralising buffer (1:5 volume of PBS) and then dialysed at 4 °C against 
PBS, containing 0.01 % / v) sodium azide.
6.2.2.5 Preparation of an HMXOR-affinity column
An HMXOR-affinity column was used to specifically purify anti-(HMXOR) IgG from 
the crude IgG fraction. Purified HMXOR (20 mg, PFR 5—5.5) was coupled to CNBr- 
activated Sepharose 4B at a ratio of 5—10 mg protein per ml swollen gel (routinely a 2 
ml column was prepared). HMXOR was gel-filtered, using a Sephadex G-25 PD-10 
column (Section 3.2.2), into Coupling Buffer (0.1 M N aH C 03, containing 0.5 M NaCl, 
pH 8.3). The required amount of CNBr-activated Sepharose 4B freeze-dried powder 
was swollen in 1 mM HC1 (ice-cold), and washed for 15 min on a sintered glass filter 
with the same solution. Washing with HC1 prevents hydrolysis of the reactive groups, 
which occurs at high pH. The gel was then transferred rapidly to the HMXOR solution 
and the suspension left to rotate end-over-end overnight at 4 °C (or for 2 h at room 
temperature). Following incubation, the gel suspension was centrifuged at 3000 g for 5 
min and the supernatant aspirated off. The gel was transferred to blocking buffer (1 M 
ethanolamine) and left to rotate end-over-end at room temperature for 2 h. Excess, or 
unadsorbed, protein was washed away with a series o f buffers: Coupling Buffer 
followed by 0.1 M Na-acetate, containing 0.5 M NaCl, pH 4, followed by several final
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washes of Coupling Buffer, on a sintered glass filter. The HMXOR-Sepharose 4B 
protein matrix was poured into a column and stored at 4 °C in 0.01 % (Vv) sodium 
azide until ready for use.
Efficient coupling was checked by assaying initial and final concentrations of protein, 
using the Bradford method (Section 3.2.3). Routinely, a coupling efficiency of between 
95 and 98 % was achieved.
6.2.2.6 Affinity purification of anti-(HMXOR) antibodies
The IgG fraction (40 ml) (Section 6.2.2.4) was applied direcdy to an HMXOR-affinity 
column (Section 6.2.2.5) and circulated on this column overnight at 4 °C. Following 
circulation, the column was washed with PBS until A280 reached baseline. Bound 
protein was eluted with 35 mM diethylamine, containing 35 mM NaCl, pH 11.5, and 
collected in tubes containing neutralising buffer (1:5 volume of PBS). Dialysis was 
carried out against three changes of PBS (containing 0.01 % (Vv) sodium azide). 
Regeneration of the column was effected by washing with PBS, followed by 0.1 M Na-  
acetate, pH 4.5. The column was then stored in PBS containing 0.01 % / v) sodium
azide. After several uses (greater than seven purifications) a new HMXOR-affinity 
column was prepared.
The purified antibodies were concentrated if necessary using Vivaspin 2ml 
concentrators (Vivascience), and analysed on SDS-PAGE gel or by ELISA. The 




6.3.1 Im m unisation of rabbits
Two rabbits, designated 256 and 257, were immunised with HMXOR (Section 6.2.2.1) 
and antiserum was prepared (Section 6.2.2.2). Anti-(HMXOR) antibody levels, also 
referred to as serum titre, were determined by ELISA (Section 3.2.5.2). Titres of pre- 
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Figure 6.3.1 Anti-(HMXOR) titration curves obtained from rabbit sera
The curves on the left correspond to the sera of the two rabbits (256 and 257) before 
immunisation (NRS), and the curves on the right following immunisation (IMM).
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Titres of the sera from the two rabbits were calculated.







Table 6.3.1 Titre of NRS and IMM sera
The values in Table 6.3.1 represent titres x 104 derived from the curves in Fig 6.3.1. 
Titre corresponds to the antilogarithm at 50 % maximal absorbance. Approximate titre 
increases of 470-fold and 320-fold were obtained following immunisation of rabbits 256 
and 257 respectively.
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6.3.2 Purification of IgG from precipitated immunoglobulin by
chromatography on Protein A-Sepharose
Precipitated immunoglobulin was prepared from rabbit serum (Sections 6.2.2.2 and
6.2.2.3). IgG was purified from precipitated immunoglobulin by chromatography on 
Protein A-Sepharose (Section 6.2.2.4). The immunoglobulin solution was circulated on 
the Protein A column until all IgG had been removed, and no change in absorbance 





Figure 6.3.2 Purification of IgG from rabbit antiserum
The trace shows the elution of bound IgG from immunoglobulin solution on Protein 
A-Sepharose. The arrow represents the addition of 35 mM diethylamine, containing 35 
mM NaCl, pH 11.5.
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6.3.3 Purification of anti-(HMXOR) IgG by chromatography on
HMXOR-affinity column
Anti-(HMXOR) IgG was purified from the dialysed rabbit IgG preparation (Section 
6.2.2A) by circulation on immobilised HMXOR (Sections 6.2.2.5 and 6.2.2.6). The IgG 
preparation was circulated on the column and elutions of anti-(HMXOR) IgG (with 35 
mM diethylamine, containing 35 mM NaCl, pH 11.5) were carried out, until absorbance 
at 280 nm was no longer detectable in the eluant. Usually three circulations were 
required to remove all specific anti-(HMXOR) IgG. It was observed that the 
characteristic brown colour due to the immobilised HMXOR was lost from the column 
during initial usage. With repeated use, the performance of the column declined, and, 








Figure 6.3.3 Purification of anti-(HMXOR) IgG from rabbit IgG
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The trace shows the elution of bound anti-(HMXOR) IgG from HMXOR-affinity 
column. The arrow represents the addition of 35 mM diethylamine, containing 35 mM 
NaCl, pH 11.5.
The total yield of anti-(HMXOR) IgG purified from rabbit IgG preparation (40 ml) was 
calculated. Three circulations and consecutive elutions were carried out from the same 
preparation of IgG.
Rabbit
Yield o f anti- 
(HMXOR) IgG  
(mg) from 
first circulation





Yield of anti- 
(HMXOR) 








256 4.8 2.1 0.7 7.6
257 3.5 1.4 0.3 5.2
Table 6.3.2 Yield o f anti- (HMXOR) IgG  purified from IgG  by
chromatography on HMXOR-affinity column
The yield of anti-(HMXOR) IgG purified from the same preparation o f IgG was 
assessed by measuring the absorbance of the eluant at 280 nm. A280 (1 mg/ml) was 
assumed to be equivalent to an absorbance of 1.4.
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6.3.4 Characterisation of affinity-purified rabbit anti-(HMXOR) IgG
The dialysed anti-(HMXOR) IgG preparation was subjected to SDS-PAGE analysis.
A B C
Figure 6.3.4 10 % SDS-PAGE gel of purified anti-(HMXOR) IgG
The affinity purified anti-(HMXOR) IgG was run on SDS-PAGE gel together with 
whole serum. Lanes A and B correspond to affinity purified anti-(HMXOR) IgG, and 
lane C corresponds to whole antiserum. Two bands are evident in the purified 
preparation, of approximately 50 kDa and 25 kDa, corresponding to heavy chain and 
light chain IgG respectively.
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6.3.5 Specificity of purified anti-(HMXOR) IgG assessed by Western
blotting
6.3.5.1 Specificity for HMXOR and BMXOR
The specificity of purified anti-(HMXOR) IgG was assessed by immunoblotting against 
HMXOR and BMXOR.
Figure 6.3.5 Western blot to show specificity of purified anti-(HMXOR)
IgG for HMXOR and BMXOR
Immunoprobing was performed using the purified and pooled antibodies to test their 
specificity towards HMXOR and BMXOR. On both the SDS-PAGE gel and the 
corresponding Western blot, lane 1 corresponds to HMXOR, lane 2 corresponds to 
BMXOR, and lane 3 corresponds to commercial BMXOR (Biozyme). The position of
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high range molecular weight markers are also shown (to the left o f the SDS-PAGE gel). 
The Western blot demonstrates recognition of the major 150 kDa band by the purified 
antibodies in all cases. Commercial BMXOR (Biozyme) is a proteolysed preparation, 
displaying five major bands on SDS-PAGE gel. The purified antibodies appear positive 
for the 150 kDa, 130 kDa, and 90 kDa fragments, but do not recognise the lower 
molecular weight degradation products evident on the SDS-PAGE gel.
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6.3.5.2 Specificity for BLXOR
The specificity of purified anti-(HMXOR) IgG was assessed by immunoblotting against 






Figure 6.3.6 Western blot to show specificity of purified anti-(HMXOR)
IgG for BLXOR
Immunoprobing was performed using the purified pooled antibodies to test their 
specificity towards BLXOR. Lane 1 corresponds to coloured high range molecular 





High titre antisera were routinely obtained from two rabbits immunised with HMXOR; 
titres showing increases of approximately 400-fold compared with those of normal 
rabbit serum. Levels o f anti-(XOR) antibodies in the rabbit serum before immunisation 
are low but real (Table 6.3.1). Low levels of antibodies to XOR are commonly found in 
most mammalian species (Bruder et al., 1984).
Rabbit polyclonal anti-(HMXOR) IgG was successfully purified from rabbit antisera 
using a combination of ammonium sulphate precipitation, protein A-Sepharose, and 
HMXOR-affinity chromatography. The purified antibodies exhibited two bands on 
SDS-PAGE gel analysis, of 50 kDa and 25 kDa. These equate to heavy and light chain 
IgG respectively. In Western blots, equal avidity was displayed towards the major 150 
kDa band of HMXOR and BMXOR (either prepared by methods detailed in this 
Chapter, or obtained commercially). In addition, the degradation fragments of the more 
proteolysed commercial BMXOR, corresponding to 130 kDa and 90 kDa, were 
recognised by the antibodies although the lower molecular weight bands were not 
detected (Fig 6.3.5). A band corresponding to BLXOR, at approximately 150 kDa, was 
detected in the post-ammonium sulphate fraction of bovine liver (Fig 6.3.6). 
Immunoprobing performed with normal rabbit serum gave negative results (data not 
shown).
It is apparent that there is cross-reactivity of the polyclonal antibodies towards XOR 
from human or bovine milk and from bovine liver. Such antibody binding appears to
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be independent of enzyme activity, as avidity is shown for the lower activity HMXOR 
as well as BMXOR. The primary sequences of HMXOR and BMXOR have been 
shown to be essentially identical to each other (Pearson, A. Ph.D. Thesis, 2001).
It was observed that the HMXOR-affinity column lost its characteristic brown colour 
during initial usage, a finding attributed to the loss of the flavin group of the enzyme in 
response to the eluant used, 35 mM diethylamine. This did not appear to affect the 
performance of the column in the initial stages, indicating that the immobilised 
HMXOR remained antigenic. The use of alternative elution buffers in the purification 
of anti-(HMXOR) IgG, such as urea and magnesium chloride, has been investigated in 
the past by previous members of the laboratory without much success.
The performance of the column declined after several runs, as judged by a decrease in 
yield of antibody purified. This may be due to slow leakage of the immobilised antigen 
through repeated elution. However, no evidence of bands corresponding to HMXOR 
was seen in the eluted protein on SDS-PAGE analysis. Ligands coupled to CNBr- 
activated matrix have been reported to show a greater degree of leakage than those 
coupled using other methods (Harris & Angal, 1995), perhaps because the covalent 
bonds between ligand and matrix are relatively labile. Nevertheless, for the purpose of 
antibody purification, this did not appear to be too problematic as the combined yields 
produced from repeated purifications, until the column significantly lost performance, 
were sufficient for considerable experimentation. Certainly, sufficient antibody was
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available for coupling to a matrix to form an immunoaffinity column, preparation and 
use of which are discussed in the next Chapter.
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7. The immunoaffinity purification of bovine fiver
xanthine oxidoreductase (BLXOR)
7.1 Introduction
Immunopurification can overcome separation difficulties that other methods are unable 
to resolve, as antibodies can be found that are able to distinguish between very similar 
antigens (Jack et al., 1987). Antibodies are particularly resistant to proteolytic attack by 
enzymes and thus are able to offer a clear advantage over affinity methods utilising 
immobilised proteins as ligands. Immunopurification is, accordingly, an attractive 
option for the purification of any protein against which an antibody, polyclonal or 
monoclonal, can be raised.
Affinity chromatography has been rarely used early on in a purification procedure 
(Bonnerjea et al., 1986), where the potentially high degree of purification would be most 
useful. This is probably because of the risk of damage to a valuable material, both from 
fouling by high levels of contaminants and proteolysis. Antibodies, whether polyclonal 
or monoclonal, are often produced by time-consuming and labour intensive methods.
There have been no reported immunopurifications o f XOR from bovine liver, although 
a purification has been reported from human liver (Saksela et al.^  1999). This Chapter 
investigates the use of an immunoaffinity matrix, prepared using affinity-purified
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polyclonal anti-(HMXOR) antibodies, as prepared in the previous Chapter, in the 
purification of XOR from bovine liver.
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7.2 Materials and Methods
7.2.1 Materials
All chemicals were obtained from Sigma-Aldrich, Poole, Dorset, unless stated 
otherwise.
7.2.2 Methods
7.2.2.1 Preparation of a polyclonal anti-(HMXOR) IgG column
As already noted, Protein A has a high specificity for the Fc domain of most classes of 
rabbit IgG. Coupling of antibodies direcdy to Protein A beads via their Fc domain, 
leaves the antigen-binding site free and available for interaction.
Anti-(HMXOR) antibodies (Section 6.2.2.6) were incubated (4 mg/ml) with wet Protein 
A-Sepharose beads (swollen in PBS). The antibody and Protein A-Sepharose slurry was 
incubated at room temperature for 1 h, with gentle rocking on a shaker. The beads 
were washed twice with ten volumes of 0.2 M Na-borate, pH 9. Washes were 
performed by centrifugation at 3000 g for 5 min, and aspiration of the resulting 
supernatant. The beads were resuspended in ten volumes of 0.2 M Na-borate, pH 9, 
and dimethylpimelimidate (a bifunctional coupling reagent) was added to bring the final 
concentration to 20 mM. The suspension was mixed on a shaker at room temperature 
for 30 min and the reaction was stopped by washing with 0.2 M ethanolamine, pH 8, 
and incubation at room temperature for 2 h with gentle mixing. This ensured blocking
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of uncoupled sites. The beads were resuspended in PBS (containing 0.01 % (Vv) 
sodium a2ide), poured into a column and stored at 4 °C until ready for use.
Coupling was assessed by taking small samples of the beads before and after coupling 
(with dimethylpimelimidate) and analysing using SDS-PAGE to check for presence of 
antibody. Efficient coupling is indicated by the absence of bands corresponding to 
antibody heavy chain in the sample taken after coupling.
1.2.2.2 Preparation of ammonium sulphate fraction from liver
An ammonium sulphate fraction was prepared from bovine liver and dialysed against 
PBS as described in Section 5.2.2.1. Protease inhibitors were added to the liver fraction 
as follows: 5 |iM leupeptin, 10 pM chymostatin, 1 pM pepstatin A and 10 pM APMSF. 
The inclusion of protease inhibitors is crucial at this stage, both to minimise proteolysis 
of protein and also to protect the valuable antibody matrix used at the next stage, from 
degradation.
7.2.2.3 Pre-purification of liver ammonium sulphate fraction on Protein 
A-Sepharose
Protein A-Sepharose (4 ml) was poured into a column and equilibrated in PBS. The 
ammonium sulphate liver fraction, dialysed against PBS (Section 7.2.2.2), was circulated 
for 2 h at 4 °C on an uncoupled Protein A-Sepharose column, pre-equilibrated in PBS. 
This was to minimise non-specific binding of protein to the matrix and also to remove 
any IgG that may be present in the liver fraction and potentially co-purify with XOR. 
Bound protein was eluted with 35 mM diethylamine, containing 35 mM NaCl, pH 10.5,
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and discarded. The non-bound protein fraction was retained for immunoaffinity 
purification.
7.2.2.4 Immunoaffinity purification of BLXOR
The ammonium sulphate fraction o f bovine liver, which had been pre-treated with 
Protein A-Sepharose (Section 7.2.2.3), was diluted 1:10 in PBS (containing 0.01 % ("/ v) 
sodium azide) and applied to the anti-(HMXOR) immunoaffinity column (Section 
7.2.2.1), which had been previously equilibrated in the aforementioned buffer. 
Circulation was allowed to occur for 2-3 h at 4 °C in order to saturate antibody-binding 
sites. Following circulation, the column was washed extensively with PBS, followed by 
PBS containing 1 M NaCl, to remove unbound or weakly bound protein, until A280 
reached baseline values. To elute XOR, 25 mM diethylamine, containing 35 mM NaCl, 
pH 10.5, was applied to the column. The bound protein was collected in 50 mM Na- 
Bicine, pH 8.3 (5-fold excess) to neutralise the alkalinity of the diethylamine. The eluted 
fraction was immediately dialysed against one change of 50 mM Na-Bicine, containing 
0.05 M NaCl, 1 mM EDTA and 4 mM DTT, pH 8.3. The dialysed material was 
incubated with 1 mM FAD for 10 min at room temperature.
Incubation with FAD was carried out in order replace flavin loss from XOR. Such loss 
has been observed upon incubation of intact HMXOR with diethylamine (personal 
communication, R. Bryant). FAD is rapidly hydrolysed to riboflavin 4’-5’-cyclic 
phosphate in alkali solutions. Therefore, the FAD incubation step has been 
incorporated following dialysis o f the eluted protein against 50 mM Na-Bicine, pH 8.3. 
Following incubation with FAD, further dialysis was carried out against several changes
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of 50 mM Na-Bicine, containing 0.05 M NaCl, 1 mM EDTA and 4 mM DTT, pH 8.3, 
to remove the unbound FAD.
The same liver fraction was subjected to four consecutive circulations and elutions from 
the immunoaffinity column. Following each elution of bound protein, the column was 
regenerated by washing with PBS, followed by 0.1 M Na-acetate, pH 4.5. When not in 
use, the column was stored in PBS with 0.01 % (Vv) sodium azide added to prevent 
microbial growth. Enzyme was concentrated using Vivaspin 2 ml concentrators 
(Vivascience), drip-frozen into liquid nitrogen and stored at -70°C.
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7.3 R esults
7.3.1 Pre-purification of liver ammonium sulphate fraction on Protein
A-Sepharose
Bovine liver (40 g) was homogenised and an ammonium sulphate fraction was prepared 
(Section 5.2.2.1). The ammonium sulphate fraction was then circulated on an
uncoupled Protein A-Sepharose column (Section 7.2.2.3), to remove protein with an 









Figure 7.3.1 Elution profile from Protein A-Sepharose
There was an apparent small increase in the A280 upon elution with 35 mM diethylamine, 
containing 35 mM NaCl, pH 10.5 (highlighted by arrow). The eluted fraction was 
subsequently electrophoresed on SDS-PAGE gel but no protein was detected,
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indicating that protein quantity was minimal. Alternatively, the small increase in 
absorbance could be a consequence of buffer change. The non-bound protein fraction 
was retained for immunoaffinity chromatography.
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7.3.2 Immunoaffinity chromatography on anti-(HMXOR) column
The resulting liver protein was subjected to immunoaffinity chromatography (Section
7.2.2.4). The traces below show three typical consecutive elutions from the anti- 




1st Elution 2nd Elution 3rd Elution
Elution Volume
Figure 7.3.2 Elution profiles showing elution of bound protein from
anti-(HMXOR) immunoaffinity column
In all three consecutive circulations bound protein eluted from the column with 25 mM 
diethylamine, containing 35 mM NaCl, pH 10.5. This is represented by the sharp peak 
on the left o f each trace. This peak gets smaller with progressive circulations on the 
column, indicating removal o f XOR protein from the liver fraction.
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7.3.3 SDS-PAGE gel of immunoaffinity-purified protein
Following incubation with 1 mM FAD and further dialysis (Section 7.2.2.4), the purified 







Figure 7.3.3 7.5 % SDS-PAGE gel of immunoaffinity-purified protein
Lane 1 corresponds to immunoaffinity-purified protein, lane 2 corresponds to 
commercial BMXOR (Biozyme) and lane 3 corresponds to high range molecular weight 
standards. It can be seen that the purified BLXOR runs with a mobility equal to that of 
the second highest molecular weight band of commercial BMXOR. It can also be 
observed that there is an additional faint lower molecular weight band.
1 2 3
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7.3.4 Western blot of immunoaffinity-purified protein
The purified protein was subjected to Western blotting (Section 3.2.1.3), whereby 
monoclonal mouse anti-(HMXOR) (clone 1D9D1), kindly supplied by Eurogenetics, 






Figure 7.3.4 Western blot of immunoaffinity-purified BLXOR
Lane 1 corresponds to commercial BMXOR and lane 2 corresponds to immunoaffinity- 
purified protein. As in the SDS-PAGE gel (Fig 7.3.3), it can be seen that the 
immunopurified protein runs as two bands, both bands of similar molecular weight as 
those represented in lane 1, corresponding to commercial BMXOR.
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7.3.5 Molecular weight
The molecular weights of immunoaffinity-purified BLXOR and commercial BMXOR 
as estimated by SDS-PAGE gel (Fig 7.3.3) were determined by plotting log molecular 
weight against Rf.
2.5




Figure 7.3.5 Determination of the molecular weight of BLXOR and
BMXOR by SDS-PAGE gel
Molecular weight was determined as described in Section 3.2.1.1. Molecular weight 
standards are represented by squares (blue), BMXOR is represented by triangle (light 
blue) and BLXOR by circle (red). The calculated molecular weights o f BMXOR (major 
band) and BLXOR are 145 kDa and 134 kDa respectively.
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7.3.6 UV-visible absorbance spectrum of immunoaffinity-purified
protein












Figure 7.3.6 UV-visible absorbance spectra of immunoaffinity-purified
BLXOR and purified HMXOR
BLXOR is represented by the grey line and HMXOR is represented by the red line. 
The spectra were obtained in 50 mM Na-Bicine, containing 0.05 M NaCl, pH 8.3.
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7.3.7 Specific activity of immunoaffinity-purified protein
The specific activities were calculated at each stage of the purification procedure. 









(nm ol/m in /  mg)
% Oxidase
Ammonium 
sulphate fraction 0.09 53 5 24
Immunoaffinity- 
purified fraction 936 1.3 720 46
Table 7.3.1
Urate activity assays (Section 3.2.4.2) were performed on the ammonium sulphate 
fraction from bovine liver prior to immunoaffinity column purification, and on the 
purified protein following immunoaffinity column chromatography. The total yield of 
immunoaffinity-piirified protein was 1.3 mg from 40 g liver.
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7.4 Discussion
With the use of a three-step purification method, consisting of ammonium sulphate 
precipitation, circulation on Protein A-Sepharose and a single immunoaffinity step, 
XOR has been purified from bovine liver to near homogeneity as judged by SDS- 
PAGE gel. Furthermore, this purified preparation exhibited a UV-visible spectrum 
bearing strong similarities to that of purified human milk XOR.
The post ammonium sulphate bovine liver fraction was circulated on uncoupled Protein 
A-Sepharose (Fig 7.3.1), in order to remove any IgG likely to be present in liver 
homogenate. Other proteins with affinity for Protein A itself, as apposed to Protein A 
coupled to anti-(HMXOR) antibody, will also be removed prior to immunoaffinity 
purification on the latter column. Immunoaffinity chromatography, involving three 
consecutive circulations and elutions on the anti-(HMXOR) column, resulted in a 
distinct peak at 280 nm (Fig 7.3.2), corresponding to the elution of bound protein from 
the column in each case. There is a decrease in si2e of peak noted with progressive 
elutions, indicating removal and reduction of XOR protein in the liver fraction. 
Complete removal of XOR from the liver fraction was routinely observed after three 
elutions, as a further circulation and elution produced no change in absorbance at 280 
nm.
SDS-PAGE analysis of purified protein (Fig 7.3.3) showed a band of approximately 
134 kDa, calculated by plotting log molecular weight against Rf (Fig 7.3.5), and a lower 
molecular weight band of approximately 50 kDa. Western blotting performed using a
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monoclonal anti-(HMXOR) antibody (Fig 7.3.4), and therefore a different antibody to 
the polyclonal used in purification, was specific towards both the 134 kDa band and the 
50 kDa band. This indicates that the band corresponding to 134 kDa is XOR and the 
lower molecular weight band is likely to be an XOR proteolysis product. The 134 kDa 
band is similarly sized to the second largest proteolysis or degradation product of 
commercial BMXOR, as can be seen from both the SDS-PAGE gel and Western blot. 
The 50 kDa band, initially thought to be a contaminant, is recognised by the 
monoclonal antibody and is also o f a similar size to a proteolysis fragment of 
commercial BMXOR. It can thus be assumed that the purified BLXOR is mildly 
proteolysed, although to a lesser extent than commercial BMXOR, with BLXOR 
producing only two visible bands on SDS-PAGE gel compared with five distinct bands 
belonging to commercial BMXOR. Whether the 135 kDa band represents a proteolysis 
product as well, equivalent to those bands of similar molecular weight observed with 
BMXOR and HMXOR, is unclear. There is no evidence of a higher molecular weight 
band representing unproteolysed enzyme. It is interesting to note that the two XORs, 
when subjected to proteolysis, produce similarly sized fragments. Proteolysis of rat liver 
XDH with trypsin cleaves the enzyme into three fragments of 20 kDa, 40 kDa, and 85 
kDa (Amaya et al.t 1990). This cleavage is accompanied by the conversion of the 
dehydrogenase to the oxidase form of the enzyme (Hille & Nishino, 1995). However, 
this represents considerably more fragmentation than that observed in the present work.
The molecular weight of BLXOR was estimated (Section 7.3.5), by plotting log 
molecular weight against Rf calculated from SDS-PAGE, and was found to be 134 kDa.
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The major band of commercial BMXOR was calculated to be 145 kDa. This method of 
measuring molecular weight shows a slighdy lower value for BLXOR than for BMXOR. 
The molecular weight of 134 kDa compares well with the BLXOR preparation of Cabre 
& Canela (1986), which upon SDS-PAGE analysis showed four protein bands, two of 
which possessed molecular masses of 135 kDa and 45 kDa, the latter also being a 
similar mass to the lower band obtained here. In the present work it is possible that the 
band at 135 kDa, in addition to the band at 50 kDa, represents a proteolysis product. 
However, BLXOR purified using non-immune methods (Chapter 5) showed a very 
close molecular weight of 135 kDa, and a similarly sized band to this was also noted in 
freshly prepared homogenate on Western blotting (Fig 5.3.4), indicating that perhaps 
this is not due to proteolysis, and instead may indicate a smaller size XOR, when 
compared with BMXOR and HMXOR.
The epitope sequence recognised by the monoclonal antibody used in Western blotting 
is again clearly conserved between bovine liver and bovine milk XORs (as discussed 
previously in Section 6.4), accounting for the binding of monoclonal antibody to XOR 
degradation products. From observations so far, it also appears that the affinity- 
purified polyclonal anti-(HMXOR) antibody and the monoclonal anti-(HMXOR) 
antibody (Eurogenetics, Belgium) have similar specificities.
The yield o f immunopurified BLXOR was 1.3 mg, from 40 g liver tissue. This is over 
10-fold higher than the yield obtained using the affinity purification methods (0.1 mg) in 
Chapter 5, using a similar starting amount of liver (Section 5.3.6). The specific activity
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of the immunopurified preparation (720 nmol/min/mg) is also significandy higher than 
the activity reported for BLXOR purified using non-immune methods (1.6 
nmol/min/mg), described in the previous Chapter (Table 5.3.2).
Purified BLXOR displayed a UV-visible absorption spectrum very similar to that of 
HMXOR, which also resembles BMXOR (Fig 7.3.6). Peaks were present at 
approximately 320 and 450 nm; absorbance in this region is contributed by the flavin 
and Fe/S groups. However, there is a lower absorbance in the 320-350 nm region of 
BLXOR, when compared with the spectrum of HMXOR. This may be due to a lower 
composition of either flavin or iron-sulphur in the purified enzyme, upon comparison 
with HMXOR. If the preparation of BLXOR is lacking in one or both of these groups, 
this, as discussed in the Introduction, will result in a lowered activity enzyme, depending 
on the extent of this deficiency. It is possible that the formation of deflavo-XOR 
during this purification will occur, due to the use of diethylamine, which, as an elution 
buffer, has been found to strip enzyme of its FAD group. Deflavo-XOR can also be 
prepared within the laboratory by incubation with a range of bivalent metal salts, such 
as calcium chloride and magnesium sulphate (Morell, 1952). Komai et al. (1969) found 
that high concentrations of calcium chloride result in the hydrolysis of FAD to FMN, 
producing an altered UV-visible spectrum. This group further demonstrated that 
deflavo-XOR could be reconstituted with the addition of FAD, restoring the majority 
(60 %) of the original enzymic activity. To correct for loss of flavin in this study, 
addition of FAD to the preparation following elution from the column and subsequent 
dialysis has been incorporated. The PFR calculated from this UV-visible scan is 5.75,
Chapter 7 108
indicative of reasonably pure enzyme. Highly purified HMXOR and BMXOR within 
the laboratory typically have PFRs in the range of 5.2 — 5.7.
The BLXOR produced by the methods described in this Chapter consists of 46 % 
oxidase form (Table 7.3.1). The proportion of oxidase enzyme has thus increased from 
24 % to 46 % during immunoaffinity purification. DTT (4 mM) has been incorporated 
at each stage in the procedure to prevent spontaneous formation of reversible XO and 
to retain the enzyme in its native dehydrogenase form. The fact that we see an increase 
in oxidase form following immunoaffinity purification may be due to proteolysis or 
protein degradation.
It appears from these results that immunoaffinity chromatography utilising polyclonal 
antibodies is an extremely successful tool in the isolation of BLXOR from a 
heterogeneous protein mixture, without proving too deleterious to the activity and 
properties of the enzyme, as shown by activity assays and UV-visible scan. The 
polyclonal antibodies utilised demonstrate a high specificity towards BLXOR and are 
relatively inexpensive to incorporate as a ligand in an immunoaffinity column, as several 
purifications can be performed until the column shows a loss in performance.
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8. The immunoaffinity purification of human fiver
xanthine oxidoreductase (HLXOR)
8.1 Introduction
XOR has been purified from human liver (Krenitsky et al.^  1986; Moriwaki et al., 1993; 
Saksela et al., 1999). In 1986, Krenitsky et al. purified XOR 2000-fold from post­
mortem human liver, using a combination of affinity procedures. Their preparation was 
moderately proteolysed and in its oxidase form, displaying a specific activity, with purine 
substrates, similar to that of bovine milk XOR. This is in contrast to human milk XOR, 
which has a much lower specific activity. Parks & Granger (1986) found XOR activity 
in whole human tissues to be generally low, with the exception of liver and intestine. 
While this could reflect a higher content of the enzyme in the liver and intestine, it 
would also be consistent with a relatively high specific activity of XOR in these two 
tissues.
In 1993, Moriwaki et al. reported the affinity purification of XOR from cadaver liver. 
They obtained a final purification of 1600-fold, claiming homogeneity as judged by 
SDS-PAGE, with an estimated mass o f 150 kDa, although these data are not shown. 
They went on to use the purified enzyme to raise polyclonal antibody in rabbits, for 
tissue immunolocalisation studies. That their enzyme is apparently unproteolysed 
differs from the earlier purification of liver enzyme (Krenitsky et al., 1986), SDS-PAGE 
of which showed five bands. Krenitsky et al. prepared XOR from human liver total
Chapter 8 110
homogenate, whereas Moriwaki et al. used human liver cytosol as a basis for their 
purification. This may have affected the differing extent of proteolysis. Alternatively, 
proteolysis may have occurred to a greater extent in the post-mortem tissue, used by 
Krenitsky et al., prior to purification.
Samesto et al. (1996), used fresh human liver, preserved for transplantation, then frozen 
in liquid nitrogen, before homogenisation in the presence of protease inhibitors. The 
homogenate itself showed multiple bands on Western blotting with polyclonal anti- 
(HMXOR) antibody, leading them to suggest that the enzyme might exist in a partially 
proteolysed form in the liver, and possibly other intact tissue.
Saksela et al. (1999) reported the immunoaffinity purification of XOR from human liver, 
using rabbit polyclonal anti-(XOR) antiserum coupled to Sepharose. The purified liver 
protein showed three bands on SDS-PAGE analysis, of 150 kDa, 130 kDa and 85 kDa. 
Their method of purification was not described in detail, however, nor were the SDS- 
PAGE results shown in the report. This study also proposed that cytoplasmic human 
liver XDH is irreversibly cleaved to XO by a heat-labile mitochondrial protease, which 
is released from the mitochondrial intermembrane space into the cytosol upon 
mitochondrial damage. This would support the claims of Moriwaki et al. (1993) to have 
purified unproteolysed XOR from liver cytosol.
Hellsten-Westing (1993) generated a range of monoclonal antibodies in order to 
determine the tissue distribution of the enzyme. As part of the study they performed
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affinity chromatography on human liver and skeletal muscle extracts, using monoclonal 
antibody immobilised to Protein A-Sepharose. They found that the eluate from human 
liver contained a fragmented enzyme as judged by SDS-PAGE, with molecular weights 
of 155 kDa, 143 kDa and 95 kDa. Their monoclonal antibodies also bound a 155 kDa 
protein displaying xanthine oxidase activity in human milk and skeletal muscle, 
reflecting tissue cross-specificity of their antibody.
The work in this Chapter extends to human liver the immunoaffinity methodology 
developed for the isolation of XOR from bovine liver tissue (Chapter 7). The efficacies 
of polyclonal and monoclonal antibodies as purification ligands are compared.
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8.2 Materials and Methods
8.2.1 Materials
Frozen human liver (normal and primary biliary cirrhotic) was obtained from the Royal 
Free Hospital, London. Sephadex G-25 PD-10 gel filtration columns were obtained 
from Pharmacia, Uppsala, Sweden. CNBr-activated Sepharose 4B was supplied by 
Amersham Pharmacia Biotech AB. All other chemicals were obtained from Sigma- 
Aldrich, Poole, Dorset, unless stated otherwise. Monoclonal anti-(HMXOR) antibody 
clones (1D9D1, 3E7A6, 3C9D5) were kindly donated by Eurogenetics, Belgium. 
Protein L-Agarose was obtained from Sigma—Aldrich.
8.2.2 Methods
8.2.2.1 Homogenisation of human liver and preparation of an ammonium
sulphate fraction
All operations were carried out in a fume cupboard and all equipment was cooled to 
4 °C before use. Suitable precautions were taken when handling human tissue and to 
avoid contamination of apparatus. Frozen human liver (40 g) was thawed on ice, and 
rinsed in ice-cold PBS, containing protease inhibitors as follows: 5 pM leupeptin, 10 pM 
chymostatin, 1 pM pepstatin A and 10 pM APMSF, with the addition of 1 mM EDTA 
and 4 mM DTT. Homogenisation, followed by ammonium sulphate precipitation, was 
carried out as described in Section 5.2.2.1. The resultant pellet from ammonium 
sulphate precipitation was redissolved in PBS. Dialysis of the ammonium sulphate
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suspension was carried out overnight against two changes o f PBS (3000 ml), containing 
protease inhibitors as previously described, together with 1 mM EDTA and 4 mM 
DTT. The dialysed ammonium sulphate liver fraction was syringe-filtered using a 0.2 
pm  disposable filter. Prior to further purification, low molecular weight inhibitors, such 
as purines, were removed by gel filtration using a Sephadex G-25 PD-10 column 
(Section 3.2.2).
For requirements of small amounts of crude liver protein (e.g. for activity and protein 
assays, or SDS-PAGE and Western blotting purposes), the ammonium sulphate liver 
fraction was frozen. The pelleted fraction from ammonium sulphate precipitation was 
redissolved in 50 mM Na-Bicine, containing 1 mM EDTA and 4 mM DTT, pH 8.3, and 
dialysed against the same buffer. Phosphate buffer was avoided in this case, as the pH 
drop upon freezing in this buffer is likely to be detrimental to the protein. Following 
dialysis, the crude liver protein was drip-frozen into liquid nitrogen and stored at —70 °C 
for future use. Rapid freezing in this way did not appear to influence the specific 
activity of the enzyme, nor did it seem to initiate dehydrogenase to oxidase conversion.
8.2.2.2 Pre-purification of liver ammonium sulphate fraction
The ammonium sulphate liver fraction, dialysed against PBS (Section 8.2.2.1), was 
circulated for 2 h at 4 °C on an uncoupled Protein A-Sepharose column, pre- 
equilibrated in PBS (Section 7.2.2.3).
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8.2.2.3 Preparation of a polyclonal anti-(HMXOR) column
A polyclonal anti-(HMXOR) immunoaffinity column (3-4 ml) was prepared as 
described in Section 7.2.2.1.
8.2.2.4 Preparation of a monoclonal anti-(HMXOR) column
Two ways of immobilising monoclonal antibody using different means of coupling were 
investigated, coupling to CNBr-activated Sepharose and coupling to Protein A- 
Sepharose. Mouse monoclonal anti-(HMXOR) clone 1D9D1 was selected for 
immunoaffinity column use because it was found to be highly specific, as can be seen 
from the following Results section.
8.2.2.4.1 Coupling to CNBr-activated Sepharose 4B
The antibody solution (10 mg) was extensively dialysed against 0.5 M Na-phosphate, pH
7.5, to remove extraneous compounds containing amino or thiol groups (which would 
interfere with the coupling). The CNBr-activated Sepharose 4B beads (1 ml) were 
added (after which a small volume was routinely retained and assayed in order to 
determine the coupling efficiency), and the suspension was mixed gendy at room 
temperature overnight on a rocker. The beads were washed twice with 0.5 M Na- 
phosphate, pH 7.5, and then with 0.05 M Na-phosphate, containing 2 M NaCl, pH 7.5. 
10 vol of 100 mM ethanolamine, pH 7.5, were then added, followed by incubation at 
rpotn temperature overnight with gentle rocking. The coupling efficiency was 
calculated at this stage and was consistently between 70 % and 80 %. Two washes were
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performed with PBS, and 0.01 % ("/ v) sodium azide was added. The beads were 
poured into a column and the column matrix was stored at 4 °C until required.
8.2.2.4.2 Coupling to Protein A-Sepharose
Protein A has varying affinities for antibodies from different species, classes and 
subclasses. Although it has a high affinity for rabbit IgG (all subclasses), it has a much 
lower affinity for mouse IgG, particularly mouse IgG,. The mouse monoclonal 1D9D1 
antibody used for the present studies was of the subclass IgG,, necessitating coupling 
under conditions modified from those used when preparing the polyclonal rabbit anti- 
(HMXOR) IgG column (as described in Section 7.2.2.1).
The affinity of IgG, for Protein A can be increased by adjusting the binding conditions 
by using high salt concentrations that favour the hydrophobic Protein A-Fc binding. 
The antibody solution 1D9D1 (10 mg at 5 mg/ml) was adjusted to pH 9, and NaCl was 
added to raise the concentration to 3 M. The antibody was mixed with Protein A beads 
(2 ml) at room temperature for 1 h, with gende rocking. The beads were washed twice 
with 10 volumes of 50 mM Na-borate, containing 3 M NaCl, pH 9, by centrifugation 
and aspiration. The beads were resuspended in 10 volumes of 0.2 M Na-borate, 
containing 3 M NaCl, pH 9. Dimethylpimelimidate (solid) was added to bring the final 
concentration to 20 mM. The suspension was mixed at room temperature for 30 min 
on a shaker. The reaction was stopped by washing the beads in 0.2 M ethanolamine, 
pH 8, incubating at room temperature for 2 h with gende mixing. The beads were
Chapter 8 116
resuspended in PBS with 0.01 % ("/ v) sodium azide, and poured into a column. The 
column matrix was stored at 4 °C until required.
8.2.2.5 Polyclonal immunoaffinity purification of HLXOR
This method is the same as that described in the previous Chapter (Section 7.2.2.4) for 
the purification of XOR from bovine liver. The ammonium sulphate fraction of human 
liver, which had been pretreated with Protein A-Sepharose (Section 8.2.2.2), was diluted 
1:10 in PBS (containing 0.01 % ("/ v) sodium azide) and applied to the anti-(HMXOR) 
immunoaffinity column (Section 8.2.2.3), which had been previously equilibrated in the 
aforementioned buffer. Circulation was allowed to occur for 2-3 h at 4 °C in order to 
saturate antibody-binding sites. Following circulation, the column was washed 
extensively with PBS, followed by PBS containing 1 M NaCl, to remove unbound or 
weakly bound protein, until A2g0 reached baseline values. To elute XOR, 25 mM 
diethylamine, containing 35 mM NaCl, pH 10.5, was applied to the column. The bound 
protein was collected in 50 mM Na-Bicine, pH 8.3 (5-fold excess), to neutralise the 
alkalinity o f the diethylamine. The eluted fraction was immediately dialysed against one 
change of 50 mM Na-Bicine, containing 0.05 M NaCl, 1 mM EDTA and 4 mM DTT, 
pH 8.3. The dialysed material was incubated with 1 mM FAD for 10 min at room 
temperature. Following incubation with FAD, further dialysis was carried out against 
several changes of 50 mM Na-Bicine, containing 0.05 M NaCl, 1 mM EDTA and 4 mM 
DTT, pH 8.3, to remove the excess FAD.
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The same liver fraction was subjected to four consecutive circulations and elutions from 
the immunoaffinity column. Following each elution of bound protein, the column was 
regenerated by washing with PBS, followed by 0.1 M Na-acetate, pH 4.5. When not in 
use the column was stored in PBS with 0.01 % (w/ v) sodium azide added to prevent 
microbial growth.
8.2.2.6 Immunoprecipitation
The antibody solution 1D9D1 (2 mg, 3 mg/ml) was coupled to CNBr-activated 
Sepharose beads (200 pi) (Section 8.2.2.4.1). The beads were incubated with 200 pi 
ammonium sulphate human liver fraction (prepared as described in Section 8.2.2.1) for 
2 h at 4 °C with gentle rocking. The beads were washed three times with PBS by 
centrifugation and aspiration. 6 M urea was added to dissociate bound protein from the 
beads, followed by centrifugation. The supernatant was electrophoresed (Section 
3.2.1.1).
8.2.2.7 Monoclonal immunoaffinity purification of HLXOR
This was performed essentially as described in Section 8.2.2.5, except that 100 mM 
glycine, pH 2.5, replaced 25 mM diethylamine, containing 35 mM NaCl, pH 10.5, as an 
eluant.
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8.2.2.8 Removal of immunoglobulin by circulation on Protein L-
Sepharose
This step was performed immediately after immunoaffinity chromatography to remove 
immunoglobulin that may have co-purified with XOR, or have leached from the 
immunoaffinity column. Protein L is produced by Peptostreptococcus magnus and contains 
four immunoglobulin-binding domains. Unlike other bacterial immunoglobulin (Ig) 
binding proteins such as Protein A and Protein G, Protein L binds Ig through the K 
light chain. As a result, Protein L binds with equal strength to all subclasses of human, 
mouse and rat IgG. In addition, it binds strongly to IgA, IgD, IgE, and IgM, as well as 
to Fab and scFv fragments.
Protein L-Sepharose (4 ml) was poured into a column and equilibrated in 50 mM Na- 
Bicine, pH 8.3. The immunopurified liver fraction (Sections 8.2.2.5 and 8.2.2.7) was 
filtered and circulated on an uncoupled Protein L-Sepharose column for 2 h at 4 °C in 
order to remove immunoglobulin. Such a procedure is termed ‘negative’ or subtractive 
immunopurification. Bound protein was eluted with 0.1 M glycine, pH 2. The bound 
fraction was discarded, and the remaining circulated fraction was retained. Enzyme was 
concentrated using Vivaspin 2ml concentrators (Vivascience), drip frozen into liquid 
nitrogen and stored at -70°C.
8.2.2.9 Blotting method for N-terminal protein sequencing
A 7.5 % reducing SDS-PAGE gel was run as described in Section 3.2.1.1. Powder-free, 
low protein gloves were worn at all times. The blotting buffer contained 10 mM CAPS
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(4.42 g), 10% MeOH (200 ml) made up to 2000 ml, pH 11. Membrane (Problot) was 
cut to the size of the gel, and soaked in methanol for a few minutes. Two pieces of 3 
mm filter paper and fibre pads were also cut to the same size as the gel and soaked in 
blotting buffer. The gel was soaked in blotting buffer for at least 10 min, with frequent 
changes, to remove all traces of glycine. Blotting was carried out essentially as described 
in Section 3.2.1.2. The transfer was run at 300 mA for 2 h, ensuring that the voltage did 
not go over 100 V. Following transfer, membrane was stained with 0.1 % Amido Black 
(40 % methanol/1 % acetic acid) for 30 s. Destaining was carried out by agitation of 
membrane in distilled water, with frequent changes. Bands of interest were cut from 
the membrane and stored in an Eppendorf tube at —20 °C until ready for sequencing.
Chapter 8 120
8.3 Results
8.3.1 Polyclonal immunoaffinity purification of HLXOR
Ammonium sulphate fraction from human liver was first circulated on an uncoupled 
Protein A-Sepharose column (Section 8.2.2.2), and then subjected to immunoaffinity 
chromatography (Section 8.2.2.5).
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8.3.1.1 SDS-PAGE gel and Western blot
Upon elution from the anti-(HMXOR) immunoaffinity column, with 25 mM 
diethylamine, containing 35 mM NaCl, pH 10.5, a peak was detected by UV absorbance 
at 280 nm. The protein representing this peak was collected, dialysed, incubated with 1 
mM FAD, and further dialysed (Section B.2.2.5). Following dialysis, the eluted fraction 








Figure 8.3.1 7.5 % SDS-PAGE gel of immunoaffinity-purified protein
Lane 1 corresponds to high range molecular weight standards, lane 2 corresponds to
human liver homogenate and lanes 3 and 4 correspond to immunoaffinity-purified 
protein (15 jig).
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Figure 8.3.2 7.5% SDS-PAGE gel and Western blot
In both the SDS-PAGE gel and corresponding Western blot, lane 1 corresponds to 
HMXOR, lane 2 corresponds to immunoaffinity-purified protein (15 pg) and lane 3 
corresponds to high range molecular weight standards, with coloured standards used for 
the Western blot. Western blotting (Sections 3.2.1.3 and 3.2.1.4) was carried out, using 
the monoclonal antibody 1D9D1, this being an alternative antibody to the affinity- 
purified polyclonal antibody used to prepare the column. From these results, it appears 
that HLXOR is represented by a doublet of bands, of approximately 150 kDa and 135 
kDa, with the latter being the major band. Both of these bands are positively stained on 
the corresponding Western blot. It can be seen that there is an additional band with a 
molecular weight of approximately 50 kDa, highlighted by the arrow. This band is 
neither a proteolysis nor a degradation product of HLXOR, as a band of this si2e is not 
apparent from the Western blot. It is thus likely to represent a contaminating protein.
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8.3.1.2 Specific activity
The specific activity was calculated at each stage of the purification, as shown in the 
table below. Similar starting amounts of liver were used in all purifications.
Purification 1 
(nm ol/m in/m g)
Purification 2 
(nm ol/m in/m g)
Purification 3 
































Specific activities were calculated using the urate assay (Section 3.2.4.2). The percentage 
of enzyme in the oxidase form was also calculated at each stage (Section 3.2.4.2). Total 
yield of protein (mg) was measured using the Bradford method (Section 3.2.3).
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8.3.1.3 UV-visible spectrum
The UV-visible spectrum of immunoaffinity-purified HLXOR is represented below, 
measured as described in Section 4.2.2.4.
0.7













Figure 8.3.3 UV-visible spectrum of immunoaffinity-purified HLXOR
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8.3.1.4 N-tetminal sequencing
Immunoaffinity-purified protein was subjected to N-terminal sequencing for further 
identification. The protein was blotted as described in Section 8.2.2.9. The sequencing 
was kindly carried out by Paul Talbot and Graham Kemp at University of St. Andrews, 
Scotland (Protein Sequencing Facility).
The major band of 135 kDa (refer to Fig 8.3.2) was sequenced, along with the lower 
band of approximately 50 kDa, corresponding to a likely contaminant. A BLAST query 
search was carried out to determine the match of the peptide sequence.
Results:
There were about 200 residues (20 kDa) missing from the start of the sequence at the 
N-terminal end. The N-terminal sequence of the 135 kDa band through nine cycles 
was Lys-Lys-Asp-His-Ser (KKDHS).
1 mtadklvffv ngrkwekna dpettllayl rrklglsgtk lgcgeggcga ctvmlskydr 
61 lqnkivhfsa naclapicsl hhvavttveg igstktrlhp vqeriakshg sqcgfctpgi 
121 vmsmytllm qpeptmeeie nafqgnlcrc tgyrpilqgf rtfardggcc ggdgnnpncc 
181 mnqKKDHS lspslfkpee ftpldptqep ifppellrlk dtprkqlrfe gervtwiqas 
241 tlkelldlka qhpdaklwg nteigiemkf knmlfjpmivc pawipelnsv ehgpdgisfg
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BLAST query search 
KKDHS was matched to:
XDH Human Xanthine Dehydrogenase/Oxidase
Length =133 kDa 
184 KKDHS 188
Human calcium/calmodulin-dependent 3’, 5’-cyclic nucleotide phosphodiesterase 1C 
(HCAM-3)
Length = 71 kDa
616 KKDHS 620
Human hypothetical protein Zap3
Length = 33 kDa
159 KKHDS 163
The lower 50 kDa band contained peptide sequences that were matched to 
immunoglobulin heavy chains.
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8.3.2 Monoclonal immunoaffinity purification
Purification of HLXOR was attempted using immobilised monoclonal antibodies. 
There are a number of advantages to using monoclonal antibodies over polyclonals. 
They are essentially available in an unlimited supply, and have the potential to produce a 
greater overall purification — high-affinity monoclonals are able to bind a large 
proportion of antigen. In addition, they are desirable because there is less variation 
between purifications as the monoclonal antibodies are all identical, and bind to the 
same epitope, compared with polyclonal antibodies, which typically bind to multiple 
epitopes on the antigen. However, problems with the use o f monoclonal antibodies can 
include low-affinity interactions with antigen, or possible cross-reactions.
For the purpose of immunoaffinity purification, it was necessary to determine which 
monoclonal antibody clone had a suitable affinity towards HLXOR. A range of anti- 
(HMXOR) monoclonal antibody solutions were kindly provided (Eurogenetics, 
Belgium) for testing.
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8.3.2.1 Testing specificities of monoclonal antibody clones using
Western blotting
Western blotting was performed with three monoclonal antibody clones: 3C9D5, 
3E7A6 and 1D9D1. The Western blot results are shown below.
3C9D5 3E7A6 1D9D1
1 2 3 4  1 2 3 4 5  1 2 3 4
Figure 8.3.4 Western blots using different monoclonal anti-(HMXOR)
clones
3C9D5: Lane 1 corresponds to coloured high range molecular weight standards,
lane 2 corresponds to purified BMXOR, lane 3 corresponds to human liver ammonium 
sulphate fraction, and lane 4 corresponds to purified HMXOR.
3E7A6: Lane 1 corresponds to coloured high range molecular weight standards,
lane 2 corresponds to purified BMXOR, lane 3 corresponds to purified HMXOR, lane
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4 corresponds to commercial BMXOR (Biozyme), and lane 5 corresponds to human 
liver ammonium sulphate fraction.
1D9D1: Lane 1 corresponds to human liver ammonium sulphate fraction, lane 2
corresponds to purified BMXOR, lane 3 corresponds to purified HMXOR, and lane 4 
corresponds to commercial BMXOR (Biozyme).
From these results, it can be seen that the clone 1D9D1 is immunoreactive with human 




Two immunoprecipitations were performed (Section 8.2.2.6), using monoclonal 
antibody 1D9D1 coupled to CNBr-activated Sepharose 4B. The coupled antibody 
beads were incubated with pure HMXOR and human liver ammonium sulphate 
fraction, in two separate experiments.
1 2 3
Figure 8.3.5 Immunoprecipitation Western blot
Following elution with 6M urea and centrifugation, samples were concentrated using a 
Vivaspin concentrator (Vivascience) and electrophoresed on a 7.5% SDS-PAGE gel. 
Immunoprobing was performed using affinity-purified polyclonal anti-(HMXOR) as the 
primary antibody.
Lane 1 corresponds to coloured high range molecular weight standards, lane 2 
corresponds to precipitated human liver ammonium sulphate fraction, and lane 3 
corresponds to precipitated HMXOR.
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8.3.2.3 Testing the monoclonal immunoaffinity column with pure
HMXOR
A small monoclonal anti-(HMXOR) column (0.5 ml) was prepared (Section 8.2.2.4.1). 
Purified HMXOR (diluted in PBS) was circulated on the column. 100 mM glycine, pH
2.5, and 25 mM diethylamine, containing 35 mM NaCl, pH 10.5, were tested as eluants. 
Glycine was investigated as a possibly gender alternative to diethylamine in view of the 
lesser number of bonds involved in a monoclonal antdgen-antibody complex compared 
with a polyclonal antigen-antibody complex.
Purified HMXOR (0.5 mg) was diluted in PBS to a final volume of 5 ml. The enzyme 
solution was circulated onto the column pre-equilibrated in the same buffer for 2-3 h at 
4°C. HMXOR elutions and subsequent dialysis were carried out, and incubation with 
FAD, followed by further dialysis (Section 8.2.2.5) was effected.
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8.3.2.3.1 Elution of HMXOR with glycine
Bound protein was eluted from the column with 100 mM glycine, pH 2.5. The trace 
below shows the elution of bound HMXOR, monitoring the absorbance at 280 nm. 





Figure 8.3.6 Elution profile of HMXOR using glycine as eluant
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8.3.2.3.2 Elution of HMXOR with diethylamine
Bound protein was eluted from the column with 25 mM diethylamine, containing 35 
mM NaCl, pH 10.5. The trace below shows the elution of bound HMXOR, monitoring 






Figure 8.3.7 Elution profile of HMXOR using diethylamine as eluant
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8.3.2.3.3 UV-visible absorbance spectra of glycine-eluted HMXOR
and diethylamine-eluted HMXOR
The UV-visible spectra of the eluted HMXOR enzymes, measured as described in 
Section 4.2.2.4, are represented below.
8.3.2.3.3.i  Giycine-eluted HMXOR
Wavelength (nm)
Figure 8.3.8 UV-visible absorbance spectrum of glycine-eluted
HMXOR
The red line corresponds to untreated HMXOR, the grey line corresponds to HMXOR, 
following elution from the column with 100 mM glycine, pH 2.5, and subsequent
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incubation with 1 mM FAD (Section 8.2.2.5). The spectra are obtained by dilution of 
protein with 50 mM Na-Bicine, containing 0.05 M NaCl, pH 8.3.
8.3.2.3.3.2 Diethylamine-eluted HMXOR
/ 1 \






300 400 500 600 
Wavelength (nm)
700
Figure 8.3.9 UV-visible absorbance spectrum of diethylamine-eluted 
HMXOR
The red line corresponds to untreated HMXOR, the blue line corresponds to HMXOR, 
following elution from the column with 25 mM diethylamine, containing 35 mM NaCl, 
pH 10.5, and subsequent incubation with 1 mM FAD (Section 8.2.2.5). The spectra are
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obtained by dilution of protein with 50 mM Na-Bicine, containing 0.05 M NaCl, pH 
8.3.
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8.3.2.3.4 Specific activities of glycine-eluted and diethylamine-eluted
HMXOR
The specific activities of HMXOR eluted from the monoclonal anti-(HMXOR) column 
with the two eluants: 100 mM glycine, pH 2.5 and 25 mM diethylamine, containing 35 
mM NaCl, pH 10.5, were determined. These activities were measured following dialysis 
and incubation with 1 mM FAD (Section 8.2.2.5).
Sample Specific activity towards 
xanthine 
(nmoles /  m in/m g)
Specific activity 
towards NADH  
(nm oles/m in/m g)
Untreated HMXOR 72 ± 5 126 ±14
Glycine-eluted
HMXOR
54 ± 3 95 ± 6
Diethylamine-eluted
HMXOR
47 ± 5 70 ± 4
Table 8.3.2
Activities towards xanthine were calculated using the urate assay (Section 3.2.4.2). 
Activities towards NADH were calculated by using the NADH oxidase assay (Section 
3.2.4.3). Values are means ± SD (n = 3).
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8.3.2.3.5 SDS-PAGE gel of glycine-eluted and diethylamine-eluted
HMXOR
Glycine-eluted and diethylamine-eluted enzyme were subjected to SDS-PAGE gel 
analysis to observe whether molecular weight was altered as a result of immunoaffimty 







Figure 8.3.10 7.5% SDS-PAGE gel showing HMXOR following elution
from monoclonal anti-(HMXOR) column with glycine and 
diethylamine
Lane 1 corresponds to glycine-eluted HMXOR, lane 2 corresponds to diethylamine- 
eluted HMXOR and lane 3 corresponds to untreated HMXOR (prior to application to 
the column). The position of high range molecular weight standards are shown 
alongside the right of the gel.
Chapter 8 140
It can be concluded from the above results that the use of both 100 mM glycine, pH 
2.5, and 25 mM diethylamine, containing 35 mM NaCl, pH 10.5, as eluants displaced 
bound HMXOR from the immunoaffinity column, within a similar time period, 
producing comparable elution profiles.
The two bound fractions (enzyme eluted with glycine, and enzyme eluted with 
diethylamine) were subjected to UV-visible scanning to determine whether there had 
been any changes to the spectral properties as a result of exposure to the eluant. 
Scanning was performed following incubation with 1 mM FAD, to reconstitute FAD 
loss as a result of exposure to the eluant. The UV-visible scan of glycine-eluted enzyme 
(Fig 8.3.7) shows lower absorbance in the region of 310 nm to 400 nm, when compared 
with the superimposed scan of untreated HMXOR. The remainder of the scan 
(showing UV absorption above 400 nm) does not seem to have been strongly affected, 
when compared with untreated HMXOR. The UV-visible scan of diethylamine-eluted 
enzyme (Fig 8.3.8) appears to be significantly altered. There is considerably lower 
absorbance in the entire region of 300 nm to 500 nm, when compared with untreated 
HMXOR. This is despite incubation of enzyme with 1 mM FAD, suggesting either 
irreversible loss of FAD, or perhaps alteration of the FAD-binding site as well as Fe/S 
sites of the enzyme, which also contribute to absorbance in this region, resulting in a 
‘flattening’ effect of the scan.
Specific activities towards xanthine and NADH were measured in enzyme eluted from 
the immunoaffinity column with the two eluants, glycine and diethylamine. Enzyme
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was processed for activity assays following dialysis, FAD incubation, and further dialysis 
to remove excess FAD. The specific activities towards xanthine of the eluted enzyme 
were lower than that of untreated HMXOR, in both cases, whether eluted with glycine 
or diethylamine (Table 8.3.2). These activities were 75% and 65% of the original 
untreated enzyme, when eluted with glycine and diethylamine respectively. This 
lowered activity could be ascribed to a number of criteria, including protein 
denaturation or proteolysis, or the formation of inactive enzyme, as a result o f loss of 
Fe/S and/or flavin groups. Incubation with FAD following dialysis was a 
precautionary measure taken to restore the flavin group, but it may be possible that not 
all deflavo-enzyme can be reconverted back to its active form by these means. Hille and 
Massey (1991) reported a restoration of 60 % of original activity upon incubation of 
deflavo-XOR with free flavin. In terms of NADH-oxidation, which occurs at the FAD 
site of the enzyme, enzyme eluted with glycine displayed 75% of the original NADH- 
oxidising activity, and enzyme eluted with diethylamine showed 55% of the original 
activity, substantiating a greater proportion of deflavo-XOR in the latter preparation. 
The formation of deflavo-HMXOR is likely to account for the lower specific activities 
towards xanthine in the immunoaffinity purified preparations. These specific activities 
suggest that glycine has less of a deleterious effect on the enzyme; a conclusion also 
supported by the UV-visible scans. Based on these results, it was decided to use 100 
mM glycine, pH 2.5, as an eluant in the immunoaffinity purification of HLXOR.
Chapter 8 142
8.3.2.4 Monoclonal immunoaffinity purification of HLXOR
A larger monoclonal immunoaffinity column (5 ml) was constructed, using CNBr- 
activated Sepharose 4B (Section 8.2.2.4.1). Ammonium sulphate fraction from human 
liver was first circulated on an uncoupled CNBr-activated Sepharose 4B column, 
essentially as described in Section 7.2.2.3, to remove non-specific protein. The 
remaining liver fraction was then subjected to immunoaffinity chromatography (Section
8.2.2.7), using 100 mM glycine, pH 2.5, in elution, in the place of diethylamine. The 




Figure 8.3.11 Elution profile of HLXOR from monoclonal
immunoaffinity column
The column eluate was monitored using a UV detector linked to a chart recorder. The 
sharp peak on the left of the trace represents bound protein eluted with 100 mM
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glycine, pH 2.5. The bound fraction was a pale yellow in colour, which seemed to 
indicate the presence of XOR. The piifified milk enzymes, in particular the bovine, are 
a distinctive yellow-bro^ii, the colblii: of which can be attributed to the Fe/S and flavin 
present. Three circulations itid  stftisequent elutions were performed from the same 
ammonium sulphate liver fraction, and a peak indicating removal of bound protein 
from the column occurred in each case. Following elution, enzyme was dialysed and 
incubated with 1 mM FAD (Section 8.2.2.5).
The eluted protein was then circulated on a Protein L-Sepharose column (Section
8.2.2.8). An optimal purification, so described, could be performed over two 
consecutive days, from tissue homogenisation to completion of column 
chromatographic steps.
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8.3.2.5 SDS-PAGE gel of monoclonal immunoaffinity-purified HLXOR
Following dialysis, the eluted fractions were concentrated using Vivaspin concentrators 







1 2 3 4 5
Figure 8.3.12 7.5% SDS-PAGE gel
Lane 1 corresponds to HMXOR, lane 2-4 corresponds to three successive elutions of 
HLXOR (4 pg) from the monoclonal immunoaffinity column. Lane 5 corresponds to 
high range molecular weight standards.
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The immunoaffinity-purified HLXOR was run alongside HMXOR and BMXOR, and 
the subsequent SDS-PAGE gel was processed for Western blotting with affinity- 
purified polyclonal and-(HMXOR) antibodies.






Figure 8.3.13 7.5 % SDS-PAGE gel and Western blot
In both the SDS-PAGE gel and Western blot, Lane 1 corresponds to HMXOR, lane 2 
corresponds to HLXOR (4 fig), and lane 3 corresponds to BMXOR. In the 






The specific activity of the monoclonal immunoaffinity-purified enzyme preparation 
was calculated, and is shown in the table below, together with the specific activity of the 
polyclonal immunoaffinity-purified enzyme (as calculated in Section 8.3.1.2). All 

















168 ± 13 
55% oxidase







162 ± 10 
38% oxidase






Specific activities were calculated using the urate assay (Section 3.2.4.2). Values are 
means ± SD (n = 3). The percentage of enzyme in the oxidase form was also
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calculated at each stage (Section 3.2.4.2). Total yield of protein was estimated using 
the Bradford method (Section 3.2.3).
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8.3.2.7 UV-visible spectra
The UV-visible spectra of immunoaffinity-purified HLXOR and that of purified 
HMXOR are represented below.
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Figure 8.3.14 UV-visible spectra of pure HLXOR and HMXOR
The spectrum of immunoaffinity-purified HLXOR is shown on the left, and the 
spectrum o f pure HMXOR is shown on the right.
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8.3.2.8 Coupling monoclonal 1D9D1 anti-(HMXOR) antibody to Protein
A-Sepharose
The previously described work involved coupling antibody to CNBr-activated 
Sepharose 4B to form a monoclonal immunoaffinity column. CNBr-activated 
Sepharose 4B was selected for use following the success of the immunoprecipitadon 
(shown in Section 8.3.2.2). However, successful earlier purification o f HLXOR using a 
polyclonal immunoaffinity column, described at the beginning of this Chapter, involved 
the immobilisation of polyclonal antibody to Protein A-Sepharose 4B. It was thus 
attempted to construct an alternative column by coupling monoclonal antibody 1D9D1 
to Protein A-Sepharose, as described in Section 8.2.2.4.2. Coupling was performed with 
minor modifications to the method used in the coupling of polyclonal antibody to 
Protein A-Sepharose (Section 7.2.2.1), and a small column (1.5 ml) was constructed. 
Bound protein was eluted with glycine (as in Section 8.3.2.4). The resulting eluted 
protein was run on SDS-PAGE gel, which is shown below, together with the 
corresponding Western blot.
1 2  3 1 2  3
mm
Figure 8.3.15 7.5% SDS-PAGE gel and Western blot
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Lane 1 corresponds to high range molecular weight standards, lane 2 corresponds to 
immunoaffinity-purified protein and lane 3 corresponds to purified HMXOR.
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8.4 Discussion
The work in this chapter concerns the immunopurification of human liver XOR 
utilising both polyclonal and monoclonal anti-(HMXOR) antibodies.
Polyclonal immunoaffinity purification utilised 25 mM diethylamine, containing 35 mM 
NaCl, pH 10.5, as an eluant. This is the same eluant as that used in the purification of 
bovine liver XOR. The method gave a reasonably good result, showing two distinct 
bands on SDS-PAGE analysis, of approximately 150 kDa and 135 kDa, with the major 
band at 135 kDa (Fig 8.3.1). There was one other band on SDS-PAGE analysis, with 
molecular weight of approximately 50 kDa. This latter band was not detected by the 
monoclonal anti-(XOR) antibody (Fig 8.3.2), suggesting that it was not likely to be a 
proteolysis or degradation product of XOR. Subsequent N-terminal sequence analysis 
performed on the 135 kDa band substantiated the identity of the enzyme as XOR 
(Section 8.3.1.4). The sequence of this band was Lys-Lys-Asp-His-Ser, which resulted 
in a match to human dehydrogenase/oxidase. The sequence of the lower molecular 
weight band at 50 kDa resulted in matches to immunoglobulin heavy chain. This is in 
good agreement with the size of the protein, as judged by SDS-PAGE.
The positive sequencing of the 135 kDa XOR band confirms the worth of this method 
of purification; successful sequencing indicates that there is no blocking of the amino 
terminus of the enzyme, something that could occur as a result of alternate purification 
methods. This is particularly common with the use of urea in elution.
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The polyclonal immunoaffinity purification method delivered an overall purification of 
approximately 65000-fold (Section 8.3.1.2). This is significandy higher than the 1600- 
fold purification achieved by Moriwaki et al. (1993), and the 2000-fold purification 
obtained by Krenitsky et al. (1986). However, it must be noted that such an estimate 
does not take into account the likely presence of intrinsic inhibitors of XOR e.g. 
purines, in the total liver homogenate, contributing to a lower than true specific activity. 
In addition, further inaccuracies may be incorporated at this stage with the calculation 
of total protein in the homogenate. From ammonium sulphate fraction to following 
immunoaffinity purification there is a purification factor of 975-fold (Table 8.3.1). The 
proportion of enzyme in the total preparation existing as xanthine oxidase was found to 
fluctuate at each purification stage. The proportion of oxidase form in the ammonium 
sulphate fraction is approximately 50 %. In the purified HLXOR preparation, activity 
due to XO ranged from 38 % to 75 % of the total activity. This differs from the 
preparation obtained by Krenitsky et al. (1986), which was fully converted to oxidase 
form, reflected in the extensive proteolysis of the enzyme that had taken place. 
Irreversible conversion of dehydrogenase form to oxidase form is a common 
occurrence during purification procedures, although the extent of conversion can be 
minimised by rapid processing, with minimal manipulation of the enzyme (Saksela et al., 
1999). Even taking such precautions, tissue preparations have been reported to 
consistently contain at least 10-15 % oxidase form (McKelvey et al., 1988). Reasons for 
the dehydrogenase/oxidase ratio variation throughout this purification are unclear. As 
DTT was kept constant throughout the purification it may be that the proportion of
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irreversible xanthine oxidase fluctuates, for example, some irreversible enzyme may be 
lost between the homogenisation step and the ammonium sulphate precipitation step.
The UV-visible scan of this polyclonal affinity-purified enzyme from liver (Fig 8.3.3) did 
not resemble that of purified enzyme from milk, for reasons that are discussed at a later 
stage.
It is not possible to compare fully these results with the polyclonal immunoaffinity 
purification reported by Saksela et al. (1999). These workers did not comment on the 
degree of purification achieved nor their yield. Their purified preparation exhibited 
three bands on SDS-PAGE, of 150 kDa, 130 kDa and 85 kDa. The purified HLXOR 
described in the present work displayed two bands on SDS-PAGE gel of 150 kDa and 
135 kDa, with no bands of lower molecular weight due to XOR present. This is likely 
to be because this preparation is less proteolysed than that obtained by Saksela et al.
Affinity methods of purification were employed by Krenitsky et al. (1986), who obtained 
five bands upon SDS-PAGE gel analysis of their purified human liver enzyme, of 
molecular weights 150 kDa, 135 kDa, 95 kDa, 55 kDa and 38 kDa, with the major band 
at 95 kDa. Their enzyme preparation was reported to have undergone a moderate 
degree of proteolysis, although it appeared to retain its physical properties, which were 
reported to be similar to those of the bovine milk enzymes. This preparation also 
appears to be significantly more proteolysed than the purified enzyme described here. 
However, Moriwaki et al. (1993) acquired a single band of 150 kDa from their affinity-
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purified HLXOR preparation, with no other bands detectable, using both SDS-PAGE 
and activity staining techniques. Variable degrees of proteolysis reflect differences in the 
methods of purification and analysis — either before the processing of samples, during 
purification itself, or on freezing and thawing of the enzyme preparation (Samesto et al., 
1996). It has been suggested that active enzyme exists in partially proteolysed form in 
the intact liver tissue (Samesto et al., 1996). However, this would be inconsistent with 
the findings of Moriwaki et al. (1993), whereby liver XOR was homogeneous as judged 
by PAGE. Variable degrees of proteolysis in post-mortem liver maintained under 
different conditions prior to tissue processing should not be overlooked.
The use of monoclonal antibodies in the isolation of XOR, as opposed to affinity- 
purified polyclonal antibodies was investigated (Section 8.3.2). Three monoclonal 
antibody clones (3D9D5, 3E7A6, 1D9D1) were tested for their relative specificities 
towards HLXOR (in homogenate), and purified XOR enzymes from human and bovine 
milk (Fig 8.3.4). The testing was performed using Western blot analysis. O f the three 
clones, 1D9D1 was the most strongly immunoreactive towards liver XOR, with this 
immunoreactivity being comparable to that towards bovine milk XOR, although highest 
towards the human milk enzyme. No immunoreactivity towards human liver XOR was 
detected with either of the other two antibody clones, although both of these were more 
strongly reactive with enzyme from bovine milk than that from human milk. It is clear, 
therefore, that all three clones are cross-reactive, albeit to different extents, with XOR 
from both milk sources. It must be noted that XOR concentration in total liver 
homogenate is likely to be extremely low, and although maximal amounts of protein
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were used in the Western blots, there may not be sufficient enzyme present for 
reactivity to be seen with a weaker avidity antibody. It is noteworthy that the antibody 
1D9D1 displays strongest specificity towards human milk XOR, against which it was 
raised. This antibody clone was thus chosen to be suitable for the purpose of 
monoclonal immunoaffinity purification of HLXOR.
Immunoprecipitation was carried out in order to further establish whether the 
monoclonal antibody immobilised by coupling to CNBr-activated Sepharose 4B was 
capable o f binding human liver XOR present in a crude mixture (Section 8.3.2.2). This 
was achieved by incubating coupled antibody beads with human liver ammonium 
sulphate fraction. A faint band of approximately 150 kDa was detected after 
incubation, equating to purified human liver XOR, and a similarly sized although more 
pronounced band was detected following incubation with pure HMXOR.
An immunoaffinity matrix of small volume was constructed using 1D9D1 monoclonal 
antibody coupled to CNBr-activated Sepharose 4B. The resulting column was tested 
with purified HMXOR to determine the conditions necessary to dissociate the complex 
(Section 8.3.2.3). In addition, the effect of such a procedure on the enzyme was taken 
into account, by assessing the activity, electrophoretic and UV-visible properties. 
HMXOR was circulated and eluted from the column using essentially the same method 
as that used for polyclonal immunoaffinity purification. However, two elution buffers 
were tested, these being 100 mM glycine, pH 2.5, and 25 mM diethylamine, pH 10.5 
(containing 35 mM NaCl). Both buffers promoted dissociation of antigen-antibody
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complex, producing similar elution profiles. Neither buffer produced any changes in 
the electrophoretic properties of the enzyme (Fig 8.3.10). The most notable differences 
were observed in the UV-visible absorbance spectra. Diethylamine appeared to 
adversely affect the absorbance spectrum of HMXOR, producing a ‘flattened’ scan, 
apparendy lacking absorbance attributable to the Fe/S and flavin groups of the enzyme 
(Fig 8.3.9). Glycine resulted in a scan more closely resembling that of untreated 
HMXOR (Fig 8.3.8). Elution with diethylamine more adversely affected the specific 
activity of the enzyme than did elution with glycine. For these reasons, glycine was 
selected for use as eluant in the purification of HLXOR.
Subjection of human liver ammonium sulphate fraction to monoclonal immunoaffinity 
chromatography produced a sharp increase in protein upon elution with glycine, 
indicating removal of bound protein from the column matrix. The pooled bound and 
eluted protein fractions were then applied to a Protein L-Sepharose column to remove 
residual immunoglobulin, the presence of which was observed with polyclonal 
immunoaffinity chromatography, as evidenced by SDS-PAGE patterns and N-terminal 
protein sequencing. Such immunoglobulin may derive from an endogenous source, 
present in the human liver homogenate from the beginning of the purification, possibly 
co-existing with XOR as an immune complex. Anti-(XOR) antibodies have been 
reported to occur in human serum (Oster et al., 1974; Bruder et al, 1984; Harrison et al., 
1990; Ng et al., 1990; Benboubetra et al., 1997). It is proposed that the IgM anti-(XOR) 
antibodies may play a protective role in the removal of circulating and potentially
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damaging XOR (Benboubetra et al’, 1997). It is unclear whether such antibodies and 
corresponding immune complexes exist in tissues, however.
A second source of immunoglobulin contaminating the purified enzyme preparation 
may be degradation or leaching from the immunoaffinity column itself. Degradation 
seems unlikely, as it is known that antibodies as a group are highly stable, particularly 
resistant to proteolytic attack, and are cleaved selectively by only a limited number of 
enzymes. However, leaching of the antibody from the column is a common problem 
with CNBr-activated Sepharose, as the covalent bonds formed between the ligand and 
the matrix are relatively labile. Although such leakage of antibody was not detected 
during SDS-PAGE analysis, when testing the monoclonal column with purified 
HMXOR, it was decided to incorporate a further ‘subtractive’ immunopurification step 
using Protein L-Sepharose, as a precaution. The presence of anti-(XOR) antibody in 
the immunopurified XOR preparation is particularly undesirable as it may inhibit by 
binding to the enzyme, producing an inaccurate calculation of specific activity. Such an 
effect has been observed with affinity-purified anti-(human XOR) antibodies displaying 
partial inhibition of XOR enzymic activity (Benboubetra et al., 1997).
SDS-PAGE analysis of the final purified protein resulted in two distinct bands, with the 
major band at approximately 155 kDa and the minor band at 135 kDa (Fig 8.3.12), 
showing a similar pattern to the doublet of 150 kDa and 135 kDa obtained with 
polyclonal immunoaffinity purification. The observation that the major band is 
equivalent to the higher molecular weight band of the doublet differs from polyclonal-
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affinity purified HLXOR where the major band is of 135 kDa as opposed to 150 kDa. 
This could be because the monoclonal affinity-purified HLXOR is less proteolysed than 
the polyclonal affinity-purified preparation. HeUsten-Westing (1993) identified three 
main bands on SDS-PAGE attributable to human liver XOR, with molecular weights of 
155 kDa, 143 kDa, and 95 kDa, following affinity purification using monoclonal 
antibody. The first two bands obtained by Hellsten-Westing are similar to those 
obtained in the results here, although no lower band at 95 kDa was apparent. As 
discussed previously, different proteolytic states of the original liver samples are clearly a 
potentially complicating factor.
Western blotting of the monoclonal immunopurified protein using polyclonal affinity- 
purified anti-(HMXOR) antibody produced staining of both the 155 kDa and 135 kDa 
bands. The immunopurified HLXOR was electrophoresed alongside BMXOR and 
HMXOR, and it is interesting to note that there are apparent differences in molecular 
weight between the three XOR enzymes. HLXOR is represented by a distinct doublet 
of bands on SDS-PAGE gel, at 155 kDa and 135 kDa. HMXOR typically displays a 
single band on SDS-PAGE gel, corresponding to a molecular weight of approximately 
150 kDa, although when slighdy proteolysed, a second band is commonly observed 
corresponding to approximately 135 kDa, similar to that observed with HLXOR in this 
study. This has been observed within the laboratory and has been reported by Abadeh 
et al. (1992). It can be seen from the SDS-PAGE results in Figs 8.3.12 and 8.3.13 that 
the two human enzymes run essentially as the same molecular weight.
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Bovine milk XOR, on the other hand, appears to differ slighdy in molecular weight, as 
judged by SDS-PAGE. The major band of the bovine enzyme corresponds to a 
fractionally lower molecular weight than that of HMXOR, of approximately 147 kDa 
(Godber, B., Ph.D. Thesis, 1998). However, it appears that the three enzymes do share 
similar patterns of degradation. A commercially obtainable form of BMXOR produces 
multiple degradation bands on a gel, routinely observed within our laboratory. The 
molecular weights of these bands bear similarities to a proteolysed preparation of 
human milk enzyme. Samesto et al (1996) comment that the cleavage of purified 
HMXOR and enzyme in tissue homogenates is not random, due to the observation that 
similarly sized fragments are consistently apparent on SDS-PAGE analysis and Western 
blotting. As previously mentioned, it cannot be ruled out that the variations in number 
of, and apparent sizes of minor bands seen on SDS-PAGE, might reflect variable 
extents of proteolysis of the enzyme.
Nevertheless, differences between the mobility of bovine and human milk enzymes 
have long been observed in our laboratory, and these cannot themselves be explained in 
terms of tertiary structure of the proteins (Godber B., Ph.D. Thesis, 1998). The amino 
acid sequences of BMXOR (Berglund et al, 1996) and HLXOR (Ichida et al., 1993) have 
been reported and are very similar, although the liver sequence contains 143 amino acid 
changes. The sequence of human mammary gland epithelial cell XDH has been 
determined (Pearson, A., Ph.D. Thesis, 2001) and is identical to those sequences already 
determined for human liver and small intestine (Ichida et al., 1993; Saksela & Raivio, 
1996; Yamamoto et al, 2001). The primary sequence of HMXOR is also identical to
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that determined for BMXOR, and it appears that differences between the two enzymes 
are mainly in the 3-dimensional structure of HMXOR, which is lacking molybdenum 
cofactor (Pearson, A., Ph.D. Thesis, 2001). If the differences in molecular weight were 
observed under non-denaturing, native conditions, they might be explained in terms of 
enzymic structure, for example, HMXOR will have a more open conformation due to 
the lack of molybdenum cofactor (Godber et al., 1997; Pearson, A., Ph.D. Thesis, 2001). 
However, as separation by SDS-PAGE is dependent on molecular size alone, and the 
net charges of all proteins are made constant, it is difficult to explain these observations. 
In view of this, the difference in the apparent molecular weights of the human and 
bovine enzymes pose a quandary that is very difficult to explain.
There is not much difference observed between the specific activities towards xanthine 
of the polyclonal and the monoclonal immunopurified enzymes, nor in the yields 
obtained using the two methods (Table 8.3.3). The mean specific activity of the purified 
liver enzyme using monoclonal immunoaffinity purification (166 nmol/min/mg) is 
significantly higher than the specific activity of the enzyme purified by Moriwaki et al. 
(1993) (0.96 nmol/min/mg), using a range of non-immune affinity methods. Moriwaki 
et al. used essentially the same procedure to calculate enzyme activity towards xanthine 
and it is unclear why the specific activity should differ so greatly. Such disparity may be 
attributed towards differences in the purification procedures used, and if this is the case, 
one may conclude that immunoaffinity methods are less detrimental towards the activity 
of the enzyme than non-immune methods of purification. On the other hand, the 
difference in activity may be due to isolation of active enzyme using affinity methods of
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Moriwaki et al., whereas the immunoaffinity methods used in this study do not 
distinguish between active and inactive forms of enzyme. This, and the specific activity 
of HLXOR in relation to the respective specific activities of the two milk XORs will be 
discussed further in the next Chapter.
The UV-visible spectrum of the monoclonal immunopurified enzyme was compared 
with that of purified HMXOR (Fig 8.3.14). However, the spectrum of the liver enzyme 
was disappointing in that it did not show the distinctive peaks at 350 and 420 nm, 
suggesting that the flavin and Fe/S sites had been affected as a result o f the purification. 
Although some yellow-brown colour (usually indicative of both flavin and Fe/S groups) 
was observed in the column eluate, this did not appear to be reflected in the scan. 
HLXOR was incubated with FAD following dialysis, to reconstitute the enzyme if 
flavin concentration was low, as a result of exposure to the eluant glycine. In addition, 
during earlier experiments subjecting purified HMXOR to immunoaffinity 
chromatography and elution with glycine there were no such detrimental effects to the 
enzyme apparent from the UV-visible spectrum. However, there may be some alternate 
damage to the structure of the immunopurified liver enzyme, accounting for the 
irregularities in the UV-visible properties.
As a final experiment, it was attempted to conjugate monoclonal antibody to Protein A- 
Sepharose (Section 8.3.2.8), as was performed with polyclonal anti-(HMXOR) antibody, 
described at the beginning of this Chapter. This was performed in order to compare 
the relative efficacy of the resulting purification with the purification achieved using
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monoclonal antibody coupled to CNBR-activated Sepharose 4B, which has already been 
established to be a viable method. It is evident from the numerous bands observed 
upon SDS-PAGE of the immunopurified protein that the purification was not effective. 
Although XOR was evident in the bound fraction, as determined by the Western blot, 
several other proteins co-purified. This could indicate some problem with the antibody 
coupling, or perhaps the orientation of the antibody did not promote a stable 
interaction with the ligand. It is known that mouse monoclonals have a far lower 
affinity towards Protein A than the rabbit polyclonals used previously. Thus, the low 
affinity of the antibody may result in a weak coupling with the Protein A matrix, leading 
to leaching of antibody during column usage, and an inefficient purification.
Considering the two immunoaffinity methods described in this Chapter, employing 
both polyclonal and monoclonal anti-(HMXOR) antibodies, it is reasonable to conclude 
that both are effective and rapid means of XOR purification, as opposed to non- 
immune affinity procedures. Enzyme purified using monoclonal antibodies appeared to 
be purer than that purified with polyclonal antibodies. Thus, for all further studies 
requiring purified HLXOR, monoclonal immunoaffinity-purified enzyme was chosen.
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9. Human liver xanthine oxidoreductase (HLXOR):
specific activity, immunolocalisation and crystallisation
9.1 Introduction
9.1.1 XO and liver disease
It is known that hereditary xanthinuria is characterised by undetectable levels of 
xanthine oxidoreductase (XOR) activity in patients. There is, however, litde known 
about the extent and nature of variations of XOR activity in human individuals, nor 
about the significance of such variation in drug metabolism (Guerciolini et al\, 1991). 
One investigation attempted to study functional variation of xanthine oxidase (XO) 
activity by measuring the urinary metabolites of caffeine, which is pardy metabolised by 
XO (Grant et al., 1983). This study found an approximately 2.8-fold variation among a 
total of 68 subjects studied, with no indication of the existence of subgroups within this 
population sample. A more recent study (Guercolini et al., 1991) used a sensitive 
radiochemical assay to study activity in 189 hepatic tissue samples, taken from patients 
undergoing partial hepatectomy or open liver biopsy. Interestingly, the results indicated 
an average 21 % higher XO activity in samples taken from male patients than in those 
from female patients. In patients with normal liver function, results suggested the 
presence of a subgroup of samples with relatively low XO activity in 21 % of male 
patients and 27 % of female patients. The authors proposed that these observations
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may be associated with individual variation in the biotransformation o f drugs 
metabolised by XO.
As a potent generator of ROS and free radicals, XOR has been implicated in the 
pathogenesis of many diseases, particularly ischaemia-reperfusion injury (McCord, 
1995). XO levels in human serum are almost undetectable under normal conditions. 
However, increases have been reported in numerous pathological states, most notably 
those affecting the liver, in which the hepatocytes, sinusoidal endothelial cells and 
Kupffer cells are reportedly rich in the enzyme (Wiezorek et al, 1994). Elevated levels 
o f human serum XO have been found in several cases of liver damage, such as viral 
hepatitis (Shamma’a et al, 1965; Ramboer et al, 1972; Wolko & Krawczynski, 1974; 
Giler et al, 1975; Yamamoto et al, 1996), in alcoholism (Grattagliano et al, 1996), and 
following halo thane anaesthesia (Giler et al, 1977). Increased XO activity in serum has 
been observed after tourniquet ischaemia in patients undergoing reconstructive surgery, 
whereby effluent blood was evaluated following reperfiision (Friedl et al, 1990). 
Reperfusion during liver transplantation has also been found to be associated with 
release of XO, as well as hypoxanthine and xanthine, from the liver into the circulation 
(Pesonen et al, 1998). Circulating XO has been suggested to cause oxidative damage at 
other sites through the production of ROS (Yokoyama et al, 1990). Higher levels of 
XO were measured in the plasma of preterm neonates (Supnet et al, 1994). This is of 
particular significance as liver damage is very common among extremely premature 
infants. Elevated levels of XO are also found in the plasma of hypoxic patients with 
adult respiratory distress syndrome (Grurn et al, 1987). A recent study has established
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levels of XO in the sera of patients with various inflammatory and autoimmune 
rheumatic diseases to be up to 50-fold higher when compared to the sera of healthy 
donors and patients with non-rheumatic diseases (Miesel & Zuber, 1993). The 
determination of XO levels in sera could have a clinical value, at least in the evaluation 
o f liver diseases. Various tests have been designed for this purpose, including those 
based on activity assays (Yamamoto et al'., 1996) and ELISA (Batelli et al., 1999). It has 
been suggested that release of XO into the serum could occur as a result of hepatic cell 
damage, or severe Ever necrosis (Batelli et al., 1996). The administration o f ricin induced 
Ever necrosis in rats, causing Ever XO to be markedly increased, although serum XO 
remained the same. On the other hand, treatment with saporin resulted in elevated 
serum XO, but not in levels of Ever enzyme, suggesting functional differences in 
necrotic Ever lesions (BatelE et al., 1996).
BatelE et al. (2001) investigated, by ELISA, the level o f XO in the serum of patients with 
various Ever disorders, including cirrhosis, chronic viral hepatitis and cholestasis (a 
disorder of the biliary tract). They found XO levels to be significandy higher in aU 
patients, compared with controls. Cholestatic patients had serum XO values higher 
than those of patients with cirrhosis or chronic hepatitis. There appeared to be no 
correlation between serum XO levels and evidence of hepatocyte necrosis in these 
patients, however, leading to the proposal that the enzyme is either not released during 
hepatocyte injury, or it is released, but only in the very early stages of damage.
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Primary biliary cirrhosis (PBC) is a chronic autoimmune-mediated biliary disease, 
resulting in a loss of bile ducts. It is characterised by the spontaneous destruction and 
obliteration of septal and intrahepatic bile ductules, associated with an infiltration of 
plasma cells and lymphocytes in the portal tracts, hepatitis, fibrosis, and slowly 
progressive intrahepatic cholestasis, ending with established biliary cirrhosis (Kaplan, 
1987; Moreno-Otero et al., 1989). The disease is believed to be the result of an altered 
autoimmune response mediated by T cells, or by disease-specific antimitochondrial 
autoantibodies, thought to be less likely (James et al., 1983). A connection between the 
accumulation of free radicals, and the process of lipid peroxidation, has been implicated 
in PBC (Ono et al, 1991), in addition to other hepatic disorders, including alcoholic 
hepatitis and hepatocarcinogenesis (Marklund et al., 1982; Klein et al., 1983; Kubota et 
al., 1985).
Chronic cholestasis, a feature of PBC, results in the accumulation o f cytotoxic bile acids 
in the liver, thought to be the major cause of liver necrosis and subsequent liver fibrosis 
(Poli et al., 1993; Parola et al, 1996). Schimpl et al. (2000) investigated the hepatic XO 
and XDH activities in the livers of chronic cholestatic rats. Their results showed a 
significant increase in XO activity, leading to the hypothesis that the oxidative hepatic 
parenchymal cell damage seen in this disease might at least be partially initiated by XO- 
generated ROS. Treatment with allopurinol attenuated hepatic XO activity, exerting a 
hepatocellular protective effect.
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9.1.2 Localisation o f  liver X O R
Kooij et al. (1992) investigated the localisation of both the dehydrogenase and oxidase 
forms of XOR in post-mortem human liver, using an activity-based detection method. 
Activity was higher in the periportal sinusoidal cells of the liver lobule, whereas the 
pericentral area was less intensely stained. In addition, activity was observed in the 
hepatocytes of both the pericentral and periportal areas. Individual variation in the 
XOR activity of the human livers measured in this study was also apparent, confirming 
the earlier findings of Guerciolini et al. (1991).
Immunohistochemical localisation of XOR has been reported in various tissues from 
various animal species, reviewed by Kooij (1994) and Moriwaki et al (1997) but there 
have been fewer reports on the localisation in human tissues. These reports, particularly 
those concerning the liver, show conflicting results. The immunohistochemical 
localisation of human liver XOR was examined in 1993 by Moriwaki and co-workers. 
They used polyclonal antibodies raised against HLXOR and an avidin-biotin-peroxidase 
detection system. XOR was detected in the cytoplasm of hepatocytes and endothelial 
lining cells, but not in the bile ducts. They confirmed the cytoplasmic location o f the 
enzyme, first reported from the biochemical data of Jarasch et al. (1981). A second 
study by the same group, based on essentially the same method, found XOR localisation 
in the cytoplasm of hepatocytes once again, with more intense staining in the pericentral 
and periportal regions than the mid-zonal area, and in the sinusoidal cells. Staining of 
the bile duct was also seen, in contrast to the previous findings (Moriwaki et al., 1996b).
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In a more recent study, Linder et al. (1999), using an immunohistochemical method with 
a polyclonal antibody raised against HMXOR, detected a strong lobular gradient of 
XOR protein. Staining was evident in the cytoplasm of periportal hepatocytes, in the 
Kupffer cells of some liver samples, and absent in the perivenous region. Bile duct 
epithelia were negative, as well as portal vein and hepatic artery endothelium. These 
findings are pardy at variance with the previous findings of Moriwaki et al. (1996b). The 
staining of XOR in Kupffer cells, which Linder et al. found in one-third of liver samples 
was not reported by Moriwaki et al. (1996b). Linder et al. went on to propose that XOR 
expression in the Kupffer cells, which are the resident macrophages of the liver, could 
either be the result o f induction in these cells, or the uptake of protein from the 
circulation. The failure of Linder et al. to find staining in the bile ducts is also at 
variance with Moriwaki et al. (1996b).
The disparity between these immunohistochemical results in human liver could well be 
the result o f the varying natures of antibodies used in detection. There is a considerable 
need for reliable and consistent information regarding XOR distribution in the liver, 
using a well-characterised and highly specific antibody. Such information will provide 
us with greater understanding of the pathophysiological role o f this enzyme.
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9.1.3 Crystallisation o f X O R
Small crystals of bovine milk XO were obtained as early as 1954, during the purification 
of the enzyme (Avis et al'., 1954). They were not, however, of a sufficient quality to 
allow analysis. Diffraction to 2.1 A was briefly reported from crystals of bovine milk 
XO in 1993 (Eger et al., 2000) but it was only recently that the solution of the crystal 
structures o f both BMXO and BMXDH (complexed to the inhibitor salicylate) to 2.1 A 
and 2.5 A respectively, were presented (Enroth et al., 2000). In this report, Enroth and 
colleagues described the major three-dimensional changes occurring in the proteolytic 
conversion of the dehydrogenase to the oxidase form of the enzyme. Rat liver XO 
crystals have been produced, diffracting to 2.6 A, although a solution has not yet been 
reported for these (Carvalho et al., 1998).
Crystals of human milk XOR, in its demolybdo form, diffracting to 3.5 A, have been 
very recently obtained (Pearson, A., Ph.D. Thesis, 2001). This is the first report of the 
crystal structure of both human XOR, and of a demolybdo form of XOR.
Prior to the elucidation of the crystal structure of XOR, that of aldehyde oxidoreductase 
(MOP) from D. gigas, which shows a 50 % sequence identity with XOR, was the only 
such information from a representative of the XOR family (Thoenes et al., 1994; Romao 
et al, 1995). MOP contains a molybdopterin and two Fe/S cofactors, although it lacks 
the FAD domain. Study of its structure allowed understanding of the role of the metal 
coordination site in catalysis and the proposal of a catalytic mechanism for XOR. The 
crystal structures of other XOR family members followed. These included aldehyde
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oxidoreductase (MOD) from D. desulfuricans (Rebelo et a l 2000), carbon monoxide 
dehydrogenase (CODH) from O. carboxidovorans (Dobbek et al!, 1999) and the 
demolybdo CODH from H. pseudoflava (Hanzelmann et al., 2000). Together these 
structures have succeeded in providing us with details of the environment and 
arrangement of the various prosthetic groups, as well as contributing to knowledge of 
structure-based mechanisms of XOR activity.
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The work in this Chapter investigates the specific activity o f human liver XOR, isolated 
using the monoclonal immunoaffinity purification described in the previous Chapter, 
and relates this activity to that of enzymes from bovine and human milk. Quantification 
of XOR protein in human liver homogenate, using ELISA, is also attempted. XOR 
activity in homogenates of human primary biliary cirrhotic liver is then discussed, and 
contrasted with that in normal human liver. Immunohistochemical staining is employed 
using 1D9D1 monoclonal antibody to detect localisation of XOR in human liver 
sections. Finally, the crystallisation of HLXOR is reported.
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9.2 Materials and Methods
9.2.1 Materials
Frozen human liver (normal and primary biliary cirrhotic) was obtained from the Royal 
Free Hospital, London, as before. Blocking reagent used in tissue immunostaining was 
obtained from Roche Diagnostics, Germany. Mounting medium (Vectashield) was 
obtained from Vector Laboratories Inc., Burlingame, California. Terasaki plates used in 
crystal screening were obtained from Hampton Research. All other chemicals were 
obtained from Sigma-Aldrich, Poole, Dorset, unless stated otherwise.
9.2.2 Methods
9.2.2.1 Native (non-reducing) PAGE
6 % and 7 % gels and buffers were prepared as described as in Section 3.2.1.1, but with 
the omission of SDS and 2-mercaptoethanol. The concentration of acrylamide: 
bisacryiamide was varied accordingly. Samples were diluted in 25 mM Na-phosphate, 
pH 7.4, and mixed 1:1 with sample buffer (Section 3.2.1.1) and loaded onto the gels. 
Electrophoresis was carried out at 75 V, until samples had passed through the stacking 
gel, and then at 200 V until the dye had reached the bottom of the gel, upon which
e W t r r . n h o t f s L  wa« C Q t n n l e t e  G eb were s t a i n e d  for rtrotein a g a i n  a s  d e s r r i b e d  in“r — — - j- ” - ” ~ r ’ 5
Section 3.2.1.1.
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9.2.2.1.1 XOR activity staining
The gel was incubated for 10-30 min, in 50 mM Tris-HCl, pH 7.5, containing 20 mM 
hypoxanthine and 3 mM nitroblue tetrazolium (NBT). To remove substrate, and 
prevent further development of staining, the gel was rinsed several times in distilled 
water.
9.2.2.2 ELISA for the determination of XOR protein
This wTas carried out as described in Section 3.2.5.1.
9.2.2.3 Immunostaining of liver sections
Paraffin-embedded sections were prepared from frozen liver and mounted on glass 
slides. This was kindly performed by colleagues at the University of Bath.
Sections were dewaxed by placing slides in xylene with two changes, for 3 min each. 
Rehydration was effected by immersion in a succession of graded alcohols (100 % 
ethanol, two changes, 95 % industrial methylated spirit, 90 % industrial methylated 
spirit, 70 % industrial methylated spirit, 1 min each), followed by distilled H20- The 
slides were incubated in pre-warmed Na-citrate/citric acid, pH 6.5, at 37 °C, for 30 min, 
for antigen retrieval. They were then rinsed in PBS (three times, 15 min/wash, shaking 
gently) and 0.5 % Triton X-100 (diluted in PBS) was added for permeabilisation. Slides 
were rinsed as before. Blocking was performed with 10 % heat-inactivated horse 
serum/6 % BSA, or Blocking reagent (Roche Diagnostics), for 1 h 45 min, while 
shaking gendy.
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Primary antibody (1D9D1, diluted 1:100 in blocking solution) was added to cover the 
surface of slides, which were incubated overnight, at 4 °C. Washes were carried out as 
before. Secondary antibody (Anti-Mouse IgG (whole molecule) FITC conjugate 
(developed in rabbit); 1:100 dilution in blocking buffer as before) was added to cover 
slides. Following the addition of this light-sensitive aptibody conjugate the slides were 
kept in the dark. Slides were incubated with antibody for 2 h at room temperature. 
Washes were performed as before. A coverslip was mounted on top of the sections on 
each slide, using mounting medium (Vectashield), and sealed round the edges using 
clear nail varnish.
Slides were viewed with the use of a confocal laser scanning microscope. Settings: 
Argon laser 488 nm wavelength, times 63 oil immersion lens with s 63 (NA 1.40). A 
FITC (Cy 2) filter was used.
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9.2.2A Crystallisation of XOR
A protein crystal is a fairly open three-dimensional lattice, in which each repeating motif 
is a single protein molecule or group of molecules. Water represents a major 
proportion of the crystal volume, and the water molecules surrounding the protein are 
well organised, forming hydrogen bonds with the protein and each other. Only a small 
portion of the protein surface is in contact with other protein molecules. Interactions 
involved in contacts between protein molecules are similar to those believed to stabilise 
the protein structure, such as hydrogen bonding, hydrophobic and ionic interactions, 
and less commonly, metal coordination. As a result, the crystals are soft and very 
sensitive to environmental factors such as humidity.
Crystallisation of proteins and other biological macromolecules occurs from an aqueous 
solution containing a variety of cosolutes, the major cosolute being the precipitant. The 
crystallisation process involves manipulation of the protein’s solubility, and the 
maintenance of a single and stable state of homogeneous content and conformation. 
There are three phases o f crystallisation: nucleation, growth and cessation of growth. 
The process is dependent on the formation of a supersaturated solution from which the 
desired molecule will precipitate in a crystalline or amorphous state.
There are many variables influencing crystallisation, such as purity and concentration of 
protein, temperature, pH and buffer, precipitant type and concentration, biological or 
enzymic contamination and the presence of chelators, to name but a few. The protein 
to be crystallised must be of the highest purity obtainable, soluble, stable and clean.
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Preliminary crystallisation experiments used the Hampton Research Crystal Screen 
(Crystal Screen 1), which is based on the sparse matrix screen described by Jancarik & 
Kim (1991). This is the most widely used general screen and involves 50 different 
conditions, using a wide range of precipitants, buffers and salts which, combined, 
provide the most common crystallisation conditions recorded at that time. This 
procedure makes it more likely to obtain a positive result, or ‘hit’ with most proteins. A 
‘hit’ can be anything from a crystalline precipitate to the formation of stars, or 
spherulites, to the appearance of a single crystal. Once a ‘hit’ is found, further screening 
experiments can be designed to optimise the conditions to promote crystallisation. In 
addition, the absence of any ‘hit’ under a particular condition can provide us with more 
information about the solubility of the protein of interest.
The method used here is known as the “microbatch” method, where a droplet of 
protein solution is immersed in paraffin oil, which slows the evaporation of the 
solution. Very small volumes can be used (1 jj.1), making the method ideal in the initial 
stages of screening. This approach involves the addition o f precipitant or changing pH 
until the protein comes to the limit of its solubility, and enters a state of supersaturation. 
If successful, a few nuclei are generated from which crystals will grow. All conditions in 
such a method are static, with protein concentration decreasing over time. Growth 
stops when the solution becomes so depleted of protein that no further growth can 
occur, or the surface of the growing crystal becomes contaminated with impurities, 
ending growth.
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Purified HLXOR (1.5 mg/ml) used in trials was in 50 mM Na-Bicine, pH 8.3 
(containing 0.05 M NaCl, 1 mM EDTA and 4 mM D TI). A Terasaki microbatch plate 
(Hampton Research) was used, containing 72 cone shaped wells, each holding up to 20 
jtl. The wells were filled with paraffin oil (liquid colourless light paraffin; 15 |tl). 
Purified HLXOR (1 pi) solution (pre-incubated with 10 mM DTT for 1 h) was added to 
each well, with care taken to pipette under the oil surface. Each precipitant solution (1 
pi) was added to each well, and the drop was allowed to sink to the bottom. Mixing of 
protein and precipitant solution was performed with pipetting. The plate was covered 
and stored in a quiet room, at 20 °C. The plate was inspected at daily intervals for 
recording observations.






9.3.1 Specific activity of immunoaffinity-purified HLXOR and BLXOR,
affinity-purified HMXOR and BMXOR
The specific activities of HLXOR purified by the monoclonal immunoaffinity 
chromatography described in the previous Chapter (Section 8.3.2.4), and BLXOR 
purified by polyclonal immunoaffinity chromatography (Section 7.3) were compared 
with the activities of HMXOR and BMXOR, purified within the laboratory using 
affinity methods (detailed in Chapter 3).
Enzyme Specific activity towards 
xanthine (fim ol/m in/m g)
HLXOR 0.17 ± 0.02
BLXOR 0.72 ± 0.04
HMXOR 0.068 ±0.005
BMXOR 1.38 ± 0.9
Table 9.3.1 Specific activities of purified XOR enzymes
Chapter 9 179
The specific activities of XOR enzyme towards xanthine have been calculated using the 
urate assay (Section 3.2.4.2). Total protein was estimated using the Bradford method 
(Section 3.2.3). Values are means ± SD (n =  3).
A graphical representation o f these activities is shown below:
1.6 -  
1.4 J
1.2 j
Specific activity j 





0  - J
HLXOR BLXOR HMXOR BMXOR
Figure 9.3.1 Graph showing specific activities of purified XOR from
hum an liver, bovine liver, hum an milk and bovine milk




HLXOR, HMXOR and BMXOR were subjected to native-PAGE and activity staining 
(Section 9.2.2.1). The results are shown below:
1 2 3 4 5 6
6 % Native-PAGE
1 — carbonic anhydrase
2 — chicken egg albumin
3 — urease
4 - BMXOR
5 - HMXOR 
6 -  HLXOR
1 2 3 4 5 6 7
6 % Native-PAGE
1 — carbonic anhydrase
2 — chicken egg album in
3 — urease
4 -  BMXOR 
5 - HMXOR
6 -  HLXOR
7 — w hole liver hom ogenate
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7 % Native-PAGE
1 -  a-lactalbumin
2 - carbonic anhydrase
3 — chicken egg albumin
4 - BMXOR
5 - HMXOR
6 -  HLXOR
7 — whole liver homogenate
Figure 9.3.2 6 % and 7 % native-PAGE of HLXOR, HMXOR and
BMXOR
Purified XOR enzymes (7.5 pg) were run alongside markers.
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9.3.3 XOR quantification by ELISA
ELISA quantification was performed (Section 3.2.5.1). Whole bovine milk, whole 
human milk, human liver homogenate and bovine liver homogenate were assayed.
Assay ELISA estimation of 
XOR protein 
concentration 
(ng HXO/mg total 
protein)
Specific activity 
(pm ol/m in/m g 
XOR protein)
Bovine milk 37 ±11 9.2 ± 2
Human milk 25 ± 9 0.8 ± 0.06
Bovine liver homogenate 182 ±47 5.8 ±1.2
Human liver homogenate 204 ± 35 1.6 ±0.6
Table 9.3.2 XOR quantification by ELISA
XOR protein concentration was calculated by ELISA. Total protein was estimated
using the Bradford assay (Section 3.2.3). Specific activity was calculated using the urate
assay (Section 3.2.4.2). Values are means ± SD (n = 3).
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9.3.4 Specific activities of primary biliary cirrhotic liver and normal liver
Specific activities were measured in the homogenates (Section 8.2.2.1) from these two 




(pm ol/m in/m g total 
protein)
% Oxidase
PBC liver 0.65 ± 0.1 65
Normal liver 0.16 ± 0.01 52
Tabte 93.3 Specific activities of primary biliary cirrhotic liver and/
normal liver
Pterin assay was conducted (Section 3.2.4.1) and total protein was estimated using the 
Bradford method (Section 3.2.3). Values are means ± SD (n = 3).
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9.3.5 Immunohistochemical staining of XOR in liver
1D9D1 monoclonal antibody was used for the purpose of immunohistochemical 
localisation of XOR in liver sections. Previous studies within our laboratory had 
obtained successful results using this antibody to localise XOR in cell lines (personal 
communication, C. Hoare).
Immunohistochemistry was carried out as described in Section 9.2.2.3. The negative 
control liver sections were incubated with blocking solution and then with secondary 
antibody only to ensure that there were no trace amounts of XOR in the blocking 
solution, or non-specific binding occurring.
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Distribution of XOR in normal liver sections
The negative controls (A) and (B), where the liver sections were incubated with 
secondary antibody only, yielded no staining of XOR. Slides (C) — (F) were stained for 
XOR. There is an uneven pattern of positive staining in the hepatocytes (C), where the 
arrow highlights hepatocytes with weaker XOR expression. (D) and (F) illustrate 
punctate or granular staining of hepatocytes. In (E), the Kupffer cells appear to be both 
positive (highlighted by short arrow), and negative. Also in (E), there is apparent a bile 
ductule, exhibiting strong staining of XOR (highlighted by long arrow).
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9.3.5.2 Primary biliary cirrhotic (PBC) human liver
A B
Atypical bile ductule conformation in primary biliary cirrhotic liver sections
C
Typical bile ductule in normal human liver
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(A) and (B) show atypical bile ductules in primary biliary cirrhosis (highlighted by 
arrows), where an elongated configuration is observed. (C) represents normal liver and 
here the typical ductule shows distinct lumen and cell borders. Both PBC and normal 
liver exhibit very strong staining of XOR in the ductules.
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9.3.6 Crystallisation of HLXOR
9.3.6.1 Hampton crystal screen
Crystallisation of immunopurified HLXOR was attempted, as described in Section 
9.2.2.4. The Hampton Research Crystal Screen was used as an initial set of conditions 
and all subsequent crystallisation experiments were carried out at 20 °C.
The table below illustrates the conditions that produced positive results:
Crystal Screen Result
1. 30 % PEG 4000, 0.1 M Tris-HCl pH 
8.5, 0.2 M magnesium chloride crystalline precipitate
2. 20 % iso-propanol, 0.1 M Na-acetate 
pH 4.6, 0.2 M calcium chloride microcrystals
3. 18 % PEG 8000, 0.1 M Na-cacodylate 
pH 6.5, 0.2 M Zinc acetate crystalline precipitate
Table 9.3.4 Positive results obtained with the Hampton Crystal Screen
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9.3.6.2 Further screens
Further screens were designed, based on the second combination o f precipitant, buffer 
and salt (Table 9.3.4) in the H am pton screen, yielding microcrystals. This condition 
included 20 % iso-propanol, 0.1 M Na-acetate, 0.2 M calcium chloride, pH  4.6. All 
screens also contained 10 mM DTT, which has been found to be a prerequisite for the 
crystallisation o f  HM XOR (Pearson, A., Ph.D. Thesis, 2001).
12 % iso-propanol 14 % iso-propanol 15% iso-propanol 17% iso-propanol
pH 4.5
0.15 M CaCl2 
0.1 M Na-acetate 
precipitate
0.2 M CaCl2 
0.1 M Na-acetate 
negative
0.25 M CaCl2 
0.1 M Na-acetate 
needles
0.2 M CaCl2 
0.1 M Na-acetate 
plate on edge
pH 4.6
0.2 M CaCl2 
0.1 M Na-acetate 
precipitate
0.15 M CaCl2 
0.1 M Na-acetate 
precipitate
0.15 MCaCl2 
0.1 M Na-acetate 
small plates
0.25 M CaCl2 
0.1 M Na-acetate 
single needle
pH 4.7
0.25 M CaCl2 
0.1 M Na-acetate 
precipitate
0.25 M CaCl2 
0.1 M Na-acetate 
precipitate
0.2 M CaCl2 
0.1 M Na-acetate 
plates
0.15 M CaCl2 
0.1 M Na-acetate 
starbursts
Table 9.3.5 Further screens
Observations are indicated in the table.
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9.3.6.3 Crystals
The following photographs illustrate the different types o f crystals obtained. The 
pictures were taken with the use of a Leica microscope and a 35 mm film camera. Figs 
a) (i) & (ii), b), e) and f) are taken under polarised light.
a) 15 % iso-propanol, 0.1 M Na-acetate, 0.2 M CaCl2, pH 4.7 
©
Three-dimensional crystal on edge o f plate, approximately 0.13 mm in length
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Crystals in centre o f oil droplet, approximately 0.13 mm in length
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b) 17 % iso-propanol, 0.1 M Na-acetate, 0.2 M CaCl2, pH 4.5
‘Chunky plate  ’  on edge of well, growing on surface o f oil
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c) 15 % iso-propanol, 0.1 M Na-acetate, 0.15 M CaCl2, pH 4.6
Very sm all 'plates’ on top layer o f oil
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d) 15 % iso-propanol, 0.1 M Na-acetate, 0.25 M CaCl2, pH 4.5
Single ‘needles’ on base o f well
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e) 17 % iso-propanol, 0.1 M Na-acetate, 0.25 M CaCl2, pH 4.6
Single ;needle *
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f) 17 % iso-propanol, 0.1 M Na-acetate, 0.15 M CaCl2, pH 4.7
Several starbursts
It was attempted to solubilise a few of the smaller crystals and process them for 
Western blotting to ensure that they were indeed HLXOR. However, no result was 
evident on Western blotting, which was very likely due to insufficient protein present.
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9.4 Discussion
In all mammals studied, liver and intestine have shown the highest XOR activity (Parks 
& Granger, 1986). This is also true for humans, although in this case activities are 
relatively low in all tissues. Particularly well studied have been human serum (Al-Khalidi 
et al, 1965; Yamamoto et al. 1996) and heart (Eddy et a l 1987; Muxfeldt & Schaper, 
1987; Grum et al’, 1989; de Jong et al., 1990), in which levels of XOR activity have been 
variously reported as being very low or undetectable. Low overall activity can reflect 
either low levels of enzyme protein and/or low specific activity of that protein. In 
comparisons of human and bovine milk, the very much lower XOR activity o f the 
former has been shown to result from low specific activity of XOR protein, levels of 
which are similar in the two species (Abadeh et al., 1992; Harrison, 1997; Godber, B., 
Ph.D. Thesis, 1998). Preliminary purification of XOR from human heart using 
immunoaffinity techniques, has indicated that a similar situation occurs in this tissue 
also (Abadeh et al, 1993).
Purifications of XOR from human liver have been reported by Krenitsky et al. (1986) 
and Moriwaki et al. (1993), with widely differing specific activities towards xanthine of 
1.8 pm ol/m in/m g and 0.96 x 10~3 pm ol/m in/m g respectively. The activity of the 
preparation obtained by Krenitsky et al. is comparable with that of XOR, purified from 
bovine milk (1.38 pmol/min/mg) in the present study (Section 9.3.1). The human liver 
enzyme, purified by immunoaffinity chromatography (Section 8.3.2.6) showed specific 
activity of only 0.17 pmol/min/mg, some ten-fold lower than the previous value 
reported by Krenitsky and colleagues. In contrast, this specific activity of the human
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liver enzyme detailed in the present work is some 200-fold higher than the value 
reported by Moriwaki et al. above for their preparation from human liver.
There are several possible explanations for the discrepancies observed in specific 
activity of human liver XOR. Firstly, the immunoaffinity purification suffers from the 
disadvantage that successful elution conditions result in partial loss o f FAD from XOR. 
This can, however, be largely rectified by incubation with FAD. Circulation of 
HMXOR on the column, followed by re-addition of FAD led to approximately 25 % 
loss of NADH oxidase activity (Section 8.3.2.3.4). Assuming that similar losses 
occurred in purification of HLXOR, we arrive at a specific activity of 0.23 
pmol/min/mg, still only a fraction of the earlier value reported by Krenitsky.
It is important to take into consideration that Krenitsky et al. (1986) employed an 
affinity purification that depended on binding of active enzyme. Thus, Krenitsky used a 
guanine analogue, which, although much less studied, almost certainly is similarly 
selective. It is, accordingly, probable that, of the activity-based, affinity-purified 
preparations of HLXOR, only that described in this thesis is representative of enzyme 
in whole tissue. However, this cannot explain the significandy lower specific activity 
enzyme obtained by Moriwaki et al. (1993), who used a succession of affinity procedures 
including immobilised folate, which is well known to bind only XOR with active 
molybdenum sites (Ventom et al.y 1988).
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HMXOR, prepared by affinity chromatography on heparin, had a specific activity of 
0.068 pm ol/m in/m g (Section 9.3.1). This is comfortably within the range (0.03 — 0.1 
pm ol/ min/mg) quoted by Godber (Ph.D. Thesis, 1998) for very many preparations 
using the same procedure. Specific activities of heparin-affinity purified BMXOR 
reported by Godber (1.2 — 1.5 pmol/min/mg) are similarly in accord with that found in 
the present studies (1.38 pmol/min/mg). Based on average values, Godber estimated 
the BMXOR/HMXOR activity ratio to be approximately 20. A similar ratio was 
obtained for whole milk by comparison of overall enzymic activities and yields of XOR 
protein (Section 9.3.3).
If the specific activity of immunoaffinity-purified BLXOR is ‘corrected’ for FAD loss, 
as described above for HLXOR, we obtain 0.96 pmol/min/mg. Comparisons of XOR 
purified in this thesis then lead to the following conclusions. Bovine XOR shows 
generally higher specific activity than human enzyme, but the 20-fold difference in the 
milk XORs is not matched in liver, where the corresponding ratio is closer to 4.
The relatively low specific activities of the human enzymes are most probably 
attributable to the presence o f inactive forms. BMXOR and HMXOR have been 
shown to contain approximately 40 % and 97 % respectively o f demolybdo-enzyme, 
lacking molybdenum and possibly also the molybdopterin cofactor (Godber et al., 1997; 
Bray et al., 1999). O f the remaining molybdo-enzyme, some 40-50 % is likely to exist as 
inactive desulpho-form. Although the limited amounts of purified enzyme precluded 
direct estimation of the molybdenum content of HLXOR, its specific activity would be
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consistent with a content of approximately 12 % molybdenum. BLXOR would, 
correspondingly, contain some 40 % molybdenum.
While the above discussion is reasonably self-consistent, it is not supported by ELISA 
data. Based on activity and ELISA data from whole tissue homogenates, Sarnesto et al. 
(1996) reported activity of 2.7-3.0 pm ol/m in/m g for HLXOR; an order o f magnitude 
higher than that of my purified enzyme. Specific activities similarly derived in this thesis 
are also high (HLXOR, 1.6 pmol/min/mg; BLXOR, 5.8 pmol/min/mg; BMXOR, 9.2 
pmol/min/mg; HMXOR, 0.8 pmol/min/mg). In view of the fact that the maximum 
specific activity of fully active BMXOR is calculated to be approximately 5 
pm ol/m in/m g (Bray, 1975), these values are clearly inflated, possibly by about 6-fold. 
The most likely explanation lies in underestimation, by ELISA, of XOR protein, 
although the reason for this is not obvious. Whatever their relationship to true levels of 
XOR protein, relative ELISA values are of interest. These show XOR protein to be 
some 8-fold richer in human liver (204 ng/mg total protein) than in breast milk (25 
ng/m g total protein), demonstrating that both higher levels of XOR protein and higher 
specific activity contribute to the greater activity of the enzyme in liver.
The activity staining results (Section 9.3.2) support the above. This was performed with 
the pure enzymes (human liver, human and bovine milk), which were subjected to 
electrophoresis under native conditions, and staining for activity with hypoxanthine and 
nitroblue tetrazolium. BMXOR stained most strongly, HLXOR stained second most 
strongly, and HMXOR produced the weakest staining, in accordance with their relative
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specific activities. Staining of a faint band in human liver homogenate was also 
apparent.
Measurement of XOR specific activities in normal liver homogenate and primary biliary 
cirrhotic liver homogenate produced some interesting results. The more sensitive pterin 
assay method was used in this instance, due to the low activity in the homogenates. 
Primary biliary cirrhotic liver was over 4-fold richer in XOR activity than normal liver, 
and its homogenate contained a higher proportion of oxidase form enzyme than that 
from normal liver. Battelli et al. (2001) reported relatively high XO activity in the sera of 
patients with cholestasis, which is a feature of primary biliary cirrhosis. The 
accumulation of hydrophobic bile salts in this disorder is thought to lead to increased 
conversion of XDH to XO and the resulting ROS have been implicated in the oxidative 
damage of hepatic parenchymal cells, leading to liver fibrosis and cirrhosis (Schimpl et 
al., 2000). During the early stages o f injury, the raised levels of serum XO might be 
attributed to release of enzyme from liver cells. It is a possibility that upon injury, there 
is some upregulation of liver XO mRNA, possibly associated with interferon 
production (Terao et al, 1992).
The immunolocalisation of XOR in liver sections was determined by using monoclonal 
anti-(human XOR) antibody 1D9D1, which displays crossreactivity with human liver 
XOR. Positive XOR expression was observed in all sections with very low background 
staining, as can be seen from the negative controls. In normal human liver, an uneven 
pattern of positive staining was found in the hepatocytes. While there appeared to be
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little staining of sinusoidal endothelial cells, some Kupffer cells showed a positive 
response (Section 9.3.5.1, Figs (A)-(F)). An uneven pattern of staining in the 
hepatocytes, similar to that observed in the present study, has been reported by both 
Moriwaki et al. (1996b) and Linder et al. (1999). Both of these groups found a lobular 
gradient of XOR expression, with intense staining in the cytoplasm of the periportal 
hepatocytes, and weaker expression in the perivenular hepatocytes. It was not possible 
to determine, from the present limited study, whether the hepatocyte staining observed 
is periportal or pericentral, however. Linder et al. (1999) also reported strong staining in 
the Kupffer cells o f approximately one-third of samples, in agreement with the present 
findings.
O f particular interest are the bile ducts, in which, in the present study, strong staining of 
XOR protein was observed. In primary biliary cirrhotic liver, atypical bile ductules were 
observed, with an elongated configuration, and these were also strongly stained. 
Normal ductules are characterised by well-formed lumina and distinct cell borders 
(Section 9.3.5.2, Fig ©). Atypical ductules have vague or no visible lumen and indistinct 
cell borders (Figs (A) & (B)). The occurrence of atypical ductules in primary biliary 
cirrhosis and other long-term cholestatic diseases has been well documented (Rubin et 
al., 1965; Ludwig et al., 1978; Nakanuma & Ohta, 1986; Van Eyken et al., 1988). Primary 
biliary cirrhosis, in particular, is characterised by progressive destruction of normal bile 
ducts and proliferation of atypical ductules (Harada et al, 1998), displaying an elongated 
or anastomosing configuration. The typical ductules were found to express complete 
biliary-type cytokeratins, while atypical ductules lacked complete biliary-type
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cytokeratins and often connected with periportal hepatocytes. In the present work, bile 
ductules of both types, typical and atypical, were strongly stained and it seems likely that 
their proliferation could be a major factor in the observed increase in overall XOR 
activity observed in cirrhotic liver. The presence of XOR protein in bile ducts is in 
accord with the findings of Moriwaki et al (1996b), but not of Linder et al. (1999), who 
failed to detect the enzyme in these structures.
It is possible that discrepancies arising from the results of immunolocalisation of XOR 
in the liver is due to the antibodies used, and also perhaps to the different procedures o f 
detection. Linder et al. (2001) used a polyclonal anti-(HMXOR) antibody raised in 
rabbits in their study for the detection of XOR, whereas Moriwaki et al (1996b) used a 
polyclonal anti-(HLXOR) antibody. This present study used a monoclonal anti- 
(HMXOR) antibody, with strong affinity towards both human milk and human liver 
enzyme. It is possible that the polyclonal anti-(HMXOR) antibody used by Linder et al 
may not have been of sufficient sensitivity to detect XOR expression in the bile ducts, 
for example. Moriwaki et al (1996b) used an antibody raised against purified human 
liver XOR. This may offer superior specificity to the antibody raised against human 
milk XOR used by Linder et al (2001), particularly in the detection of human liver 
XOR. Such improved specificity might explain the positive XOR expression observed 
in the bile ducts in the study by Moriwaki et al (1996b). The monoclonal anti- 
(HMXOR) antibody used in the present study may offer a specificity and sensitivity 
similar to the polyclonal antibody used by Moriwaki et al, which might account for the 
similar findings.
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Small crystals were obtained from purified HLXOR, using the microbatch under oil 
technique. Using the Hampton Research Crystal Screen conditions, a ‘hit’ was apparent 
in 20 % iso-propanol, 0.1 M sodium acetate, 0.2 M calcium chloride, pH 4.6. Further 
experiments were designed based on this condition, and several more ‘hits’ resulted. 
Crystals in the form of plates, and starbursts, were observed in both 15 and 17 % iso­
propanol, 0.1 M sodium acetate, with varying concentrations of calcium chloride, and 
with pH between 4.5 and 4.7. The largest crystal was observed in 15 % iso-propanol, 
0.1 M Na-acetate, 0.2 M calcium chloride, pH 4.7. All crystallisation conditions also 
contained 10 mM DTT, which has been found to be essential in the crystallisation of 
HMXOR. Unfortunately, due to the time constraints of this study, it was not possible 
to obtain diffraction data from these crystals.
Crystallisation of demolybdo human milk XOR has been recendy reported (Pearson, A., 
Ph.D. Thesis, 2001). Hexagonal orthorhombic and trigonal HMXOR crystals were 
obtained (see Appendices). The human milk enzyme was found to crystallise under 
slighdy different conditions, to that found in this study for liver, including 20-30% 
polyethylene glycol 4000, 0.1 M Na-acetate, Na-citrate or Tris, 0.15-0.25 M ammonium 
acetate or ammonium sulphate, pH 5-8, and 10 mM DTT.
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10. Discussion
XOR from bovine milk, rat and chicken liver has been well characterised, however, up 
until recendy, there has been litde work carried out on the human enzyme, probably 
because of the abundance and ease of extraction of the enzyme from bovine milk. 
Interest in human XOR was greatly stimulated in 1981, when Granger et al. reported 
XDH to XO conversion in ischaemic tissues as a source of damaging ROS following 
reperfusion (Granger et al, 1981). Since this finding, XOR-derived ROS have been 
implicated in a multitude of human diseases involving ischaemia-reperfusion injury 
(McCord et al., 1985). Animal models have been used to investigate the role of XOR in 
reperfusion injury, and the XOR inhibitors, allopurinol and oxypurinol, as well as pre­
treatment with tungsten, have been shown to prevent organ damage (Greene & Paller, 
1992; Wiezorek et al., 1994; Kurose & Granger, 1994). However, the interspecies 
variability in the tissue-specific expression of XOR activity does not allow conclusions 
from animal model experiments to be extrapolated to humans.
jpathojpgjp^l ^jid physiological significance of XOR in humans is unclear. The low 
specific activity of the human milk enzyme for conventional reducing substrates remains 
intriguing. Furthermore, XOR expression and activity is largely confined to the liver 
and intestine, with specific activity of the enzyme in these organs reported to be higher 
than that in breast milk. These findings suggest a specialised distribution of XOR, 
which is not fully understood.
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This thesis describes the purification and characterisation of XOR from human liver, 
with further investigation as to its localisation in this tissue. Previous purifications of 
XOR from human liver have been based on affinity (Krenitsky et al., 1986; Moriwaki et 
al, 1993) and immunoaffinity (Saksela et al., 1999) methods.
The purification of XOR from bovine liver provided a starting point for the 
development of a suitable immunoaffinity purification procedure for the isolation of the 
enzyme from human liver. Initially, a procedure for the isolation of BLXOR based on 
non-immune affinity methods was developed, which provided a useful comparitor for 
purification using immunoaffinity procedures. BLXOR was affinity-purified to near 
homogeneity, with a molecular weight of approximately 135 kDa as judged by SDS- 
PAGE, using a combination o f chromatographic methods, involving benzamidine- 
Sepharose, heparin-Sepharose, and HiTrap Q ion-exchange. The first of these, 
benzamidine-Sepharose chromatography, was based on a method described by 
McManaman et al. (1996) for the isolation of XOR from rat liver, while the latter two 
methods were derived from the purification of milk XOR used within the laboratory 
(Godber, B., Ph.D. Thesis, 1998). An overall purification factor of approximately 275- 
fold was obtained, which was higher than the 199-fold purification reported by 
McManaman et al. (1996), for rat liver XOR. The yield of BLXOR was comparable 
with that obtained by McManaman et al. Cabre & Canela (1986) reported the only 
published affinity purification of XOR from bovine liver. Their purification consisted 
o f five chromatographic steps, together with heating and acetone precipitation (both of 
which were avoided in the present study, as potentially damaging to the enzyme). These
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harsh methods possibly contributed to their finding of multiple bands on SDS-PAGE 
analysis of their preparation, indicating significant degradation. Despite this apparent 
heterogeneity, an absorption curve was acquired from their BLXOR, from which a PFR 
of 5.64 was calculated. In the present work, it was not possible to obtain a UV-visible 
scan resembling XOR from the affinity-purified BLXOR, indicating possible 
contamination with other proteins.
Rabbit polyclonal anti-(HMXOR) antibodies were affinity-purified, for use in 
immunoaffinity purification. Western blotting of bovine liver homogenate with these 
polyclonal antibodies showed a band approximating to 150 kDa. A three-step 
purification method was devised, consisting of ammonium sulphate precipitation, 
Protein A-Sepharose and immunoaffinity chromatography. This resulted in an almost 
homogeneous preparation of BLXOR as judged by SDS-PAGE. Two bands were 
evident on SDS-PAGE gel, corresponding to molecular weights of 134 kDa and 50 
kDa. A monoclonal anti-HMXOR antibody reacted with both bands in Western 
blotting. The major band at 134 kDa was comparable to the band at 135 kDa observed 
previously, with affinity-purified BLXOR. BLXOR purified by Cabre & Canela (1986) 
also displayed a major band with molecular weight of 135 kDa, similar to that obtained 
here.
Immunoaffinity-purified BLXOR showed a UV-visible spectrum characteristic of XOR 
from bovine and human milk. A PFR of 5.75 was calculated from the scan, indicative 
of reasonably pure XOR, with the typical range for highly purified XOR from milk
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between 5.2 and 5.7. This is comparable to the PFR of 5.62 reported by Cabre and 
Canela (1986) for their BLXOR preparation. The yield of immunoaffinity-purified 
BLXOR obtained was ten-fold higher than that obtained in my non-immune affinity 
purification. The rapid processing, higher yield, and the relative purity of enzyme 
obtained, as indicated by the PFR, give immunoaffinity purification distinct advantages 
over the non-immune purification procedure.
The polyclonal immunoaffinity method used in the BLXOR purification was further 
optimised for the isolation of XOR from human liver. Both polyclonal and monoclonal 
anti-(HMXOR) antibodies were investigated. HLXOR purified by polyclonal 
antibodies produced three bands on SDS-PAGE gel, corresponding to approximately 
150 kDa, 135 kDa and 50 kDa. The 135 kDa band represented the major band, whilst 
the minor band was at 150 kDa. Western blotting using a monoclonal anti-(HMXOR) 
antibody identified the 150 kDa and 135 kDa bands as XOR. N-terminal sequence 
analysis of the 135 kDa and 50 kDa bands revealed matches of the 135 kDa band with 
human XOR, and the lower 50 kDa band with heavy chain immunoglobulin. Such 
immunoglobulin may have been present from the beginning of the purification, perhaps 
existing as an immune complex with XOR, or have arisen as a result o f leaching from 
the immunoaffinity column matrix into the eluate. Saksela et al. (1999), also using 
polyclonal immunoaffinity purification, reported a HLXOR preparation displaying a 
similar pattern on SDS-PAGE gel, with bands at 150 kDa, 130 kDa and 85 kDa.
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The use of monoclonal antibodies in the isolation of HLXOR required Western blot 
analysis in order to identify a clone with suitable specificity towards the enzyme. In fact, 
only one of the three clones tested displayed immunoreactivity (1D9D1) towards 
HLXOR. The corresponding antibody was accordingly selected for use in purification. 
Employment of monoclonal antibodies required modifications of the polyclonal 
immunoaffinity method: CNBr-activated Sepharose 4B was used as an alternative 
coupling medium to Protein A-Sepharose, and glycine was substituted as an eluant in 
the place of diethylamine. A final step involving a circulation on Protein L-Sepharose 
was introduced in order to remove any contaminating immunoglobulin (see above). 
Monoclonal immunoaffinity-purified HLXOR displayed two bands on SDS-PAGE gel, 
a major band at approximately 155 kDa and a minor band at 135 kDa. Western blotting 
using polyclonal affinity-purified anti-(HMXOR) identified both bands as XOR. This 
preparation appeared to be less proteolysed than HLXOR from polyclonal 
immunoaffinity chromatography, in which the major band corresponded to the lower 
molecular weight band of 135 kDa, with the minor band at 150 kDa.
The specific activities towards xanthine and the yields of HLXOR purified by the two 
methods were very similar. The monoclonal immunoaffinity method offered an 
improvement in purification over the polyclonal immunoaffinity method, as judged by 
SDS-PAGE and native gel electrophoresis. Unfortunately, neither method led to UV- 
visible spectra with features characteristic of XOR. As previously mentioned, this may 
be due to some structural damage to the enzyme, altering the UV-visible properties. It 
is unlikely that the absorption spectrum for human liver XOR should differ from those
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of XOR enzymes isolated from other sources. For example, the absorption spectrum 
of mouse liver XOR (Carpani et al., 1990) bears strong similarities to that of other XOR 
preparations from rat liver (Suleiman & Stevens, 1987) and bovine milk (Massey et al.y 
1969).
It is evident from this work that differences exist in the apparent molecular weights of 
the various XOR preparations, as judged by SDS-PAGE gels. It is well established in 
our laboratory that freshly-prepared BMXOR and HMXOR each show a strong band at 
approximately 150 kDa. A weaker band at 135 kDa, attributed to proteolysis, may or 
may not be present initially, but increases in intensity with age o f the preparation. The 
major band of HMXOR consistendy runs slighdy slower than does that of BMXOR; a 
fact that is difficult to explain in view of the close similarity of the primary structures of 
these enzymes (Section 8.4). These findings are corroborated in the present work, 
which shows that HLXOR also follows the above pattern. BLXOR, in contrast, 
whether prepared by immune or non-immune affinity chromatography, showed only 
one high molecular weight band at 134/135 kDa. Cabre and Canela (1986) similarly 
reported a band of 135 kDa on SDS-PAGE (although further lower molecular weight 
bands were also present) and a corresponding molecular weight for the non-denatured 
enzyme from gel-filtration analysis. The obvious conclusion is that the 135 kDa bovine 
liver XOR band represents a proteolysis product, equivalent to those of BMXOR, 
HMXOR and HLXOR. It is, nevertheless, a strong, clean band without evidence o f a 
higher molecular weight companion. It is possible, although improbable, that bovine 
liver contains a particularly active proteolytic enzyme, that is less active or absent in
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equivalent homogenates from other tissues. Alternatively, BLXOR could actually be 
smaller than other mammalian XORs. Clearly, further investigation is desirable.
Despite the apparent species-specific variations in molecular weight of XOR, the 
enzymes appear to share similar patterns of degradation. Samesto et al. (1996) observed 
that the cleavage of purified XOR and XOR in tissue homogenates is not random, with 
similarly sized fragments consistendy apparent on SDS-PAGE and Western blots. This 
indicates conservation of cleavage sites within the amino acid sequences of XOR 
enzymes. In human liver XDH (Ichida et al., 1993), the tryptic cleavage sites of the rat 
liver enzyme (Amaya et al., 1990) are conserved (Samesto et al., 1996). Krenitsky et al. 
(1986) reported the presence of five bands on SDS-PAGE analysis o f their purified 
HLXOR. Samesto et al. (1996) reported the presence of multiple bands in human liver 
homogenised in the presence of protease inhibitors, upon Western blotting, and 
suggested that this may reflect the existence of XOR in partially-proteolysed form in 
intact liver. HLXOR purified in the present work shows minimal proteolysis, with only 
two bands on SDS-PAGE gel. A similar pattern of bands was also observed in liver 
homogenate. This is not consistent with the proposition of the presence of in vivo 
proteolysed HLXOR (Samesto et al., 1996).
Aldehyde oxidase (AO), another molybdoflavoprotein, shares both structural and 
catalytic similarities with XOR. It has been suggested that the two enzymes arose from 
a common progenitor by gene duplication and subsequent genetic modification, a view 
supported by genetic data (Krenitsky, 1978). They are both homodimers with a
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molecular weight of 300 kDa. Furthermore, the subunits from the two proteins each 
contain one atom of molybdenum, one molecule of FAD and four Fe/S groups, and 
thus have very similar absorption spectra. It was clearly important to ascertain, during 
the course of this study, that enzyme purified was XOR and not AO. Purified 
preparations of XOR were routinely assayed for AO contamination by using 1- 
methylnicotinamide, a compound readily oxidised by AO, but not by XOR (Krenitsky et 
al., 1972). No activity was detected in the purified preparations, although activity was 
present in whole bovine and human liver homogenate. AO also has a similar 
distribution to XOR in mammals, with high levels of enzyme present in the small 
intestine and liver (Krenitsky et al., 1974) leading to the proposal that the two enzymes 
together may constitute a protective barrier in these organs, capable of detoxification of 
mainly nitrogen-containing heterocycles (Krenitsky, 1978). However, this proposal is 
less attractive in the case of humans, where the levels of enzyme activity attributed to 
AO are very low (Krenitsky et al., 1974). XOR activity levels, on the other hand, have 
been reported to be in the same order of magnitude, albeit to some extent lower, to 
levels in other mammalian species (Parks & Granger, 1986).
Affinity-purified rabbit polyclonal and mouse monoclonal anti-(HMXOR) antibodies 
have been characterised during the course of this study. Both types of antibody cross­
reacted with XOR from bovine milk, human milk, bovine liver, and human liver, 
recognising minor proteolysis bands on Western blots. No cross-reactivity has been 
observed between polyclonal anti-(XOR) antibodies and AO protein in an antibody 
specificity study carried out by Moriwaki et al. (1996a), so it is likely that the polyclonal
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antibodies used in this study were not reactive with AO. The monoclonal antibody 
1D9D1 was the only one from three clones tested that showed interaction with 
HLXOR. This antibody also displayed the strongest avidity towards the immunogen 
HMXOR, although weaker reaction was observed between this antibody and the bovine 
liver and milk XOR en2ymes. As total homogenate was used in Western blotting to 
determine the specificity of the antibody to HLXOR, it should be mentioned that the 
proportion of XOR protein of total protein in homogenate is very low, and therefore 
the negative results obtained during blotting of homogenate with the other two 
monoclonal antibody clones may simply indicate lack of sensitivity of the Western 
blotting method, rather than lack of specificity of the antibody. The specificity of 
1D9D1 for HLXOR was also confirmed by immunoprecipitation of the enzyme from 
human liver homogenate. SDS-PAGE of the immunoprecipitate showed a band 
corresponding to XOR. In view of this, the antibody 1D9D1 was selected for 
subsequent immunoaffinity purification, and for use in later immunolocalisation studies.
Perhaps the most noteworthy point, arising from this study, is the surprisingly low 
specific activity of purified HLXOR. An early report describing the first purification of 
XOR from post-mortem liver revealed this enzyme to possess a specific activity towards 
purine substrates similar to that of BMXOR, although considerable differences were 
noted between the bovine and human enzymes in their activity towards nucleoside 
substrates (Krenitsky et al., 1986). At around the same time, a report described a 
similarly high catalytic activity towards conventional reducing substrates in the liver and 
small intestine, with activity low or undetectable in other organs (Parks & Granger,
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1986). A few years later, XOR was purified from human milk, and shown to have 
surprising properties (Abadeh et al., 1992; Harrison, 1997; Godber et al., 1997). Activity 
of HMXOR towards xanthine was found to represent only 1-2 % that of the bovine 
milk or rat liver enzymes, although the NADH oxidase activity, which generates 
hydrogen peroxide and superoxide anion at significant rates, was shown to be similar to 
that of the bovine milk enzyme (Sanders et al, 1997). The low activity of the human 
milk enzyme has been explained in terms of exceptionally low molybdenum content. 
Purified HMXOR appears to contain at least 95 % demolybdo-enzyme, as apposed to 
30-40 % for purified BMXOR. Moreover, desulpho-XOR makes up at least 40 % of 
molybdenum-containing HMXOR (Harrison, 1997). The low specific activity o f XOR 
in human milk is not unique. Human heart XOR was affinity-purified and shown to 
yield enzyme with a similarly low specific activity (Abadeh et al., 1993). Based on the 
above information, a proposal that two types of XOR existed within the human was 
made, comprising of ‘low’ activity enzyme in milk and heart, and ‘high’ activity enzyme 
(similar to that of BMXOR) in liver and intestine (Abadeh et al., 1992; Harrison, 1997). 
Low activity has also recendy been identified in cultured human epithelial cells, by 
ELISA and activity assays (Page et al, 1998).
Many subsequent biochemical studies have confirmed the existence of significant XOR 
activity in human liver and small intestine with none or negligible XOR activity detected 
in other organs (Watts et al., 1965; Eddy et al., 1987; Grum et al., 1989; Smolenski et al., 
1989; de Jong et al., 1990; Kooij et al., 1992). Values for the specific activities of bovine 
and human liver XOR, based on the purifications carried out in the present work, are
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discussed in Chapter 9. BLXOR was found to have specific activity lower than, but 
nonetheless of the same order of magnitude as that of BMXOR. The specific activity of 
HLXOR, however, was surprisingly low. In contrast to the working hypothesis, noted 
above, o f ‘high activity’ XOR (i.e. ‘BMXOR-like’) in human liver and intestine, HLXOR 
showed specific activity only some 4-fold higher than that of HMXOR. The idea of 
‘bovinc-like’ specific activity in HLXOR was initially derived from the purification of 
Krenitsky et al. (1986). However, as discussed in Chapter 9, this purification involved 
affinity chromatographic procedures that selected for active enzyme only. My 
immunoaffinity-purified preparation is much more likely to be representative of the mix 
of active and inactive forms of XOR present in vivo. In summary, we are left with a 
pattern of generally high activity XOR in bovine tissues (liver and milk), and much 
lower activity enzyme in humans, although HLXOR is nevertheless more active than is 
HMXOR. The commonly observed higher activity of XOR in liver (and probably 
intestine) compared with other human tissues reflects both relative specific activities 
and levels of XOR protein, although the latter is most likely to be more important.
The different specific activities of HMXOR and BMXOR have been shown to reflect 
their relative contents of demolybdo-XOR (Godber et al., 1997; Bray et al., 1999). 
Although the low amounts of purified enzyme precluded direct analysis, it is reasonable 
to assume that the specific activities of HLXOR and BLXOR are similarly dependent 
on molybdenum content. It is, however, by no means clear what mechanism 
determines these differences. The primary sequences of HLXOR (Ichida et al\, 1993) 
and BMXOR (Berglund et al., 1996) are 90 % homologous, while those of HLXOR and
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HMXOR (Pearson, A., Ph.D. Thesis, 2001) are essentially identical. It seems that 
differences in content of molybdo-XOR are most likely to be controlled by regulation 
of molybdenum-incorporating enzymes in the host cell.
There is strong evidence that the specific activity of human XOR is subject to regulation 
within the cell. Thus, Brown et al. (1995) showed wide variation of XOR activity in 
breast milk after parturition, while the amount of XOR protein remained essentially 
constant. Inflammatory cytokines such as TN F-a and IL-1 have been found to cause 
the upregulation and post-translational activation of XOR in a human mammary gland 
cell line, implicating the enzyme as a potential mediator in inflammation (Page et al., 
1998). Again, upregulation of XOR activity was not found to be matched by an 
increase in XOR protein. As noted above, such apparendy post-translational activation 
of XOR could be brought about by regulation of the enzymic machinery that controls 
molybdenum incorporation, although this would seem to be a cumbersome mechanism. 
Simpler, at least in concept, would be conversion of inactive desulpho-XOR to its active 
sulpho form. Evidence for enzymic catalysis of this conversion has been demonstrated 
in vitro (Nishino et al., 1983; Nishino, 1986). However, the extent of activation possible 
by these means is limited. Desulpho-XOR generally makes up 40-50 % of molybdo 
enzyme. In the case of HMXOR, with, for example, 3 % theoretical molybdenum 
content, the activity, could, at most, be doubled in this way. [Brown et al. (1995) 
observed up to 50-fold activation of XOR activity in post-partum breast milk]. An 
intriguing, further possibility involves phosphorylation of XOR protein, a potential 
activation mechanism that has been identified in hypoxia (Kayyali et al., 2001). The
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above discussion of post-translational activation mechanisms excludes upregulation of 
the enzyme by de novo synthesis, which undoubtedly also occurs, particularly in response 
to both cytokines (Page et al\, 1995) and hormones (McManaman et al., 2000). Whether 
or not complex mechanisms of regulation of XOR activity are unique to man, as 
apposed to for example, rodents or cows (tissues of which appear to show uniformly 
high activity) is far from clear. The idea of evolution driven sophisticated regulation in 
humans is attractive, but entirely speculative at this stage.
It was outside the scope of the present study to measure specific activity in
homogenates from a range of normal liver tissues and so explore whether the low
specific activity observed in the liver used in this study simply reflects individual 
variations. Such variations have indeed been noted (Guerciolini et al., 1991; Kooij et al., 
1992). The specific activity of XOR was measured in primary biliary cirrhotic liver 
homogenate and found to be over 4-fold higher in XOR activity than that from normal 
liver. Although there are currendy no reports direcdy concerning enzyme activity in 
primary biliary cirrhosis, there are some indications that XOR activity is higher in 
cholestasis, a related feature of primary biliary cirrhosis (Schimpl et al., 2000; Batelli et al., 
2001). Certainly serum XOR levels are known to be elevated as a consequence of a 
range of liver disorders (Ramboer et al., 1972; Bhide et al., 1974; Wolko & Krawczynski, 
1974; Batelli et al., 2001). Interestingly, there is some evidence of an increased nitric 
oxide production in primary biliary cirrhosis (Battista et al., 2001). The enhanced nitric 
oxide production was suggested to be related to the development of strong
inflammation, and also to neutrophil activation. If XOR is upregulated in the
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pathogenesis of this disorder, it might prove to be involved in production of both nitric 
oxide and other free radicals, both of which have been implicated in the pathogenesis of 
primary biliary cirrhosis (Ono et al, 1991).
Immunohistochemical localisation of XOR in liver sections in the present work has 
been carried out with the same mouse monoclonal anti-(HMXOR) antibody as that 
used in immunoaffinity purification: 1D9D1. This antibody has also been used within 
our group in studies of the subcellular localisation of XOR in human endothelial and 
epithelial cell lines, and has proved to be more effective that affinity-purified polyclonal 
anti-(HXOR) antibodies. Preliminary results have shown some evidence of vesicular 
export of XOR to defined patches of endothelial cell membrane (Hoare, C., personal 
communication). Previous conclusions concerning the immunohistochemical 
localisation of XOR in the liver have been conflicting, which may reflect the different 
specificities and avidities of the anti-(XOR) antibodies employed. For example, Linder 
et al. (1999) used a polyclonal anti-(HMXOR) antibody to localise XOR in a range of 
human tissues, and commented on the greater sensitivity of this antibody over the 
mouse monoclonal anti-(HMXOR) used by Hellsten-Westing (1993) for localisation in 
human cardiac and skeletal muscle. However, a monoclonal antibody is generally 
expected to have greater specificity over a polyclonal antibody.
In the present work, in normal human liver, XOR expression was detected in the 
hepatocytes, bile ductules, and some Kupffer cells. An uneven pattern of staining was 
observed in the hepatocytes, in line with previous observations (Moriwaki et al., 1996b;
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Linder et al.^  1999). Similar positive staining in Kupffer cells has been reported by 
Linder et al. (1999), who found this to be the case in approximately one-third of their 
liver samples.
In primary biliary cirrhotic liver, as also seen in normal liver, strong XOR expression 
was observed in the bile ductules and the hepatocytes. Furthermore, atypical bile 
ductule configuration was noted, a finding well documented in primary biliary cirrhosis 
and other long-term cholestatic diseases, and previously reported by Harada et al. (1998). 
It was not possible, however, using these methods of immunolocalisation, which were 
non-quantitative, to elucidate whether there was increased XOR expression in the 
primary biliary cirrhotic liver sections, as opposed to the normal liver, which would 
support the higher specific activity findings, and the theory of upregulated XOR mRNA 
expression, perhaps by cytokines, in this liver disease.
The crystallisation of HLXOR has been described in this work. Small crystals of 
HLXOR were obtained, using the Hampton Research Crystal Screen set of conditions. 
Crystals of HLXOR provide an exciting basis for future work, leading to the elucidation 
of the structure of this enzyme, which can be compared to the solved crystal structures 
of the bovine milk and human milk enzymes.
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In summary, this work presents some interesting observations regarding the specific 
activity of HLXOR. The low specific activity of the liver enzyme is in contrast to the 
generally high pattern of activity reported previously for enzyme from this tissue. The 
specific activity of HLXOR is also lower than that of the bovine milk and 
corresponding liver enzyme. It would be worthwhile to further explore the basis of the 
differing kinetics, using a range of substrates in addition to pterin and xanthine, between 
these purified enzymes isolated from different species.
Additional further work might involve investigation into the molecular basis of the 
specific activity of HLXOR, by assessing the molybdenum content of this enzyme, and 
contrasting it with that of the lower activity HMXOR. In addition, the Fe/S 
composition can be examined, with X-ray analysis of the three-dimensional crystal 
structure of the enzyme; suitable conditions of crystallisation for the liver enzyme have 
been established in this study. Furthermore, it will be interesting to establish the extent 
of individual variation of human liver XOR, with particular relation to diseased liver, 
and this will help contribute to our understanding of the role of the enzyme in this 
tissue.
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Appendices
Crystals of human milk xanthine oxidoreductase (HMXOR)
Photographs kindly donated by A. Pearson (Pearson, A., Ph.D. Thesis, 2001)
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